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General introduction 
 
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder and is 
the most common cause of dementia in the elderly. In 2010, an estimated 36 
million people worldwide suffered from AD and because of growing life 
expectancy, the global prevalence of AD is expected to increase to 115 million 
people by 2050 [1]. AD affects a person’s ability to carry out daily activities 
and is characterized by severe cognitive impairment, memory loss, language 
deterioration, executive and visuospatial dysfunction, and personality and mood 
changes (such as apathy, agitation, aggression, anxiety and depression) [2]. 
Neuropathologically, AD brains are characterized by the presence of 
intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated 
tau protein, extracellular amyloid-β (Aβ) plaques, cerebrovascular alterations, 
activated astrocytes and microglia, and synaptic and neuronal loss in specific 
brain regions like the forebrain and medial temporal lobe structures 
(hippocampus, entorhinal cortex and amygdala) [3].  
 
Hypotheses on the etiology of Alzheimer’s disease 
Despite 100 years of extensive research, the cause of AD is still largely 
unknown and there are no curative treatments available. A large part of the 
research on the etiology of AD has been focused around three main hypotheses: 
the cholinergic hypothesis, the amyloid hypothesis and the tau hypothesis.  
 
The cholinergic hypothesis was put forward in the mid-1970s when it was 
found that the activity of choline acetyltransferase (CAT), an enzyme that 
parallels the distribution of cholinergic neurons, was reduced in the cerebral 
cortex and the hippocampus in post-mortem AD brains [4-6]. A few years later, 
Whitehouse et al. reported that in AD a marked selective loss of cholinergic 
neurons is observed in the nucleus basalis of Meynert, which provides the main 
cholinergic input to the hippocampus, amygdala and neocortex [7, 8]. First-
generation AD drugs available today aim at increasing cholinergic levels to 
restore cognitive deficits in AD patients. However, the benefits of these 
cholinesterase inhibitors in treating the broad spectrum of symptoms associated 
with AD are marginal and short-lasting due to the progressive degeneration of 
cholinergic neurons throughout the course of AD [9].  
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In the early nineties, the amyloid hypothesis was proposed [10, 11]. This 
hypothesis states that the accumulation of the Aβ peptide is the primary 
influence driving AD pathogenesis. The Aβ peptide is derived through the 
proteolytic cleavage of the amyloid-β precursor protein (AβPP) by β- and γ-
secretase, and it accumulates in the brain as neuritic plaques or as vascular wall 
deposits that may cause cerebral amyloid angiopathy (CAA) [12, 13]. Early-
onset familial AD (FAD) has been linked to autosomal dominant mutations in 
the genes for AβPP on chromosome 21, presenilin 1 (PS1) on chromosome 14 
and presenilin 2 (PS2) on chromosome 1 [14, 15]. The mutations in these genes 
enhance the processing of AβPP into Aβ, and they are thought to account for 
40% of early-onset AD [16]. However, only 5% of all AD cases worldwide can 
be linked to genetic mutations involved in Aβ metabolism. Furthermore, there 
are conflicting results about the neurotoxicity of Aβ plaque depositions [17]. 
Many non-demented individuals show large amount of AD pathology, whereas 
many AD patients display only few Aβ deposits, as shown in large autopsy 
studies [18, 19], and in PET [
11
C] Pittsburgh Compound-B imaging studies 
visualizing Aβ plaque burden in vivo [20, 21]. More recently, the Aβ hypothesis 
was modified to include soluble oligomers and protofibrils as the cause of AD 
[22], since these Aβ species were shown to be toxic in vitro and in transgenic 
animal models [22-24]. Immunization against Aβ has been suggested as a 
possible preventive or therapeutic treatment for AD, but so far clinical trials 
have failed to show efficacy [25, 26].  
 
The tau hypothesis offers the idea that tau protein abnormalities initiate the AD 
cascade by disrupting microtubule function, thereby impairing axonal transport 
and triggering abnormal synaptic transmission [27]. NFTs are characteristic 
neuropathological lesions of AD, but they are not pathognomonic since they 
commonly occur in a host of other neurological disorders as well [28]. Although 
it has been suggested that inhibition of abnormal hyperphosphorylation of tau 
offers a promising therapeutic target for AD [26, 29], no clinical studies have 
been carried out so far. 
  
Several other hypotheses have been proposed to explain the pathogenesis of 
AD, each based on a variety of supportive data, including the inflammatory 
hypothesis, oxidative stress hypothesis, cell cycle hypothesis and the vascular 
hypothesis (reviewed in [30]). So far however, none of the postulated 
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hypotheses have reached a firm research consensus. Rather than one sole 
mechanisms, it is much more likely that AD is a multifactorial disease, caused 
by a combination of different (risk) factors. 
 
Risk factors for Alzheimer’s disease 
The degenerative processes underlying the development and progression of AD 
are complex and far from being completely understood. Ageing is recognized as 
the most important risk factor for AD, reflected by an increased prevalence with 
advanced age. The age-specific prevalence of AD almost doubles every 5 years, 
from approximately 1.5% in persons aged 60-65 years to over 40% in people 
older than 85 years [31-33]. Besides advanced age, several other factors have 
been associated with an increased risk of developing AD, including the presence 
of the apolipoprotein Eε4 allele (apoE4), hypercholesterolemia, atherosclerosis, 
depression, diabetes mellitus, stroke, oxidative damage, inflammatory 
conditions, overweight and hypertension [34-36]. Many of these risk factors are 
vascular-related, causing chronic cerebral hypoperfusion and cerebrovascular 
pathology [34, 37-40], suggesting that vascular disorders may play an important 
role in the onset of AD. Both cerebral blood volume (CBV) and cerebral 
perfusion (CBF) have been shown to be affected in both AD patients [41, 42] 
and transgenic AD mouse models [43-47]. Although normal aging is known to 
be associated with increased vascular resistance and decreased cerebral blood 
flow [48-51], these perfusion volume changes are more pronounced in AD and 
especially the parietal and temporal cortices are consistently shown to be 
affected [42, 52]. SPECT studies in patients with mild cognitive impairment 
(MCI) have shown that most patients displaying temporoparietal hypoperfusion 
converted to AD within a few years, while patients with normal cerebral 
perfusion did not during the observation period [53-55]. These findings suggest 
that cerebral hypoperfusion and cerebrovascular pathology are among the 
earliest markers of AD and support the CATCH hypothesis of de la Torre, 
positing that advanced age in combination with a vascular risk factor converges 
to create a Critical Attained Threshold of Cerebral Hypoperfusion (CATCH), 
triggering brain microcirculatory disturbances and hypoperfusion [56, 57].  
 
Vascular hypothesis of Alzheimer’s disease 
According to the CATCH hypothesis, chronically disturbed (capillary) blood 
flow will impair normal delivery of essential nutrients to neuronal and glial 
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cells, as well as impede catabolic outflow of CNS waste products, leading to 
oxidative stress and mitochondrial dysfunction [58, 59]. In turn, these events 
contribute to regional energy metabolic changes, glucose uptake deficiency, 
abnormalities in protein synthesis, processing and phosphorylation, synaptic 
neurotransmitter dysfunction, synaptic and neuronal damage, glial reactivity, 
and cognitive decline [59]. In line with the CATCH hypothesis are findings of 
reduced glucose metabolism in AD patients, which is most pronounced in the 
temporal and parietal cortex, as shown with PET [
18
F] flurodeoxyglucose 
imaging studies [60, 61], and in line with findings of decreased expression of 
glucose transporter type 1 (GLUT-1) in the hippocampus and cerebral cortex of 
AD patients and transgenic AD mice in immunolabeling and binding 
experiments [62-66]. Furthermore, several studies have shown that 
hypoperfusion results in increased Aβ production and reduced Aβ clearance, 
favoring the formation of neuritic plaques and CAA [42, 67-69]. In turn, Aβ 
peptides can further enhance hypoperfusion of the brain due to CAA and their 
interaction with endothelial cells causing vasoconstriction of blood vessels [66, 
70-72]. In this way, the synergistic negative effects of the amyloid and the 
vascular pathway on cerebral perfusion cause a vicious cycle, further enhancing 
the pathological cascade which could ultimately result in the development and 
progression of AD.  
 
Lifestyle 
Modification of lifestyle factors, such as physical exercise and nutrition, can 
influence vascular-based risk factors and thereby alter the risk of developing 
AD later in life [39, 73-75]. In our aging Western society, high dietary intake of 
saturated fatty acids, such as cholesterol, in combination with a sedentary 
lifestyle has led to a growing incidence of cardiovascular disorders, obesity and 
diabetes, major risk factors of AD, which are even more aggravated in people 
carrying the apoE4 alleles. The link between AD and dietary fatty acids is 
further substantiated by the finding that several genes involved in lipid 
metabolism, such as APOE, CLU encoding apolipoprotein J/clusterin, 
PICALM1 and BIN1 have been associated with late onset AD [76]. In contrast, 
adherence to a Mediterrean diet, rich in omega-3 long-chain polyunsaturated 
fatty acids (n3 lc-PUFAs), vitamins and antioxidants, has been shown to reduce 
the incidence of major cardiovascular events [77-79] and to lower the risk of 
developing AD [80-82]. The potential influence of nutrition on cognitive 
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impairment and on the development and prevention of AD in particular, is a 
topic of increasing interest in the scientific community in search of alternatives 
for current medication which offer meager and temporary outcome. However, 
the mechanisms by which dietary nutrients can influence AD pathogenesis are 
still under investigation.   
 
The aims of this thesis were to investigate by which mechanisms nutrition 
influences AD development and to determine the longitudinal etiopathogenic 
processes contributing to AD.    
 
Outline thesis 
 
Research into the development of AD provides increasing evidence that 
lifestyle, vascular and genetic factors together strongly influence the 
development of vascular disorders and neuronal degeneration. Nutrition may 
affect the course of AD at many different levels, and might be important tools in 
developing preventative strategies against AD and vascular disease.  
 
To determine the longitudinal etiopathogenic processes contributing to AD and 
to investigate by which mechanisms nutrition influences AD development, we 
used three distinct transgenic mouse models. The double transgenic 
AβPPswe/PS1dE9 Alzheimer mouse model was used as a model for familial 
early-onset AD. This mouse line has rapid age-dependent accumulation of Aβ 
into extracellular plaques starting from 4-6 months of age [83]. The human 
apoEε4/ε4-carrier and the apoE knockout (B6, 129P-Apoetm1Unc/J) mouse 
models were used as models for vascular risk factors in AD development. While 
apoE4-carrier mice exhibit an increased risk of developing vascular disorders 
due to altered cholesterol metabolism, apoE knockout mice spontaneously 
develop severe hypercholesterolemia [84, 85].  
 
Several different methodologies were applied throughout this thesis to gain a 
better understanding of the potential mechanisms contributing to AD and the 
role of nutrition in these processes: Animals underwent behavioral testing in the 
open field to determine explorative and anxiety-related behavior, and in the 
Morris water maze (MWM) to study spatial learning and memory. We used 
magnetic resonance imaging (MRI) at 7 Tesla and 11.7 Tesla to determine 
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cerebral blood volume (CBV) using contrast enhanced MRI, and to analyze 
hippocampal metabolite levels using proton magnetic resonance spectroscopy 
(
1
H MRS). Neuropathology was determined using several different techniques. 
Immunohistochemical stainings were performed for Aβ plaques, capillary 
density (GLUT-1), presynaptic boutons (synaptophysin), and neurogenesis 
(doublecortin). ELISAs were performed to determine TBS-T soluble and high-
molecular weight human Aβ40 and Aβ42 levels in the AβPPswe-PS1dE9 
mouse model. Quantitative real-time PCR (qRT-PCR) was used to determine 
the mRNA levels of several inflammatory markers. Finally. gas-
chromatography-mass-spectrometry-selected ionmonitoring (GC-MS-SIM) and 
gas-chromatography-flame-ionization-detector (GC-FID) were performed to 
analyze sterol levels and fatty acid levels respectively.        
 
Chapter 2 
Since previous studies have shown that high cholesterol intake can influence 
AD development by increasing Aβ plaque load and reducing CBV [45], we 
investigated the effects of high dietary cholesterol intake and the cholesterol-
lowering liver X receptor (LXR)-agonist T0901317 on capillary density, 
amyloid-β deposition, and the amount of presynaptic boutons in the 
hippocampus of adult (8 months) and aged (15 months) AβPPswe-PS1dE9 and 
wild-type mice, to elucidate how cholesterol may affect neurodegenerative 
processes in aging and AD.  
 
Chapter 3 
1
H MRS has great potential for the early diagnosis of AD, monitoring disease 
progression and evaluating the efficacy of potential therapeutic agents. 
Providing well characterized AD animal models and better understanding of the 
underlying processes in AD is required for the development and evaluation of 
potential therapeutic targets. We therefore set out to characterize the 
neurochemical profile of the hippocampus, measured by single voxel 
1
H MRS 
at 7 Tesla, in the brains of AβPPswe-PS1dE9 and wild-type mice at 8 and 12 
months of age in a longitudinal study. Furthermore, we wanted to determine 
whether alterations in hippocampal metabolite levels coincided with behavioral 
changes, cognitive decline and neuropathological features, to gain a better 
understanding of the underlying neurodegenerative processes. In addition, we 
performed correlation analyses with the hippocampal amyloid-β deposition, 
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TBS-T soluble Aβ levels and high-molecular weight Aβ aggregate levels to gain 
a better understanding of the possible involvement of Aβ in neurochemical and 
behavioral changes, cognitive decline and neuropathological features in 
AβPPswe-PS1dE9 transgenic mice.     
 
Chapter 4 
Due to the limited and short-lasting efficacy of the current drugs available, 
recent work has focused on the use of dietary interventions for the treatment and 
prevention of AD. It has been suggested that approaches with multiple 
nutritional components might be more promising than single nutrient 
interventions, since not individual nutrients but dietary patterns were identified 
as a factor influencing the risk of developing AD. We therefore investigated to 
which extent long-term consumption of two specific multi-nutrient diets can 
modulate AD-related etiopathogenic mechanisms and behaviors in 11-12-
month-old AβPPswe-PS1dE9 and wild-type mice.     
 
Chapter 5 
Lipid metabolism and genetic background together strongly influence the 
development of both cardiovascular and neurodegenerative diseases like AD. A 
non-pharmacological way to prevent the genotype-induced occurrence of these 
pathologies is given by dietary behavior. In the present study, we aimed to 
investigate to which extent apolipoprotein E4 (apoE4) and apoE knockout mice, 
which are models for risk factors in cardiovascular disorders and AD, develop 
behavioral and neuropathological traits of AD. In addition, we determined the 
effects of long-term dietary intervention with a specific multi-nutrient diet on 
cerebral hemodynamics, behavior, cognition, brain metabolism and plasticity.  
 
Chapter 6 
All study findings presented in this thesis are summarized in Chapter 6 and are 
discussed with respect to current understanding of AD development and study 
outcomes of nutritional intervention in AD. Furthermore, the advantages and 
disadvantages of the transgenic animal models used in this thesis are discussed, 
as well as some of the potential confounding factors in the experimental setup. 
To conclude, suggestions for future experiments are provided to gain a better 
understanding of the mechanisms contributing to AD and how nutrition could 
affect these processes.  
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Abstract 
 
Research into the development of Alzheimer’s disease (AD) provides increasing 
evidence that vascular risk factors, including high serum cholesterol, might 
influence the progression of cognitive impairment and neural degeneration. In 
this study, we investigated the effects of high dietary cholesterol intake and the 
cholesterol-lowering liver X receptor agonist T0901317 on capillary density, 
amyloid-β deposition, and presynaptic boutons in the hippocampus of adult (8 
months) and aged (15 months) AβPPswe-PS1dE9 and wild-type mice to 
elucidate how cholesterol may affect neurodegenerative processes in aging and 
AD. Our results show increased number of presynaptic boutons in 15-month-old 
AβPP-PS1 mice compared to age-matched wild-type animals, but no difference 
at 8 months of age. High cholesterol intake accelerated this response by 
increasing the amount of presynaptic boutons at 8 and 15 months of age, while 
T0901317 intake decreased the amount of presynaptic boutons in 15-month-old 
AβPP-PS1 mice. These findings suggest a synaptic compensatory response to 
maintain connectivity during aging. We hypothesize that high cholesterol intake 
may cause impaired cerebral blood flow inducing ischemia, fortifying the above 
mentioned hypothesis of a compensatory mechanism. Contrarily, cholesterol-
lowering agents may positively influence cerebral circulation, thereby 
diminishing aggravation of AD-like pathology.    
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Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the 
most common cause of dementia in the elderly. Clinically, the disease is marked 
by early gradual cognitive impairment. Neuropathologically, AD is 
characterized by the accumulation of extracellular amyloid-β (Aβ) plaques, 
intracellular neurofibrillary tangles composed of hyperphosphorylated tau 
protein, and the loss of synaptic contacts in vulnerable brain regions such as the 
hippocampus and neocortex [1]. Despite 100 years of extensive research, the 
cause of AD is still largely unknown and there are no curative treatments 
available. For decades, the accumulation of the Aβ peptide in plaque deposits 
has been proposed to be the primary trigger of the pathological cascade leading 
to neurodegeneration and the development of AD, since gene mutations of 
amyloid-β protein precursor (AβPP), presenilin 1 (PS1), or presenilin 2 (PS2) in 
patients with early onset familial AD enhance the processing of AβPP into Aβ 
[2, 3]. However, only 5% of all AD cases worldwide can be linked to genetic 
mutations involved in Aβ metabolism. Furthermore, there are conflicting results 
about the neurotoxicity of Aβ plaque depositions [4]. Many non-demented 
individuals show large amounts of AD pathology, whereas many AD patients 
display only few Aβ depositions, as shown in large autopsy studies [5, 6], and in 
PET [
11
C] Pittsburgh Compound-B imaging studies visualizing Aβ plaque 
burden in vivo [7, 8]. In recent years, research focus has shifted from the 
insoluble Aβ plaques to the soluble oligomeric forms of Aβ as potential culprits 
of AD. Several lines of evidence have indicated that soluble oligomers of Aβ 
may be responsible for synaptic dysfunction and cognitive impairment in AD 
patients and transgenic animal models [9, 10]. Since the discovery of AD, 
several other (risk) factors have been proposed to play an important role in the 
development of AD, besides the Aβ peptide.  
 
Many large epidemiological studies have shown that vascular disorders are risk 
factors for AD [11-14]. There are indications that modification of lifestyle 
factors, such as physical exercise and nutrition, can influence these vascular-
based risk factors and thereby alter the risk of developing AD later in life [15-
17]. For example, high serum cholesterol, which can be caused by dietary 
intake, is an important risk factor in vascular disorders and AD [18-22]. 
Experimental animal studies have shown that high dietary cholesterol intake in 
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several transgenic AD mouse models increases Aβ accumulation [23-26], 
whereas reducing peripheral cholesterol levels decreases Aβ formation both in 
vivo and in vitro [27-29]. The link between cholesterol and AD is also amplified 
by the finding that many genes coding for proteins involved in cholesterol 
metabolism, such as apolipoprotein E (ApoE) and liver X receptor (LXR), have 
been shown to be associated with late onset AD [30-34]. LXRs are so-called 
key regulators of cellular cholesterol homeostasis, and following activation 
induce a variety of genes involved in pathways of cholesterol metabolism, 
transport, and elimination [35, 36]. Activation of LXRs has been shown to 
decrease Aβ generation, both in vitro and in vivo [37-39], and to improve 
cognitive performance in transgenic mouse models of AD [40, 41]. Taken 
together, these data indicate that dietary cholesterol levels can influence AD 
development. 
 
It is generally believed that cholesterol itself does not easily cross the blood 
brain barrier and that brain and peripheral cholesterol levels are independently 
regulated. Although brain cholesterol originates almost exclusively from in situ 
neosynthesis, a small part of the total brain cholesterol can be derived from 
systemic sources. Peripheral cholesterol can be taken up by the brain via its 
conversion into 27S-hydroxycholesterol, and inversely brain cholesterol can be 
excreted into the circulation via its conversion into 24S-hydroxycholesterol. An 
excess of serum cholesterol levels may therefore cause an increased flux of 
cholesterol from the circulation into the brain through the conversion between 
cholesterol and oxysterol, leading to increased levels of brain cholesterol, which 
in turn may affect neuron and myelin integrity [42-44]. However, a recent study 
performed in our lab showed that a Typical Western Diet (TWD) containing 1% 
cholesterol led to increased serum cholesterol levels in 8- and 15-month-old 
wild-type and AβPP-PS1 mice, while the total brain cholesterol levels remained 
unchanged [45]. In addition, serum lathosterol levels, a main precursor in the 
“de novo” synthesis pathway, decreased in the 8- and 15-month-old TWD fed 
mice, and the peripheral 24S-hydroscycholesterol levels increased, while total 
brain levels of these sterols remained unchanged, indicating decreased 
neosynthesis and increased elimination of cholesterol.  
 
Since high serum cholesterol is also involved in cardiovascular diseases such as 
hypertension and atherosclerosis [46, 47], it can be hypothesized that 
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cholesterol may promote degenerative processes in AD by influencing the 
peripheral vasculature, and subsequently the cerebral vasculature. Recent 
studies performed in our lab showed that a 1% cholesterol enriched TWD 
influenced cerebral hemodynamics like the cerebral blood volume (CBV) in 15- 
and 18-month-old double transgenic AβPP-PS1 mice without affecting total 
brain cholesterol concentrations [45, 48], which is in line with studies showing 
that CBV and cerebral blood flow are affected in AD patients [49, 50].  
 
In order to elucidate how cholesterol may affect neurodegenerative processes in 
aging and AD, we investigated the effects of high dietary cholesterol intake and 
the intake of the cholesterol-lowering LXR-agonist T0901317 (T09) [31] on 
capillary density, Aβ deposition, and amount of presynaptic boutons in the 
hippocampus of adult (8 months) and aged (15 months) AβPPswe-PS1dE9 
mice. 
 
Materials and methods 
 
Animals and housing conditions 
The AβPPswe-PS1dE9 founders were obtained from John Hopkins University, 
Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of Pathology) and a 
colony was established at the Radboud University Nijmegen Medical Centre, 
The Netherlands. In short, mice were created by co-injection of chimeric 
mouse/human AβPPswe (mouse AβPP695 harboring a human Aβ domain and 
mutations K595N and M596L linked to Swedish familial AD pedigrees) and 
human PS1dE9 (deletion of exon 9) vectors controlled by independent mouse 
prion promoter elements. The two transfected genes co-integrate and co-
segregate as a single locus [51, 52]. This line (line 85) was originally 
maintained on a hybrid background by backcrossing to C3HeJ×C57BL/6J F1 
mice (so-called pseudo F2 stage). For the present work, the breeder mice were 
backcrossed to C57BL/6J for 7 generations to obtain mice for the current study. 
The animals were housed individually in a controlled environment, with room 
temperature at 21°C, and an artificial 12:12h light:dark cycle (lights on at 07:00 
a.m.). Food and water were available ad libitum. In total 73 mice were used and 
Table 1 describes the distribution of the mice per experimental group. The 
experiments were performed according to Dutch federal regulations for animal 
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protection and were approved by the Veterinary Authority of the Radboud 
University Nijmegen Medical Centre.  
 
Table 1. Number of mice used in each experimental group 
Groups Synaptophysin  
staining 
Amyloid-β staining GLUT-1 
staining 
8-month-old 
Wild-type control 7 - 7 
AβPP-PS1 control 7 8* 7 
Wild-type 
cholesterol 
6 - 5 
AβPP-PS1 
cholesterol 
9 9* 9 
15-month-old 
Wild-type control 7 - - 
AβPP-PS1 control 6 7* - 
Wild-type 
cholesterol 
7 - - 
AβPP-PS1 
cholesterol 
5 6* - 
15-month-old subgroup 
AβPP-PS1 vehicle 7 7 7 
AβPP-PS1 T09 8 7 6 
* Aβ plaque burden in 8- and 15-month-old AβPP-PS1 littermates on control and 
cholesterol diet has been described elsewhere [45]. 
 
Wild-type and AβPPswe-PS1dE9 mice at 8 and 12 months of age 
Male AβPP-PS1 transgenic mice and their wild-type littermates were assigned 
to different diet groups, which diverge with respect to the composition of the 
5% fat in the diets (Table 2). Diets were produced by Research Diet Services 
(Wijk bij Duurstede, The Netherlands). Animals were fed the diets starting from 
2 months of age and were maintained until 8 and 15 months of age. Transgenic 
mice and their wild-type littermates were fed either 1) a cholesterol diet, 
containing 1% cholesterol, a high percentage of saturated fatty acids (53%; 
SFA), and a low percentage of long chain poly-unsaturated fatty acids (23% lc-
PUFAs); or 2) a control diet, comparable to standard rodent chow, with 
intermediate values for SFA (28%) and lc-PUFAs (38%). Mice were sacrificed 
via transcardial perfusion fixation at 8 or 15 months of age and their brains were 
processed for immunohistochemistry.  
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Table 2. Sources and contents of fatty acids in the experimental diets 
Dietary groups 
 Control Cholesterol 
Diet components   
% Soya oil 2.9 0.6 
% Coconut oil 1.6 1.7 
% Corn oil - 1.2 
% Fish oil - - 
% Sunflower oil 0.3 0.6 
% Linseed oil 0.3 - 
% Cholesterol - 1.0 
   
Diet content   
% Total n-3 2.2 0.5 
% Total n-6 16 11 
Ratio n-6/n-3 7.5 22.5 
% SFA 38 53 
% MUFA 23 23 
% PUFA 38 23 
n-3 = omega-3, n-6 = omega-6, SFA = saturated fatty acids, 
MUFA = mono-unsaturated fatty acids, PUFA = poly-unsaturated fatty acids. 
 
Subgroup AβPPswe-PS1dE9 mice at 15 months of age 
A subgroup of male AβPP-PS1 transgenic mice were fed the LXR-agonist 
T0901317 (Cayman Chemical, Ann Arbor, MI, USA) 0.015% drug in food 
(w/w) corresponding to 30 mg/kg body weight/day or vehicle containing diet 
from 12 to 15 months of age. Diets were prepared as described before [41]. 
Briefly, the experimental diet was prepared by dissolving T0901317 (T09) in 
0.15% ethanol as vehicle mixed together with miliq water:crushed (1:1) chow 
pellets (Ssniff, Soest, Germany). Subsequently the mixture was dried at room 
temperature in order to achieve a 0.015% (w/w) drug concentration in food. 
Chow for the control group was prepared likewise, containing only the ethanol 
vehicle. Mice were sacrificed via transcardial perfusion fixation at 15 months of 
age and their brains were processed for immunohistochemistry. 
 
Immunohistochemistry 
Mice (Table 1) were fixated via transcardial perfusion starting with a 0.1M 
phosphate buffered saline (PBS, pH=7.3) followed by Somogyi’s fixative (4% 
paraformaldehyde, 0.05% glutaraldehyde and 0.2% picric acid in 0.1M 
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phosphate buffer, PB, pH=7.3). Following transcardial perfusion fixation, mice 
were decapitated and brains were removed from the skull. The entire brain, 
without the spinal cord, was postfixed for 15h at 4°C in Somogyi’s fixative and 
subsequently stored in 0.1M PBS with 0.01% sodium azide at 4°C. Before 
cutting, the brain tissue was cryoprotected by immersion in 30% sucrose in PB 
at 4°C. Six series of 40 µm coronal sections were cut through the brain using a 
sliding microtome (Microm HM 440 E, Walldorf, Germany) equipped with an 
object table for freeze sectioning at -60°C. For every staining, one complete 
series, with 240 µm distance between the sections, was used. 
Immunohistochemistry was performed using standard free-floating labeling 
procedures, and was carried out on a shaker table at room temperature unless 
otherwise stated. Visualization was achieved by incubation with 3-
3’diaminobenzidin tetra hydrochloride with ammonium nickel sulphate as an 
intensifier (DAB-Ni solution, pH=7.6) with 0.006% H2O2 for 10 min. After 
subsequent washing with 0.1M PBS, all stained sections were mounted on 
gelatin-coated slides (0.5% gelatin and 0.05% chrome-alum), dried overnight in 
a stove at 37°C, dehydrated in alcohol series, cleared with xylol and mounted in 
Entellan. 
 
Amyloid-β staining  
The Aβ load was visualized using WO-2 antibody (mouse anti-human Aβ5-8, a 
kind gift of T. Hartmann, Homburg/Saar, Germany) using one subseries of 
brain sections per animal. Briefly, the sections were blocked against 
endogenous peroxidase with 0.3% H2O2 in 0.1M PBS for 30 min and pretreated 
with sodium citrate solution at 85°C for 30 min. Brain sections were incubated 
overnight at 4°C with primary antibody monoclonal mouse anti-human Aβ5-8 
(1:20,000) diluted in 0.05M Tris buffered saline with 0.5% Triton (TBS-T, pH= 
7.6). After incubating for 90 min with secondary antibody donkey-anti-mouse 
biotin 1:1500 in TBS-T (Jackson ImmunoResearch), sections were transferred 
to a solution containing Vector ABC-elite 1:800 in TBS-T (Vector Laboratories, 
Burlingame, CA, USA) for another 90 min. Visualization of Aβ plaques was 
achieved by incubation with DAB-Ni solution with 0.006% H2O2 for 10 min. 
 
Glucose transporter type-1 (GLUT-1) staining 
Capillaries were visualized using GLUT-1 antibody (rabbit anti-GLUT-1 
transporter, Chemicon AB 1340, Chemicon International Inc., Temecula, CA, 
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USA) using one subseries of brain sections per animal. GLUT-1 is an active 
glucose transporter and is primarily localized in brain vascular endothelial cells 
[53-55]. GLUT-1 expression has been shown to be decreased in the 
hippocampus and cerebral cortex of AD patients [56-58], and of transgenic 
mouse models for AD [24, 59]. In short, after blocking the brain sections 
against endogenous peroxidase with 0.3% H2O2 in 0.1M PBS for 30 min, the 
sections were pre-incubated with PBS-BT (0.1M PBS with 1% bovine serum 
albumin and 0.3% Triton-X-100) for 30 min. Brain sections were incubated 
overnight at room temperature with polyclonal rabbit anti-GLUT-1 (1:10,000 
diluted in PBS-BT) as primary antibody. After incubating for 90 min with 
secondary antibody donkey anti-rabbit biotin (1:1500 diluted in PBS-BT), 
sections were transferred to a solution containing Vector ABC-elite 1:800 in 
PBS-BT for another 90 min. Visualization of GLUT-1 was achieved by 
incubation with DAB-Ni solution as an intensifier as described above. 
 
Synaptophysin staining 
Presynaptic boutons of the 8- and 15-month-old mice were visualized with anti-
synaptophysin antibody (monoclonal mouse anti-synaptophysin clone SY38 
MAB5258, Chemicon International Inc., Temecula, CA, USA) using one 
subseries of brain sections per animal. Synaptophysin is localized in small 
synaptic vesicles of the presynaptic terminal and functions in the regulation of 
exocytosis [60]. Immunohistochemistry was carried out using the Vector Mouse 
on Mouse (M.O.M.) kit (Vector Laboratories, Burlingame, CA, USA) to 
minimize cross reactivity between the mouse secondary antibody and mouse 
tissue. Briefly, brain sections were blocked against endogenous peroxidase with 
0.3% H2O2 in 0.1M PBS for 30 min. After incubating the brain sections for 2 h 
with M.O.M. mouse IgG blocking reagent (1:25 in 0.05M Tris buffered saline 
with 0.3% Triton-X-100, TBS-T, pH= 7.5), sections were pretreated with 
M.O.M. solution (12.5 times diluted in TBS-T). Brain sections were incubated 
overnight at 4°C with monoclonal mouse anti-synaptophysin (1:6000 in M.O.M 
solution diluted in TBS-T) as primary antibody. After 90 min incubation with 
secondary antibody M.O.M. biotin anti-mouse IgG (1:2500 in M.O.M. solution 
diluted in TBS-T), sections were transferred to a solution containing Vector 
ABC-elite 1:800 in TBS-T (Vector Laboratories, Burlingame, CA, USA) for 
another 90 min. Visualization of synaptophysin was achieved by incubation 
with DAB-Ni solution as an intensifier as described above. 
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Presynaptic boutons of the 15-month-old AβPP-PS1 subgroup, fed with T09 or 
vehicle diet, were visualized with anti-synaptophysin antibody (monoclonal 
rabbit anti-synaptophysin clone EP1098Y, Abcam Inc., Cambridge, UK). In 
short, after blocking the brain sections against endogenous peroxidase with 
0.3% H2O2 in 0.1M PBS for 30 min, the sections were pre-incubated with PBS-
BT (0.1M PBS with 1% bovine serum albumin and 0.3% Triton-X-100) for 30 
min. Brain sections were incubated overnight at room temperature with 
monoclonal rabbit anti-synaptophysin (1:20,000 diluted in PBS-BT) as primary 
antibody. After incubating for 90 min with secondary antibody donkey anti-
rabbit biotin (1:1500 diluted in PBS-BT), sections were transferred to a solution 
containing Vector ABC-elite 1:800 in PBS-BT for another 90 min. 
Visualization of synaptophysin was achieved by incubation with DAB-Ni 
solution as an intensifier as described above. 
 
Quantification 
To determine the amount of Aβ and capillary density in the hippocampus (cornu 
ammonis (CA)1, CA3, and dentate gyrus (DG); containing the vessels in the 
hippocampal fissure), appropriate sections were digitized and quantified using a 
Zeiss Axioskop microscope equipped with hardware and software from 
Microbrightfield (Williston, USA). These regions were chosen because of their 
large Aβ load in humans and transgenic mice and their importance in learning 
and memory [61, 62]. Quantitative analyses were done with a computer-assisted 
analysis system (Stereo Investigator) using Cavalieri’s probe, with grid spacing 
25×25µm. Contours were drawn along the borders of the hippocampal 
subregions. Brain regions were based on the mouse brain atlas of Franklin and 
Paxinos [63]. Hippocampal regions were quantified at −2.18 up to −2.46 
posterior to bregma, using one section per animal. All measurements were 
performed double blind by two investigators, and measurements were averaged 
to obtain a single value per animal for every hippocampal region. The Aβ load 
was defined as the percentage of area covered by Aβ. Capillary density was 
defined as percentage of the area covered by GLUT-1 immunoreactivity as 
compared to the total area of the region measured. 
 
To determine the amount of synaptophysin-immunoreactive presynaptic 
boutons (SIPBs) in the hippocampus, appropriate sections were digitized and 
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photomicrographed using the Zeiss Axioskop microscope, equipped with a 
100× oil immersion objective and a 10× projection lens. SIPBs were analyzed in 
the stratum radiatum of the CA1 area (SR), stratum lucidum of the CA3 area 
(SL), and the inner molecular layer (IML) and outer molecular layer (OML) of 
the DG using one section per animal at −2.18 up to −2.46 posterior to bregma.  
 
 
Fig. 1. Representative image of the synaptophysin-immunoreactive presynaptic 
boutons (SIPBs) in the hippocampus of wild-type and AβPP-PS1 mice. a) SIPBs were 
analyzed in the inner (yellow) and outer (red) molecular layer of the dentate gyrus, 
stratum radiatum (SR) of the CA1 area (blue), and stratum lucidum (SL) of the CA3 
area (green). b) SIPBs were quantified using image analysis from digitized 
photomicrographs of the synaptophysin-immunoreactivity.  
 
For every hippocampal subregion, two contours were drawn and analyzed for 
the amount of SIPBs (Fig. 1a, b). Brain regions were based on the mouse brain 
atlas of Franklin and Paxinos [63]. All measurements were performed double 
blind by two investigators, and measurements were averaged to obtain a single 
value per animal for every hippocampal region. SIPBs were quantified by image 
analysis using AnalySIS-pro software (Soft Imaging System, Münster, 
Germany). All settings were kept identical for all analyses and background 
levels were equalized using a threshold. For every photomicrograph, the region 
of interest (ROI) was defined. Shading correction was performed before 
measurement to correct for irregularities in illumination in the microscopic 
field. A differential contrast enhancement (DCE) filter was applied to 
selectively enhance weak differences in contrast. To eliminate noise signal and 
to differentiate between possible artifacts and specific SIPBs, particles were 
classified based on size. Particles ranging between 0.1-4.5 µm
2
 were considered 
to be “normal” sized SIPBs [64, 65], and were included for statistical analyses.  
Particles smaller than 0.1 µm
2
 and larger than 4.5µm
2
 were excluded for further 
analyses. SIPB areas were, on average, 0.96 ± 0.12 µm
2
 (mean ± SD) in IML, 
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0.96 ± 0.13 µm
2
 in OML, 1.00 ± 0.12 µm
2
 in SR, and 1.33 ± 0.15 µm
2
 in SL, 
The amount of SIPBs/µm
2
 was defined as the number of particles counted 
divided by the total area analyzed. Data are represented as relative values 
compared to the wild-type mice on control diet (set as 100%) of the 
corresponding age, and as relative values compared to the AβPP-PS1 mice on 
vehicle diet (set as 100%) for the 15-month-old subgroup. 
 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed in SPSS for windows 
16.0 software (SPSS Inc., Chicago, IL, USA). To evaluate regional differences 
in Aβ load, an one-way ANOVA was used. To evaluate differences in capillary 
density and amount of SIPBs multivariate ANOVAs were conducted with 
between group factors: genotype and diet, followed by a Bonferroni post hoc to 
analyze possible interactions between genotype and diet (between group 
factors). No significant genotype×diet interactions were found for any 
parameter analyzed. Statistical significance was set at p<0.05. For clarity, F-
values are not displayed. 
 
Results 
 
Amyloid-β staining 
Aβ load was determined in hippocampal regions of the 15-month-old AβPP-
PS1 subgroup fed either a vehicle or a cholesterol lowering agent LXR-agonist 
T0901317 (T09) diet (Fig. 2a). 
 
At this age and duration of treatment, the cholesterol-lowering T09 diet had no 
effect on Aβ deposition (Fig. 2b) in the DG (p=0.567), CA1 (p=0.603), or CA3 
(p=0.998). Overall analyses revealed significant regional variation in Aβ plaque 
burden (p<0.001), such that the DG showed the highest amount of Aβ plaque 
load compared to the CA1 (p<0.001) and CA3 (p<0.001) areas, and the CA3 
area seemed to have the lowest amount of Aβ plaque load although not 
statistically different from the CA1 area (p=0.067). 
 
The effect of the cholesterol-rich diet (TWD) on Aβ plaque load in the 8- and 
15-month-old littermates from our earlier studies has been described elsewhere 
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[45]. In short, Aβ plaque load did not differ between animals fed the 
cholesterol-rich diet and the control diet both at 8 and at 15 months of age. 
 
 
Fig. 2. Immunohistochemical analysis of the amyloid-β (Aβ) load (%) in the dentate 
gyrus (DG), CA1 area, and CA3 area of the hippocampus. a) Representative image of 
the Aβ immunoreactivity in the hippocampus of 15-month-old AβPP-PS1 mice. b) Aβ 
plaque load in 15-month-old AβPP-PS1 mice on vehicle and T09 diet. Values represent 
the mean and SEM.  
 
Glucose transporter type-1 staining 
Capillary density was determined using GLUT-1 staining to visualize the 
capillaries in the hippocampal DG, CA1 area, and CA3 area of 8-month-old 
wild-type and AβPP-PS1 mice (Fig. 3a), and in the 15-month-old AβPP-PS1 
subgroup fed either a vehicle or cholesterol-lowering T09 diet (Table 1). 
Capillary density was defined as the percentage of area covered by GLUT-1 
immunoreactivity as compared to the total area of the region measured. 
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At 8 months of age (Fig. 3b), no differences were found in GLUT-1 density 
between wild-type and AβPP-PS1 mice in the DG (p=0.784), the CA1 area 
(p=0.546), and the CA3area (p=0.791). Furthermore, the cholesterol diet had no 
effect on GLUT-1 density at 8 months of age compared to control diet (Fig. 3c) 
in the DG (p=0.189), the CA1 area (p=0.276), and the CA3 area (p=0.440). 
 
At 15 months of age, the cholesterol-lowering T09 diet did not alter GLUT-1 
density (Fig. 3d) compared to vehicle diet in AβPP-PS1 mice in the DG 
(p=0.274), the CA1 area (p=0.696), and the CA3 area (p=0.466). 
 
 
Fig. 3. Immunohistochemical analysis of the capillary density (%) in the dentate gyrus 
(DG), CA1 area, and CA3 area of the hippocampus using glucose transporter type-1 
(GLUT-1) antibody. a) Representative image of the GLUT-1 immunohistochemical 
staining. b) Capillary density in 8-month-old wild-type and AβPP-PS1 mice on control 
and cholesterol diet. c) No effect of high cholesterol intake on capillary density in 8-
month-old wild-type and AβPP-PS1 mice. d) Capillary density in 15-month-old AβPP-
PS1 mice on vehicle and T09 diet. Values represent the mean and SEM.  
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Fig. 4. Immunohistochemical analysis of the amount of synaptophysin-immunoreactive 
presynaptic boutons (SIPBs) in the inner and outer molecular layer (IML, OML) of the 
dentate gyrus, stratum radiatum (SR) of the CA1 area and stratum lucidum (SL) of the 
CA3 area of the hippocampus of wild-type and AβPP-PS1 mice. Data are represented 
as relative amount compared to wild-type mice on control diet set as 100% for each 
corresponding age. a) Amount of SIPBs at 8 months of age. b) Amount of SIPBs at 15 
months of age. Values represent the mean and SEM. #trend p=0.060 compared to wild-
type animals, *p<0.05 compared to wild-type animals.  
 
Synaptophysin staining 
We assessed the amount of presynaptic boutons in sections from transgenic 
AβPP-PS1 and wild-type mice (Table 1) that were immunolabeled with a 
monoclonal antibody against synaptophysin.  
Synaptophysin-immunoreactivity was determined in the SR, SL, IML, and 
OML (Fig. 1a, b). 
 
At 8 months of age, there were no differences in the amount of SIPBs between 
AβPP-PS1 and wild-type mice (Fig. 4a) in any region analyzed (p>0.05). At 15 
months of age, AβPP-PS1 animals show significantly increased amount of 
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SIPBs in the IML (p=0.024) and OML (p=0.016) of the DG compared to wild-
type mice (Fig. 4b), as well as a slight, non-significant, increase in the SR of the 
CA1 region (p=0.060). 
 
 
Fig. 5. Immunohistochemical analysis of the effect of high-cholesterol intake and the 
cholesterol-lowering liver X receptor-agonist T0901317 (T09) on the amount of 
synaptophysin-immunoreactive presynaptic boutons (SIPBs) in the inner and outer 
molecular layer (IML, OML) of the dentate gyrus, stratum radiatum (SR) of the CA1 
area and stratum lucidum (SL) of the CA3 area of the hippocampus. Data are 
represented as relative amount compared to wild-type mice on control diet set as 100% 
for each corresponding age. a) Amount of SIPBs in 8-month-old wild-type and AβPP-
PS1 mice on control and cholesterol diet b) Amount of SIPBs in 15-month-old wild-
type and AβPP-PS1 mice on control and cholesterol diet. c) Amount of SIPBs in 15-
month-old AβPP-PS1 mice on vehicle and T09 diet. Values represent the mean and 
SEM. #trend p=0.055 compared to vehicle diet, *p<0.05 compared to control diet.  
 
High cholesterol diet increased the amount of SIPBs at 8 and 15 months of age. 
At 8 months of age, both wild-type and AβPP-PS1 mice on cholesterol diet 
show increased SIPB amount (Fig. 5a) in the SR region (p=0.013) compared to 
the animals on control diet. At 15 months of age, both wild-type and AβPP-PS1 
animals on cholesterol diet show increased amount of SIPBs (Fig. 5b) in the SL 
region of the hippocampus (p=0.027). In AβPP-PS1 mice, the amount of SIPBs 
increased in the OML (p=0.024) and slightly in the IML (p=0.052) between 8 
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and 15 months of age, while the amount of SIPBs remained stable in the SR 
(p=0.711) and SL (p=0.266) during aging.  
 
In the 15-month-old AβPP-PS1 subgroup, T09 decreased the amount of SIPBs 
in the SL (p=0.010) and slightly in the IML (p=0.055) of the hippocampus 
compared to the vehicle diet (Fig. 5c). 
 
Discussion 
  
In this study, we investigated the effects of high dietary cholesterol intake and 
the cholesterol lowering LXR-agonist T0901317 (T09) on capillary density, Aβ 
deposition, and presynaptic boutons in the hippocampus of adult (8 months) and 
aged (15 months) AβPPswe-PS1dE9 mice to elucidate how cholesterol may 
affect neurodegenerative processes in aging and AD. Our results show increased 
amount of SIPBs in the hippocampus of 15-month-old AβPP-PS1 mice 
compared to age-matched wild-type mice, but no difference in the amount of 
SIPBs at 8 months of age. High cholesterol intake increased the amount of 
SIPBs in hippocampal regions both at 8 and 15 months of age, whereas T09 
decreased the amount of SIPBs. However, neither high cholesterol intake [45] 
nor the cholesterol lowering LXR-agonist had any effect on Aβ plaque burden. 
Finally, capillary density remained unaffected by cholesterol intake in AβPP-
PS1 mice. 
 
Synaptic loss is a pathological hallmark of AD, and it is the best correlate of 
cognitive impairment [66-71]. Synaptophysin is a widely used marker for 
quantification of presynaptic terminals, but conflicting results have been 
reported on synaptophysin immunoreactivity (SYN-IR) both in AD patients 
[72-75] and AD mouse models. SYN-IR in transgenic mice that develop Aβ 
plaques has been reported to decline, increase, or not change, apparently 
depending on the interplay of mouse strain, transgene, and age [65, 76-79]. In 
line with our findings of increased amount of SIPBs in hippocampal areas, King 
and Arendash reported significantly higher SYN-IR in the OML of 19-month-
old Tg2576 mice compared to age-matched wild-type mice [80]. Since elevated 
hippocampal SYN-IR at 19 months of age was highly correlated with impaired 
acquisition and spatial reference memory in the Morris water maze (MWM), 
they suggested that elevated hippocampal SYN-IR is a manifestation of 
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pathophysiological synaptic processing within the hippocampus, which might 
involve a compensatory synaptic response that is contributory to altered 
synaptic function and resultant cognitive impairment. Also in the current study, 
we found a correlation between elevated hippocampal amount of SIPBs and 
impaired spatial reference memory in the MWM (as reported in our previous 
study [45]) at 15 months of age, but not at 8 months using Spearman ranked 
correlation coefficients (data not shown). 
 
Recent studies suggest that synapse loss might not be an early event in the 
progression of AD, as a decrease in synapses is only seen in later stages of the 
disease, where pathology is more widespread [81-83]. It has been proposed that 
the pathogenesis of synaptic damage in AD can be divided into two phases: in 
the first “initiation” phase, the disease is characterized by neuronal and synaptic 
dysfunction (loss of plasticity), which triggers a compensatory response to 
maintain synaptic connectivity by, first the formation of new synapses, and later 
on by increasing the size of remaining synapses [68, 80, 81, 84]. In the second 
“propagation” phase, cycles of aberrant sprouting and neuritic disorganization 
eventually result in synapse loss and neurodegeneration [85, 86]. Our results of 
increased normal sized SIPBs (particles ranging between 0.1-4.5 µm
2
) in the 
hippocampus of 15-month-old AβPP-PS1 mice support this hypothesis of a 
compensatory response in the “initiation” phase of AD by the formation of new 
synapses. Therefore, we suggest that our findings of increased amount of SIPBs 
reflect compensatory mechanisms for impaired synaptic function in 
neurodegenerative diseases. Furthermore, high cholesterol intake seems to 
accelerate the synaptic compensatory response, as indicated by the increased 
amount of SIPBs in the CA1 already at 8 months of age. In contrast, the 
cholesterol lowering LXR-agonist decreased the amount of SIPBs at 15 months 
of age, thereby delaying or diminishing (the need for) the synaptic 
compensatory response. 
 
Results from several studies suggest that this compensatory mechanism of 
increased synapse formation is unrelated to the deposition of Aβ plaques [76, 
87]. Aβ plaques are a neuropathological hallmark of AD, but their relationship 
to synapse loss, neurodegeneration, and dementia remains controversial [88-92]. 
Also in this study, we did not observe a relationship between the amount of 
SIPBs and Aβ load in the hippocampus of AβPP-PS1 mice. At 15 months of 
 
2 
41 
 
age, Aβ deposition and increased SIPBs are both concentrated in the DG and 
CA1 area of the hippocampus [45]. 8-month-old AβPP-PS1 mice also show an 
increased amount of Aβ deposition in the DG, although much less compared to 
15-month-old mice [45], but do not show any differences in synaptophysin 
immunoreactivity compared to wild-type mice. Therefore, it appears that Aβ 
deposition precedes the increase in presynaptic boutons in these AβPP-PS1 
mice, but may not be directly involved in the activation of the synaptic 
compensatory response. This observation is fortified by the findings that neither 
high cholesterol intake [45] nor the cholesterol lowering LXR-agonist had any 
effect on Aβ plaque burden, while they respectively increased and decreased the 
amount of SIPBs in hippocampal areas, further supporting the hypothesis that 
the synaptic compensatory response is not mediated via Aβ deposition. Several 
lines of research have suggested that soluble oligomers of Aβ may be 
responsible for synaptic and cognitive dysfunction and loss of synapses [93-98]. 
Since we did not measure soluble Aβ levels in this study, no definite conclusion 
can be drawn about the possible involvement of Aβ oligomers in the synaptic 
compensatory response. Aβ oligomers species can be detected as early as 4 
months of age in the brains of the AβPP-PS1 mice [99], and their damaging 
effect on neuronal membranes/synapses might at long last be the cause of the 
synaptic compensatory response at later stages.  
 
Cholesterol is necessary for the formation of synapses and presynaptic vesicles 
[100-103], and therefore it could be hypothesized that increased dietary intake 
of cholesterol may lead to increased amount of presynaptic boutons. However, 
as reported earlier [45], the 1% cholesterol enriched diet used in the current 
study did not alter total brain cholesterol levels in the 8- and 15-month-old wild-
type and AβPP-PS1 mice compared to the control diet fed animals, suggesting 
that the increase in SIPBs found in the cholesterol fed animals at 8 and 15 
months of age is not due to an increased availability of cholesterol in the brain. 
Since low dietary n-3 PUFA intake has also been implicated in the development 
of AD [32, 104, 105], it could be hypothesized that the present diet effects on 
the number of SIPBs are due to the low n-3 content in the cholesterol diet as 
compared to the control diet. However, the cholesterol diet did not alter the 
relative concentrations of n-3 and n-6 fatty acids in the brains of the 8- and 15-
month-old wild-type and AβPP-PS1 mice compared to the control diet fed 
animals [45], suggesting that the increase in SIPBs found in the cholesterol fed 
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animals at 8 and 15 months of age is not due to n-3 depletion in the brain. 
Moreover, it has been found that dietary n-3 PUFA depletion by itself does not 
impact synaptophysin levels [106, 107].  
 
Since cholesterol is involved in cardiovascular diseases such as hypertension 
and atherosclerosis, it could be hypothesized that high cholesterol intake may 
cause impaired peripheral and cerebral blood flow inducing a hypometabolic 
state of the brain (e.g., energy crisis due to diminished glucose supply), leading 
to neuronal and synaptic dysfunction, and thereby increasing the need for 
synaptic compensation to maintain connectivity. Contrarily, cholesterol-
lowering agents may positively influence cerebral circulation, thereby 
diminishing AD-like pathology. Although we did not observe differences in 
capillary density using GLUT-1 staining in this study, our earlier findings 
showed that relative CBV was decreased in 15-month-old animals on high 
cholesterol diet [45], supporting this hypothesis. Cholesterol accelerated the 
synaptic compensatory response in 8-month-old animals, even though no effect 
of cholesterol on CBV could be detected yet at this age. However, the 
methodology used in that study might not be sensitive enough to detect subtle 
alterations in cerebral vasculature, since changes in CBV are only detectable 
when there is around 20% or more variation in the real CBV [108]. Therefore, 
cholesterol might have already induced subtle alterations in cerebral perfusion 
and vascular health at 8 months of age, which could not be detected with our 
CBV measurements, but still could have led to synaptic dysfunction, and hence 
increased amount of SIPBs to maintain connectivity at this age. 
 
In conclusion, our results suggest a synaptic compensatory response to maintain 
connectivity in the hippocampus of AβPP-PS1 mice, which may be lost during 
aging. Moreover, this synaptic compensatory mechanism seemed to be 
accelerated by high cholesterol intake, while the cholesterol lowering LXR-
agonist diminished the need for compensation, without affecting Aβ deposition. 
We therefore hypothesize that cholesterol may affect neurodegenerative 
processes in aging and AD possibly by influencing cerebral circulation. 
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Chapter 3 
 
 
 
A longitudinal study of cognition, proton MR 
spectroscopy and synaptic and neuronal 
pathology in aging wild-type and  
AβPPswe-PS1dE9 mice 
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Abstract 
 
Proton magnetic resonance spectroscopy (
1
H MRS) is a valuable tool in 
Alzheimer’s disease research, investigating the functional integrity of the brain. 
The present longitudinal study set out to characterize the neurochemical profile 
of the hippocampus, measured by single voxel 
1
H MRS at 7 Tesla, in the brains 
of AβPPSswe-PS1dE9 and wild-type mice at 8 and 12 months of age. 
Furthermore, we wanted to determine whether alterations in hippocampal 
metabolite levels coincided with behavioral changes, cognitive decline and 
neuropathological features, to gain a better understanding of the underlying 
neurodegenerative processes. Moreover, correlation analyses were performed in 
the 12-month-old AβPP-PS1 animals with the hippocampal amyloid-β 
deposition, TBS-T soluble Aβ levels and high-molecular weight Aβ aggregate 
levels to gain a better understanding of the possible involvement of Aβ in 
neurochemical and behavioral changes, cognitive decline and neuropathological 
features in AβPP-PS1 transgenic mice. Our results show that at 8 months of age 
AβPPswe-PS1dE9 mice display behavioral and cognitive changes compared to 
age-matched wild-type mice, as determined in the open field and the (reverse) 
Morris water maze. However, there were no variations in hippocampal 
metabolite levels at this age. AβPP-PS1 mice at 12 months of age display more 
severe behavioral and cognitive impairment, which coincided with alterations in 
hippocampal metabolite levels that suggest reduced neuronal integrity. 
Furthermore, correlation analyses suggest a possible role of Aβ in inflammatory 
processes, synaptic dysfunction and impaired neurogenesis.   
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Introduction 
 
The cause of Alzheimer’s disease (AD) is still largely unknown despite many 
years of extensive research. Since AD is characterized by the presence of 
neurofibrillary tangles and amyloid-β (Aβ) containing aggregates, it has been 
suggested that the Aβ peptide is a major contributor to the neurodegenerative 
processes in AD [1, 2]. The Aβ peptide is derived through the proteolytic 
cleavage of the amyloid-β precursor protein (AβPP) by the β- and γ-secretases, 
BACE and Presenilin (PS), and it accumulates in the brain as neuritic plaques or 
as vascular wall deposits that may cause cerebral amyloid angiopathy (CAA) [3, 
4]. In recent years, research focus has shifted from the insoluble Aβ plaques to 
the soluble oligomeric forms of Aβ as potential culprits of AD. Several lines of 
evidence have indicated that soluble oligomers of Aβ may be responsible for 
synaptic dysfunction and cognitive impairment in AD patients and transgenic 
animal models [5, 6].  
 
Besides Aβ, several other potential causal mechanisms have been proposed 
since the discovery of AD. Large epidemiological studies have revealed that 
many risk factors for AD are vascular-related, causing chronic cerebral 
hypoperfusion and cerebrovascular pathology [7-11], suggesting that vascular 
disorders may play an important role in the onset of AD. Another process that 
has been implicated in the onset and development of AD is chronic 
neuroinflammation [12-14]. Activated astrocytes and microglia are found in 
abundance near Aβ plaques and neurons at risk in AD brains, producing several 
proinflammatory signal molecules, including cytokines, growth factors, 
complement molecules, and adhesion molecules [15, 16]. Furthermore, several 
studies have shown that activated microglia can suppress hippocampal 
neurogenesis [17-19], thereby contributing to cognitive dysfunction in aging 
and AD. 
 
Rather than one sole mechanism, it is much more likely that AD is a 
multifactorial disease, caused by a combination of these factors, compromising 
the functional integrity of the brain. One method of determining the functional 
integrity of the brain, or specific brain regions, is to examine their metabolism 
by using proton magnetic resonance spectroscopy (
1
H MRS). 
1
H MRS allows 
the non-invasive in vivo analysis of certain neurometabolites that indicate 
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biochemical changes in the brain, which are thought to be related to the 
pathological processes at the molecular or cellular level [20, 21]. Altered 
metabolic profiles, detected by 
1
H MRS, have been reported in patients with AD 
[22, 23]. The most consistent findings in AD patients are a reduction of the 
metabolite N-acetylaspartate (NAA) and an elevation of the metabolite myo-
Inositol (mI) in several brain regions including the hippocampus [20, 24, 25]. 
NAA is considered to be a marker of neuronal viability, and a reduction of 
NAA is commonly interpreted as a result of neuronal dysfunction or neuronal 
loss [26]. An elevation of mI has been associated with inflammatory processes, 
since mI is a putative marker for microglia and astrogliosis [27]. Furthermore, 
disturbances of several other metabolites have been found in AD patients, 
although the reports are inconsistent. Some studies identified elevated choline-
containing compounds (tCho) and creatine (Cre) in AD patients [28-30], 
whereas others did not [24, 31].  
 
Similar to AD patients, the most consistent finding in transgenic animal models 
is a reduction of NAA, although this was found to occur at different ages in 
different transgenic species apparently depending on the interplay of mouse 
strain, transgene and disease progression [32]. Furthermore, conflicting results 
have been reported for several other metabolite levels, including mI, taurine 
(Tau) and glutamate (Glu), even within the same transgenic animal model [33]. 
Since 
1
H MRS has great potential for the early diagnosis of AD, monitoring 
disease progression and evaluating the efficacy of potential therapeutic agents, 
it is important to characterize the alterations in neurometabolites in several 
transgenic animals models of AD.  
 
The present longitudinal study set out to characterize the neurochemical profile 
of the hippocampus, measured by 
1H MRS, in the brains of AβPPswe-PS1dE9 
and wild-type mice at 8 and 12 months of age. Furthermore, we wanted to 
determine whether alterations in hippocampal metabolite levels coincided with 
behavioral changes, cognitive decline and neuropathological features, to gain a 
better understanding of the underlying neurodegenerative processes. Moreover, 
the extracellular amyloid-β plaque load, TBS-T soluble Aβ levels and high-
molecular weight Aβ aggregate levels were determined in the brains of the 12-
month-old AβPP-PS1 mice used in the present study [34]. We performed 
correlation analyses with these Aβ measures, to gain a better understanding of 
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the possible involvement of Aβ in the neurochemical and behavioral changes, 
cognitive decline and neuropathological features in the AβPP-PS1 transgenic 
mice. Providing well characterized AD animal models and better understanding 
of the underlying pathological processes in AD is required for the development 
and evaluation of potential therapeutic targets.    
 
Animals, materials and methods 
 
Ethics statement, animals and housing conditions 
The experiments were performed according to Dutch federal regulations for 
animal protection and were approved by Veterinary Authority of the Radboud 
University Nijmegen Medical Centre (Permit Number: RU-DEC2008-126). All 
efforts were made to minimize suffering of the animals.  
 
The AβPPswe-PS1dE9 founders were obtained from Johns Hopkins University, 
Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of Pathology) and a 
colony was established at the Radboud University Nijmegen Medical Centre, 
the Netherlands. In short, mice were created by co-injection of chimeric 
mouse/human AβPPswe (mouse AβPP695 harboring a human Aβ domain and 
mutations K595N and M596L linked to Swedish familial AD pedigrees) and 
human PS1dE9 (deletion of exon 9) vectors controlled by independent mouse 
prion protein promoter elements. The two transfected genes co-integrate and co-
segregate as a single locus [35, 36]. This line (line 85) was originally 
maintained on a hybrid background by backcrossing to C3HeJ × C57BL/6J F1 
mice (so-called pseudo F2 stage). For the present work, the breeder mice were 
backcrossed to C57BL/6J for 9 generations to obtain mice for the current study. 
Throughout the experiment animals were housed in groups of 2-3 mice per cage 
in a controlled environment, homogenously illuminated by normal fluorescent 
room light at 60 lux, with room temperature at 21ºC, and an artificial 12:12h 
light:dark cycle (lights on at 7 a.m.). Food and water were available ad libitum.  
 
Male transgenic AβPP-PS1 mice and their wild-type littermates underwent 
behavioral testing and MRI measurements at 8 months of age, and again at 12 
months of age. In total 25 mice were used: at 8 months of age, 15 wild-type and 
10 AβPP-PS1 mice, and at 12 months of age, 9 wild-type and 7 AβPP-PS1 
mice. Due to some technical problems during the experiments, not all mice 
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could be used for the statistical analyses for each measure. For example, some 
mice were excluded from further analyses of the 
1
H MRS data, since the spectra 
obtained did not meet the inclusion criteria. The body weights of the mice were 
determined one day before the start of the behavioral tests, and again on the day 
of the MRI measurements.  
 
Behavioral analyses 
Behavioral testing was performed in the following order: First open field, 
followed by Morris water maze (MWM), and finally the reversal MWM 
(rMWM). All testing sessions were performed during the light phase (between 9 
a.m. and 5 p.m.) and were recorded for computer-assisted analysis using Noldus 
Ethovision 3.1 software (Noldus Information Technology B.V., Wageningen, 
the Netherlands). All behavioral testing was performed in the same room, 
homogenously illuminated by normal fluorescent room light at 60 lux.   
 
Open field 
To analyze explorative and anxiety-related behavior, mice were placed 
individually in the center of a square open field (50×50×50 cm) with white 
Plexiglas walls, and were observed for 30 minutes. The duration (seconds) of 
walking, wall leaning, rearing, sitting and grooming were scored and later 
analyzed in three blocks of 10 minutes. These open field parameters were 
defined as described previously [37, 38]. In addition, total walking distance, 
mean velocity, and the time spent in the corners respectively the center of the 
open field were obtained from the recorded sessions. The center of the open 
field was defined as a square measuring 20×20 cm, and the corners of the open 
field were defined as the sum of all four 10×10 cm squared corners.  
 
Morris water maze (MWM) 
To investigate spatial learning abilities, mice were tested in the Morris water 
maze (MWM). In short, mice were placed in a pool (104 cm diameter) filled 
with water (21-22°C; made opaque by the addition of milk powder) at different 
starting positions and trained to find a submerged platform by using distant 
visual cues in the room. These spatial cues were present on the four walls of  the 
test room at a distance of 0.5 meter. The 8 cm diameter round platform was 
submerged 1 cm below the water surface and placed in the middle of the 
northeast (NE) quadrant at a distance of 26 cm from the wall. During all trials 
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the researcher was present and always located at the same location in the room 
(close to the SW quadrant). 
 
Acquisition (spatial learning): Mice were trained to find the location of the 
submerged escape platform in 4 acquisition trials (maximal swimming time 120 
s; 30 s on the platform; inter-trial interval 60 min) per day during 4 consecutive 
days. The latency time (s) to find the hidden platform was scored. Starting 
positions during the 4 trails/day were: S, N, E, W. After the 2 min swim the 
mice were placed back in their home cage, and a paper towel was available 
inside the cage for additional drying.  
 
Probe (spatial memory): All mice performed a single probe trial 60 min after the 
last trial on day 4, in which the platform was removed from the swimming pool. 
Mice were allowed to swim for 60 s and the time spent swimming and 
searching in the NE quadrant (where the platform had been located), total 
swimming distance, mean velocity and total number of platform crossings (at 
the former platform location) were recorded.  
 
Reverse Morris water maze (rMWM) 
Four days after the standard MWM probe trial, a simplified reversal MWM [38] 
was performed in which the platform location was changed to the southwest 
(SW) quadrant. In this procedure, earlier platform location need to be encoded 
in the long-term memory. Memory retrieval needs to be selective for the most 
recently learned location, introducing an episodic like component in the spatial 
memory task [39]. Acquisition and probe sessions were performed similar to the 
standard MWM sessions, except that starting positions were E, W, S, and N, the 
target quadrant was SW, and training lasted only 2 days (4 trials/day).  
 
Magnetic resonance spectroscopy (MRS) 
MR measurements were performed on a 7T/300mm horizontal-bore MR 
spectrometer interfaced to a ClinScan console (Bruker Biospin, Ettlingen, 
Germany). An integrated circular polarized transmit 
1
H volume coil 
(200mm/154mm outer/inner diameter) combined with a circular polarized 
receive 
1
H surface coil was used for signal reception. During the experiments, 
mice were anesthetized with 2% isoflurane (Abott, Cham, Switzerland) in a 
mixture of N2O and oxygen (1:2) through a nose cone. Mice were placed in a 
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stereotactic holder to prevent unwanted movement during the scanning. Body 
temperature was maintained  at a physiological level with heated airflow and 
was monitored with a rectal optical temperature probe. Respiration of the 
animal was monitored using a pneumatic cushion respiratory monitoring system 
(Small Animal Instruments Inc, NY, USA). Multislice turbo spin echo images 
in the coronal, transversal and longitudinal orientation were acquired to 
visualize the anatomy and the morphology of the mouse brain structures. 
Imaging parameters were: FOV = 25×25 mm, matrix size = 256×256, slice 
thickness = 0.5 mm, TE = 46 ms, and TR = 3500 ms. 
 
 
Fig. 1. Localization of the spectroscopic volume of 1.0×1.0×1.6 mm placed in the 
hippocampus.  
 
Metabolite concentrations in the hippocampus were determined using proton 
magnetic resonance spectroscopy (
1
H MRS) with a single voxel technique. The 
spectroscopic volume of interest (VOI) of 1.0×1.0×1.6 mm was positioned in 
the hippocampus (Fig. 1), according to the mouse  brain atlas of Franklin and 
Paxinos [40]. Water-suppressed 
1
H-MRS spectra were acquired with the 
stimulated echo acquisition mode (STEAM) sequence with experiment 
parameters: TR = 1500 ms, TE = 13 ms, and 1024 signal averages. Water 
suppression was performed with variable pulse power and optimized relaxation 
delays (VAPOR). For each 
1
H MRS spectrum, a water reference spectrum was 
acquired without water suppression with experiment parameters: TR = 1500 ms, 
TE = 13 ms, and 32 signal averages. Total acquisition time for 
1
H MRS was 27 
min per animal.  
 
Quantification of the metabolite concentration was performed using the Linear 
Combination (LC) model software package (LCModel
TM
, S. Provencher, 
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Oakville, Canada). The quantification algorithm of LCModel
TM 
applies linear 
combinations of model spectra to calculate the best fit of the experimental 
spectrum. The model spectra (dataset of prior knowledge) are calibrated to 
match the magnetic field strength, sequence type and sequence parameters used 
for data acquisition. The final analysis is performed in the frequency domain 
with raw data (free induction decay (FID)) as the input. The unsuppressed water 
spectrum was used to estimate the absolute concentration of the metabolites, of 
which simulated model spectra, generated by NMRSIM
TM
 (Bruker Biospin, 
Ettlingen, Germany) were taken into the analysis.  
 
The criteria to select reliable metabolite concentrations were based on the 
Cramér-Rao lower bounds (CRLB), which are estimates of the S.D. of the fit 
for each metabolite [41] and are also determined by LCModel
TM
. Only fit 
results with a CRLB ≤ 20% were included in the analysis. Concentrations with 
CRLB > 20% were classified as not accurately detectable. Based on these 
criteria, 2 wild-type and 2 AβPP-PS1 mice at 8 months of age, and 2 wild-type 
and 3 AβPP-PS1 mice at 12 months of age were excluded from further analyses, 
since they displayed fit results with CRLB > 20%.  Only metabolite fits that had 
a CRLB ≤ 20% in more than 80% of the spectra were included, and individual 
concentrations with corresponding CRLB > 20% were not taken into account. 
 
Seven metabolites fulfilled the criteria: choline + glycerophosphocholine + 
phosphocholine (tCho), creatine + phosphocreatine (tCre), glutamate (Glu), 
glutamine + glutamate (Glx), myo-Inositol + glycine (mI+Gly), N-
acetylaspartate (NAA) and taurine (Tau). Although the exact function of these 
metabolites are not fully known, NAA is considered to be a marker of neuronal 
viability, tCre is involved in energy metabolism, mI is a putative marker for 
microglia and astrogliosis, and tCho is required for the synthesis of the 
neurotransmitter acetylcholine, and of phosphatidylcholine, a major constituent 
of membranes, and is therefore associated with membrane turnover [27]. 
 
Immunohistochemistry 
Directly following the MR measurements at 12 months of age, mice were 
sacrificed by cervical dislocation, and subsequently brains were removed from 
the skull after decapitation. Brains were weighed and cut mid sagittal for 
immunohistochemistry and biochemistry. One hemisphere was snap frozen in 
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liquid nitrogen and then stored at -80°C, before further biochemical processing. 
The other hemisphere was immersion fixated in 4% paraformaldehyde for 24 
hours, and subsequently stored in 0.1M phosphate buffered saline (PBS, 
pH=7.3)  with 0.01% sodium azide at 4°C. Before cutting, the brain tissue was 
cryoprotected by immersion in 30% sucrose in 0.1M phosphate buffer (PB, 
pH=7.3). Six series of 40 µm coronal sections were cut through the brain using 
a sliding microtome (Microm HM 440 E, Walldorf, Germany). For every 
staining, one complete series with 240 µm distance between the sections was 
used. Immunohistochemistry was performed using standard free-floating 
labeling procedures [42], and was carried out on a shaker table at room 
temperature. 
 
Presynaptic boutons were visualized with anti-synaptophysin antibody 
(1:20,000; monoclonal rabbit anti-synaptophysin clone EP1098Y, Abcam Inc., 
Cambridge, UK) using one subseries of brain sections per animal. 
Synaptophysin is localized in small synaptic vesicles of the presynaptic terminal 
and functions in the regulation of exocytosis [43]. Donkey anti-rabbit biotin 
1:1500 (Jackson ImmunoResearch, West Grove, PA, USA) was used as 
secondary antibody.  
 
Immature neurons were visualized with anti-doublecortin antibody (1:3000; 
polyclonal goat anti-doublecortin (C18): sc-8066, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA) using one subseries of brain sections per animal. 
Doublecortin is a microtubule-associated protein that is exclusively found in 
somata and processes of migrating and differentiating neurons [44, 45]. 
Donkey-goat biotin 1:1500 (Jackson ImmunoResearch, West Grove, PA, USA) 
was used as secondary antibody. 
 
Quantification 
Quantification of presynaptic boutons and doublecortin-positive immature 
neurons was performed using a Zeiss Axioskop microscope, equipped with 
hardware and software from Microbrightfield (Williston, VT, USA). 
Appropriate sections were digitized and photomicrographed using a computer-
assisted analysis system, Stereo Investigator (Microbrightfield). Brain regions 
were based on the mouse brain atlas of Franklin and Paxinos [40].  All 
measurements were performed double blind by two independent raters, and 
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measurements were averaged to obtain a single value per animal for every 
region of interest.  
 
Quantification of synaptophysin-immunoreactive presynaptic boutons 
To determine the amount of synaptophysin-immunoreactive presynaptic 
boutons (SIPBs) in the hippocampus and cortical regions, appropriate sections 
were digitized and photomicrographed using an 100× oil immersion objective. 
SIPBs were analyzed in the hippocampal regions stratum radiatum (SR) of the 
cornu ammonis (CA)1 area, stratum lucidum (SL) of the CA3 area, inner 
molecular layer (IML) and outer molecular layer (OML) of the dentate gyrus 
(DG), and in the cortical regions prelimbic area (PLA) and anterior cingulate 
gyrus (ACg). These regions were chosen because of their large amyloid load in 
AD patients and transgenic mouse models for AD and their importance in 
learning and memory [46, 47]. The ACg was quantified at level +1.10 up to 
+0.86 anterior to bregma using one appropriate section per animal, the PLA was 
quantified at +1.98 up to + 1.78 anterior to bregma using one appropriate 
section per animal, and hippocampal regions were quantified at -2.18 up to -
2.46 posterior to bregma using one appropriate section per animal. For every 
region of interest, two square boxes were placed within the borders of the 
intended area using an 2.5 or 5× objective and images were taken using an 100× 
oil immersion objective (Fig. 2). Images were further processed using ImageJ 
software (U.S. National Institutes of Health, Bethesda, MD, USA) for the 
quantification of the amount of SIPBs. All settings were kept identical for all 
analyses and background levels were equalized using a threshold. Shading 
correction was performed before measurement to correct for irregularities in 
illumination in the microscopic field. A differential contrast enhancement filter 
was applied to selectively enhance weak differences in contrast. To eliminate 
noise signal and to differentiate between possible artifacts and specific SIPBs, 
particles were classified based on size. Particles ranging between 0.1-4.5 µm
2
 
were considered to be normal sized SIPBs [48, 49], and were included for 
statistical analyses. Particles smaller than 0.1 µm
2
 and larger than 4.5 µm
2
 were 
excluded for analyses. The amount of SIPBs/µm
2
 was defined as the number of 
particles divided by the total area analyzed.   
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Fig. 2. Representative image of synaptophysin-immunoreactive presynaptic boutons 
(SIPBs) in the hippocampus of a 12-month-old wild-type mouse. A: In the 
hippocampus SIPBs were analyzed in the inner (yellow) and outer (red) molecular 
layer of the dentate gyrus, stratum radiatum (SR) of the CA1 area (blue), and stratum 
lucidum (SL) of the CA3 area (green). Scale bar=200 μm. B: SIPBs were quantified 
with an 100× objective using image analysis from digitized photomicrographs of the 
synaptophysin-immunoreactivity. Scale bar=10 μm. 
 
Quantification of doublecortin-positive cells  
For the assessment of immature neurons in the hippocampus as a measure for 
neurogenesis (Fig. 3), three alternating sections per animal (at -2.18, -2.46 and -
2.70 posterior to bregma) were digitized and contours were drawn along the 
borders of the hippocampus using an 5× objective using Stereo Investigator 
software. Doublecortin-positive (Dcx+) cells were counted with an 20× 
objective, and the values of the three alternating sections were averaged to 
obtain a single value per animal. 
 
Amyloid-β measures  
The extracellular Aβ load, soluble Aβ levels and insoluble high-molecular 
weight Aβ aggregate levels were determined in the brains of the 12-month-old 
AβPP-PS1 mice, as has been described elsewhere [34]. 
 
In short, Aβ deposits were visualized using WO-2 antibody (1:20,000, mouse 
anti-human Aβ4—10, a kind gift of K. Beyreuther, University of Heidelberg, 
Germany) using one subseries of brain sections per animal. Donkey anti-mouse 
biotin (1:1500, Jackson ImmunoResearch was used as secondary antibody. 
Extracellular Aβ plaque load was quantified in the hippocampus, prelimbic area 
(PLA) and anterior cingulate gyrus (ACg) with a computer-assisted analysis 
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system (Stereo Investigator, Microbrightfield) using Cavalieri’s probe (Fig. 4). 
The Aβ plaque load was defined as the percentage of area covered by Aβ. 
 
 
Fig. 3. Representative image of doublecortin-positive (Dcx+) cells in the hippocampus 
of a 12-month-old wild-type mouse. A: Image taken using an 10× objective. Scale 
bar=100 μm. B: Image taken with an 40× objective. Scale bar=50 μm.   
 
For biochemical Aβ analyses, frozen hemibrains were homogenized in Tris 
buffered saline with 1% Triton X-100 (TBS-T) plus protease inhibitor cocktail 
(Roche Applied Science, Mannheim, Germany) and centrifuged at 16,000g for 
30 min at 4°C.The supernatant, enriched with oligomeric Aβ, was collected and 
stored at -80°C. The pellet, containing mainly highly aggregated Aβ, was 
resuspended in guanidine chloride buffer and extracted for 4 hours. The TBS-T 
and guanidine HCl extracts were analyzed for human Aβ40 and Aβ42 (KHB3442 
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and KH3482, Invitrogen, Karlsruhe, Germany) according to the manufacturers 
protocol. Results were normalized to the protein concentration of the sample 
(Bio-Rad Protein Assay, Bio-Rad Laboratories, Munich, Germany).  
 
 
Fig. 4. Representative images of the amyloid-β plaque load in the brain of a 12-month-
old AβPP-PS1 mouse. A: The Aβ plaque load was quantified in the prelimbic area at 
level +1.98 up to + 1.78 anterior to bregma, B: in the anterior cingulate gyrus at level 
+1.10 up to +0.86 anterior to bregma, and C:  in the dentate gyrus (DG), CA1 and CA3 
areas of the hippocampus at level -2.18 up to -2.46 posterior to bregma, using one 
appropriate section per animal. Images were taken using an 2.5× objective. Scale 
bar=500 μm. 
 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed with SPSS for windows 
16.0 software (SPSS Inc. Chicago, IL, USA). The repeated measures ANOVA 
was used for the open field parameters (with the repeated measure: time) and 
the acquisition phase of the MWM and rMWM (with the repeated measure: trial 
block), followed by a Bonferroni post hoc to analyze possible interactions 
between time/trial block and genotype. If interactions between time/trial block 
and genotype (between-group-factors) were present, the data were split for the 
concerning factor and thereafter analyzed again with the repeated measures 
ANOVA. Multivariate ANOVA’s were conducted with between group factor: 
genotype, to analyze possible differences between wild-type and AβPP-PS1 
mice in the probe trials of the MWM and rMWM, the body weight, brain 
weight, metabolite concentrations, and the amount of SIPBs and immature 
neurons. Aging effects in the AβPP-PS1 mice are represented as relative values 
compared to the wild-type mice (set as 100%) of the corresponding age-group, 
and were analyzed with between group factor: age. Correlation analyses with 
the Aβ measures were performed using bivariate Pearson’s correlation method. 
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For clarity reasons, F-values are not displayed. Statistical significance was set at 
p<0.05. 
 
Results 
 
Body and brain weight 
All mice were weighed one day before starting the behavioral test battery and 
again on the day of the MR measurements. Since body weights within the 
groups did not change significantly between those two time points, the mean 
weight was used for further statistical analyses. Both at 8 months and 12 months 
of age, AβPP-PS1 mice had a tendency towards a higher body weight than wild-
type mice, but it did not reach statistical significance. At 8 months of age, 
overall mean body weight of the AβPP-PS1 mice was 29.79 ± 0.65 g compared 
to 28.24 ± 0.42 g of the wild-type mice (p=0.051). At 12 months of age, overall 
mean body weight of the AβPP-PS1 mice was 33.03 ± 1.23 g compared to 
30.13 ± 0.76 g of the wild-type mice (p=0.060).  
 
Both relative and absolute brain weights were not affected by genotype 
(p=0.812 and p=0.165 respectively). Overall mean brain weight of the AβPP-
PS1animals was 0.49 ± 0.01 g, which was 1.46 ± 0.08% of their total body 
weight. Overall mean brain weight of the wild-type mice was 0.45 ± 0.02 g, 
which was 1.49 ± 0.07% of their total body weight.  
 
Behavioral analyses 
Open field 
During the 30 min observation at 8 months of age, both in wild-type and AβPP-
PS1 mice the time spent walking (Fig. 5A; p<0.001) and wall leaning (Fig. 5I; 
p=0.038) decreased, as well as the distance traveled (Fig. 5G; p<0.001) and 
mean velocity (p<0.001). Accordingly, the time spent sitting (Fig. 5C; p<0.001) 
increased during the 30 min observation period. The time spent rearing (Fig. 
5E; p=0.632) and grooming (Fig. 5K; p=0.263), as well as the time spent in the 
center (Fig. 5M; p=0.673) and in the corners (Fig. 5O; p=0.106) of the open 
field remained constant over time.  
 
8-month-old AβPP-PS1 mice were more active in the open field than wild-type 
mice: AβPP-PS1 mice traveled a longer distance (Fig. 5G; p=0.048) and had a  
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Fig. 5. Open field behavior in AβPP-PS1 and wild-type mice at 8 and 12 months of age. 
Different open field parameters were measured within a 30 min period, and analyzed 
in three 10 min trial blocks. A and B: AβPP-PS1 mice (n=5) did not differ from wild-
type mice (n=8) at 8 months of age (A), but spent slightly less time walking than wild-
type mice at 12 months of age, # trend p=0.058 (B). C and D: The duration of sitting 
was similar among wild-type and AβPP-PS1 mice at 8 (C) and at 12 months of age (D). 
E and F: AβPP-PS1 mice spent less time rearing than wild-type mice at 8 months of 
age, * p<0.05 (E), but did not differ from wild-type mice at 12 months of age (F). G and 
H: AβPP-PS1 mice traveled a longer distance than wild-type mice at 8 months of age, * 
p<0.05 (G), but did not differ from wild-type mice at 12 months of age (H). I and J: The 
duration of wall leaning was similar among wild-type and AβPP-PS1 at 8 months of 
age (I), but was increased in AβPP-PS1 mice at 12 months of age, * p<0.05 (J). K and 
L: Both at 8 (K) and 12 months of age (L), the time spent grooming was similar among 
wild-type and AβPP-PS1 mice. M and N: AβPP-PS1 mice did not differ from wild-type 
mice at 8 months of age (M), but spent less time in the center of the open field than 
wild-type mice at 12 months of age, * p<0.05 (N). O and P: AβPP-PS1 mice (n=7) spent 
more time in the corners of the open field than wild-type animals (n=9) at 12 months of 
age, * p<0.05 (P), but did not differ from wild-type at 8 months of age (O).  
 
higher mean walking speed than wild-type mice (p=0.043; wild-type 5.6 ± 0.3 
cm/s, AβPP-PS1 6.9 ± 0.5 cm/s), although the time spent walking and sitting 
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did not differ from the wild-type animals (Fig. 5A; p=0.293 and Fig. 5C; 
p=0.964 respectively). AβPP-PS1 mice also spent less time rearing than wild-
type mice (Fig. 5E; p=0.043). No differences  were observed between the 
genotypes in the time spent wall leaning (Fig. 5I; p=0.642)  and grooming (Fig. 
5K; p=0.259), and in the time spent in the center (Fig. 5M; p=0.274) and 
corners of the open field (Fig. 5O; p=0.189). 
 
Like at 8 months of age, the time spent walking (Fig. 5B; p=0.001), the distance 
traveled (Fig. 5H; p=0.001), and mean velocity (p=0.001) decreased over time 
in both wild-type and AβPP-PS1 mice at 12 months of age. In contrast, the time 
spent grooming increased at this age during the 30 min open field (Fig. 5L; 
p=0.009), whereas the time spent sitting (Fig. 5D; p=0.104) and wall leaning 
(Fig. 5J; p=0.443) remained constant throughout the observation period. Again, 
the time spent rearing (Fig. 5F; p=0.866), as well as the time spent in the center 
(Fig. 5N; p=0.389) and the corners (Fig. 5P; p=0.465) of the open field did not 
change over time.  
 
Compared to wild-type mice, 12-month-old AβPP-PS1 mice spent more time 
wall leaning (Fig. 5J; p=0.041), and slightly less time walking (Fig. 5B; 
p=0.058), although the distance traveled (Fig. 5H;  p=0.859) and mean velocity 
of the AβPP-PS1 mice did not differ from the wild-type animals (p=0.886; wild-
type 4.7 ± 0.3 cm/s, AβPP-PS1 4.7± 0.5 cm/s). Furthermore, AβPP-PS1 mice 
spent more time in the corners (Fig. 5P; p=0.001), and less time in the center of 
the open field (Fig. 5N; p=0.021) as compared to wild-type mice. At this age, 
no differences were observed between the genotypes in the time spent sitting 
(Fig. 5D; p=0.349), rearing (Fig. 5F; p=0.359) and grooming (Fig. 5L; 
p=0.564). 
 
Aging effects in the AβPP-PS1 mice were analyzed as relative values compared 
to the wild-type mice (set as 100%) of the corresponding age. With age, the 
time that AβPP-PS1 mice spent walking decreased, from 105.7%  ± 3.8 at 8 
months of age to 79.5% ± 7.1 at 12 months of age (p=0.016), indicating 
decreased activity as disease progresses or decreased restlessness due to 
habituation to the open field. However, the traveled distance and mean velocity 
did not change with age (p=0.105) as compared to age-matched wild-type 
animals (data not shown). Over time, AβPP-PS1 mice also spent more time in 
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the corners of the open field (p=0.018). Time spent in the corners of the open 
field increased from 115.7% ± 7.1 at 8 months of age to 169.3% ± 15.1 at 12 
months of age, indicating increased anxiety-related behavior as disease 
progresses. The time spent sitting (p=0.786), rearing (p=0.481), grooming 
(p=0.086), wall leaning (p=0.087) and the time spent in the center of the open 
field (p=0.116) did not change between 8 and 12 months of age (data not 
shown).  
 
Altogether, these data show increased activity but decreased active exploration 
(rearing) in 8-month-old AβPP-PS1 mice compared to wild-type mice. This 
increased activity and decreased rearing disappear at 12 months of age, due to 
habituation to the open field and/or the older age of the animals. Instead, 12-
month-old AβPP-PS1 mice show increased anxiety-related behavior compared 
to wild-type mice, as indicated by the increased time spent in the corners and 
decreased time spent in the center of the open field, and increased time spent 
wall leaning, which is a type of exploration but with an anxiety-related 
behavioral component [38, 50]. 
 
Morris water maze (MWM) 
Both AβPP-PS1and wild-type mice showed a decrease in escape latency during 
training at 8 months of age (Fig. 6A; p<0.001). However, wild-type mice 
learned to find the location of the hidden platform faster than the AβPP-PS1 
mice, indicated by a significant time×genotype interaction (p=0.009). Overall 
escape latencies tended to differ between wild-type and AβPP-PS1 (p=0.060) at 
8 months of age, although it did not reach statistical significance. Especially on 
day 2 of the acquisition phase, AβPP-PS1 mice showed higher escape latencies 
than wild-type mice, suggesting that spatial learning might be mildly affected at 
this age.  
 
During the probe trial at 8 months of age, no differences were found between 
wild-type and AβPP-PS1 mice in the time spent in the platform quadrant (NE) 
(Fig. 6C; p=0.266). However, only wild-type mice deviated from 25% chance 
performance level, suggesting that only wild-type mice showed good 
memorization of the platform quadrant. Furthermore, AβPP-PS1 mice crossed 
the exact platform location less often than wild-type mice (Fig. 6D; p=0.019), 
reflecting impaired spatial memory for the exact platform location. No 
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significant differences were found between the genotypes in the total distance 
moved (Fig. 6B; p=0.056) and mean swim velocity (p=0.078; wild-type 17.5 ± 
1.2 cm/s, AβPP-PS1 20.4 ± 0.5 cm/s) during the probe trial, although the AβPP-
PS1 mice tended to be slightly more active than the wild-type animals. 
 
Both wild-type and AβPP-PS1 animals learned to find the platform during 
acquisition at 12 months of age (Fig. 6E), as indicated by a decrease in latency 
over trials (p<0.001). Escape latencies did not differ between the wild-type and 
AβPP-PS1 mice (p=0.525), indicating that spatial learning was no longer 
affected by genotype at this age, most likely due to the repetition of this task.  
 
AβPP-PS1 mice spent less time in the NE target quadrant compared to their 
wild-type littermates at 12 months of age (Fig. 6G; p=0.013), although both 
groups performed above 25% chance level, indicating memorization of the 
platform quadrant. No differences were found between the genotypes in the 
frequency of platform crossings (Fig. 6H; p=0.131), the total distance moved 
(Fig. 6F; p=0.221) and mean swim velocity (p=0.232; wild-type 17.2 ± 0.8 
cm/s, AβPP-PS1 18.7 ± 0.8 cm/s) during the probe trial.  
 
Aging effects in the AβPP-PS1 mice were analyzed as relative values compared 
to the wild-type mice (set as 100%) of the corresponding age. Escape latencies 
during training in the MWM decreased with age (p=0.001), such that the 
average escape latency of all 4 days was 128.2% ± 6.5 at 8 months of age 
relative to age-matched wild-type animals and 88.2% ± 7.2 at 12 months of age, 
indicating that 12-month-old AβPP-PS1 mice found the location of the hidden 
platform faster than 8-month-old AβPP-PS1 mice, most likely due to 
habituation to and repetition of the MWM task at 12 months of age. The time 
spent in target NE quadrant (p=0.380), the number of platform crossings  
(p=0.167), the distance moved (p=0.121), and mean swim velocity (p=0.173) 
did not change between 8 and 12 months of age (data not shown).  
 
Reverse Morris water maze (rMWM) 
Both wild-type and AβPP-PS1 animals learned to find the new SW platform 
location during acquisition at 8 months of age (Fig. 7A), as indicated by a 
decrease in latency over trials (p=0.046).  Overall escape latencies did not differ 
between wild-type and AβPP-PS1 (p=0.693).  
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Fig. 6. Morris water maze learning and memory in 8- and 12-month-old wild-type and 
AβPP-PS1 mice. Spatial learning was measured in a 4-day acquisition phase, by 
determining the latency to find a hidden platform in the NE quadrant. Spatial memory 
was tested in the probe phase in which the percentage of time spent in the target NE 
quadrant was measured and the total number of platform crossings (where formerly 
the platform had been located). A: Both 8-month-old wild-type (n=14) and AβPP-PS1 
mice (n=10) showed a decrease in latency during training. Overall latencies tended to 
be higher in AβPP-PS1 mice, although it did not reach statistical significance, # trend 
p=0.060. B: During the probe trial, the 8-month-old AβPP-PS1 mice traveled a slightly 
longer distance than wild-type animals, although it did not reach statistical 
significance, # trend p=0.056. C: No differences were observed between the 8-month-
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old mice in the percentage of time spent in the target NE quadrant, although only wild-
type mice deviated from 25% chance performance level. D: 8-month-old AβPP-PS1 
mice crossed the exact platform location less often than wild-type mice, * p<0.05. E: 
Both 12-month-old wild-type (n=9) and AβPP-PS1 mice (n=7) showed a decrease in 
latency during training. Overall latencies did not differ between the genotypes. F: 
During the probe trial, no differences were observed in the distance moved between 12-
month-old wild-type and AβPP-PS1 mice. G: 12-month-old AβPP-PS1 mice spent less 
time in the target NE quadrant, although both groups performed above 25% chance 
level,* p<0.05. H: No differences were observed between the 12-month-old mice in the 
frequency of platform crossings.  
 
No differences were found between wild-type and AβPP-PS1 in the time spent 
in the SW quadrant during the probe trial at 8 months of age (Fig. 7C; p=0.271). 
However, only wild-type mice deviated from 25% chance performance level, 
suggesting that only wild-type mice showed good memorization of the new 
platform quadrant. No differences were found between the genotypes in the 
number of platform crossings (Fig. 7D; p=0.187), total distance moved (Fig. 
7B; p=0.129) and mean swim velocity (p=0.111; wild-type 17.6 ± 1.0 cm/s, 
AβPP-PS1 19.8 ± 0.7 cm/s) during the probe trial.  
 
At 12 months of age, the wild-type animals showed a significant decrease in 
escape latency over time in the acquisition phase (Fig. 7E; p=0.001), indicating 
spatial learning. In contrast, escape latencies did not change over time in the 
AβPP-PS1 mice at 12 months of age (p=0.649), due to unexpected low latencies 
at the initial trials. In spite of that, there was no difference in average escape 
latencies between AβPP-PS1 and wild-type animals (p=0.134).  
 
During the probe trial at 12 months of age, AβPP-PS1 mice tended to spent less 
time in the target SW quadrant than wild-type mice (Fig. 7G; p=0.066), 
although it did not reach statistical significance. Furthermore, only wild-type 
mice deviated from 25% chance performance level, suggesting that only wild-
type mice showed good memorization of the new platform quadrant. AβPP-PS1 
mice also crossed the former platform location significantly less often than 
wild-type animals (Fig. 7H; p=0.029), reflecting impaired spatial memory as 
well. No significant differences were found between the genotypes in the total 
distance moved (Fig. 7F; p=0.066) and mean swim velocity (p=0.066; wild-type 
17.1 ± 1.0 cm/s, AβPP-PS1 19.9 ± 0.9 cm/s), although the AβPP-PS1 mice 
tended to be slightly more active than the wild-type animals.   
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Fig. 7. Reverse Morris water maze learning and memory in 8- and 12-month-old wild-
type and AβPP-PS1 mice. Spatial learning with an extra episodic memory component 
was measured in a 2-day acquisition phase, by determining the latency to find a hidden 
platform in the SW quadrant. Spatial memory was tested in the probe phase in which 
the percentage of time spent in the target SW quadrant was measured and the total 
number of platform crossings (where formerly the platform had been located). A: Both 
8-month-old wild-type (n=14) and AβPP-PS1 mice (n=10) showed a decrease in latency 
during training. Overall latencies did not differ between the genotypes. B: During the 
probe trial, the 8-month-old wild-type and AβPP-PS1 mice traveled a similar distance. 
C: No differences were observed between the 8-month-old mice in the percentage of 
time spent in the target SW quadrant, although only wild-type mice deviated from 25% 
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chance performance level. D: No differences were observed between the 8-month-old 
mice in the frequency of platform crossings E: Only 12-month-old wild-type mice (n=9) 
showed a decrease in latency during training. 12-month-old AβPP-PS1 mice (n=7) did 
not improve their performance during acquisition. However, overall latencies did not 
differ between the genotypes. F: During the probe trial, the 12-month-old AβPP-PS1 
mice traveled a slightly longer distance than wild-type animals, although it did not 
reach statistical significance, # trend p=0.066. G: 12-month-old AβPP-PS1 mice tended 
to spent less time in the target SW quadrant, although it did not reach statistical 
significance, # trend p=0.066. Only wild-type animals deviated from 25% chance 
performance level. H: 12-month-old AβPP-PS1 mice crossed the exact former platform 
location less often than wild-type animals, * p<0.05. 
 
Aging effects in the AβPP-PS1 mice were analyzed as relative values compared 
to the wild-type mice (set as 100%) of the corresponding age. Escape latencies 
during training in the rMWM did not change with age and repetition of the 
rMWM test (p=0.123). 
 
During the probe trial,  the swim distance increased with age (p=0.049) from 
111.4% ± 3.7 at 8 months to 116.2% ± 5.2 at 12 months, indicating 
hyperactivity as disease progresses. The time spent in the SW target quadrant 
(p=0.165) and number of platform crossings (p=0.456) did not change between 
8 and 12 months of age (data not shown). 
 
Magnetic resonance spectroscopy (MRS) 
No differences were observed in the neurochemical profile of the hippocampus 
of 8-month-old wild-type and AβPP-PS1 mice (Fig. 8C). Wild-type and AβPP-
PS1 mice had similar concentrations of choline-containing compounds (tCho; 
p=0.514), creatine and phosphocreatine (tCre; p=0.712), glutamate (Glu; 
p=0.785), glutamine and glutamate (Glx; p=0.181), myo-Inositol and glycine 
(mI+Gly; p=0.272), N-acetylaspartate (NAA; p=0.456), and taurine (Tau; 
p=0.245).    
 
At 12 months of age, AβPP-PS1 mice had significantly lower concentrations of 
NAA (p=0.012) than wild-type mice, indicating decreased neuronal health 
and/or increased neurodegeneration (Fig. 8D). No differences were observed 
between wild-type and AβPP-PS1 mice in the levels of tCho (p=0.123), tCre 
(p=0.986), Glu (p=0.162), Glx (p=0.807), mI+Gly (p=0.082) and Tau 
(p=0.804). 
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Fig. 8. Neurochemical profile of the hippocampus measured by single voxel 
1
H MRS at 
7 Tesla. A: Representative 
1
H MR spectra acquired from the hippocampus of a 12-
month-old wild-type mouse. B: Representative 
1
H MR spectra acquired from the 
hippocampus of a 12-month-old AβPPswe-PS1dE9 transgenic mouse. Notice the 
decreased NAA peak in AβPP-PS1compared to wild-type. C: At 8 months of age, no 
differences between wild-type (n=13) and AβPP-PS1 mice (n=8) were observed in the 
hippocampal neurochemical profile. D: At 12 months of age, AβPP-PS1 mice (n=4) had 
significantly lower concentrations of NAA than wild-type mice (n=7), * p<0.05. 
tCho=choline-containing compounds; tCre=creatine and phosphocreatine; 
Glu=glutamate; Glx=glutamine and glutamate; mI+Gly=myo-Inositol and glycine; 
NAA=N-acetylaspartate; Tau=taurine.  
 
Aging effects in the AβPP-PS1 mice were analyzed as relative values compared 
to the wild-type mice (set as 100%) of the corresponding age. With age, the 
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concentration of NAA decreased from 94.7% ± 6.0 at 8 months of age to 65.1% 
± 8.4 at 12 months of age (p=0.017), indicating decreased hippocampal 
neuronal viability as disease progresses.  
 
Immunohistochemistry 
 
At 12 months of age, there were no significant differences in the amount of 
synaptophysin-immunoreactive presynaptic boutons (SIPBs) between AβPP-
PS1 and wild-type mice (Fig. 9) in any of the regions analyzed (p>0.10).  
Furthermore, no significant differences were found in the amount of 
doublecortin-positive (Dcx+) immature neurons between 12-month-old AβPP-
PS1 and wild-type mice (p=0.082; wild-type 9.2 ± 1.5 Dcx+ cells, n=6; AβPP-
PS1 5.5 ± 0.3 Dcx+ cells, n=4).   
 
 
Fig. 9. Amount of  synaptophysin-immunoreactive presynaptic boutons (SIPBs) per 
µm
2 
in 12-month-old wild-type and AβPP-PS1 mice. The amount of SIPBs were 
quantified in the hippocampal  inner (IML) and outer molecular layer (OML) of the 
dentate gyrus, the stratum radiatum (SR) of the CA1 area, and the stratum lucidum 
(SL) of the CA3 area, and in the cortical prelimbic area (PLA) and anterior cingulate 
gyrus (ACg). No differences in the amount of SIPs between 12-month-old wild-type 
(n=9) and AβPP-PS1 mice (n=6) were observed in any region analyzed (p>0.10). 
 
Amyloid-β measures 
Correlation analyses with the extracellular amyloid-β deposition, TBS-T soluble 
Aβ levels and high-molecular weight Aβ aggregate levels found in the brains of 
12-month-old AβPP-PS1 mice [34] were performed using bivariate Pearson’s 
correlation method. 
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No significant interactions were found between any of the Aβ measures and the 
open field data (p>0.05), and the MWM and rMWM acquisition and probe data 
(p>0.05).  
 
A significant negative correlation was found between the Aβ plaque load in the 
hippocampus and the tCho levels measured with 
1
H MRS (p=0.005; R=-0.995). 
Furthermore, increased mI+Gly levels significantly correlated with increased 
levels of the high-molecular weight Aβ40 (p=0.007; R=0.993) and Aβ42 
(p=0.003; R=0.997) aggregates. 
 
A significant negative correlation was found between the TBS-T soluble Aβ42 
levels and the amount of SIPBs in the PLA region (p=0.040; R=-0.895). In 
contrast, positive correlations were found between the amount of SIPBs in the 
SR region of the hippocampus and the levels of high-molecular weight Aβ40 
(p=0.009; R=0.962) and Aβ42 (p=0.027; R=0.920) aggregates.  However, these 
correlations between the amount of SIPBs and Aβ measures did no longer reach 
significance when Bonferroni’s correction for multiple comparisons was applied 
(p>0.008).   
 
Finally, we found a significant negative correlation between the amount of 
immature neurons and the level of high-molecular weight Aβ40 (p=0.041; R=-
0.959) aggregates, suggesting impaired neurogenesis with increasing levels of 
Aβ40 aggregates. 
 
Discussion 
 
The present longitudinal study set out to characterize the neurochemical profile 
of the hippocampus, measured by 
1H MRS, in the brains of AβPPSswe-PS1dE9 
mice at 8 and 12 months of age as compared to age-matched wild-type 
littermates. Furthermore, we wanted to determine whether alterations in 
hippocampal metabolite levels coincided with behavioral changes, cognitive 
decline and neuropathological features, to gain a better understanding of the 
underlying neurodegenerative processes. Moreover, we determined the 
extracellular amyloid-β load, TBS-T soluble Aβ levels and high-molecular 
weight Aβ aggregate levels of the 12-month-old AβPP-PS1 mice in our 
laboratory [34]. We performed correlation analyses using bivariate Pearson’s  
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correlation method to gain a better understanding of the possible involvement of 
Aβ in neurochemical and behavioral changes, cognitive decline and 
neuropathological features in AβPP-PS1 transgenic mice.  
 
In agreement with previous results from our lab [38], 8-month-old AβPP-PS1 
mice already display behavioral changes in the open field, such as increased 
locomotor activity and decreased exploration. The increased activity is a 
specific characteristic of many AβPP transgenic mice [51-54] and may be 
explained as a result of elevated anxiety levels [53, 55] or impaired habituation 
learning [51, 52]. In our view increased anxiety is most likely, since the AβPP-
PS1 mice also showed less rearing behavior (exploring the environment) 
compared to age-matched wild-type mice. Curiosity motivates mice to explore a 
novel environment, but this exploratory drive is in conflict with fear of the 
unknown. Moreover, 12-month-old AβPP-PS1 mice also showed increased 
anxiety-related behavior, as indicated by the increased time spent in the corners 
of the open field, increased time spent wall leaning, and decreased time spent in 
the center of the open field (i.e. anxious mice prefer the borders of the open 
field). Increased anxiety and restlessness, as noticed as hyperactivity in several 
AβPP transgenic mouse models, also occur in AD patients [56, 57]. However, 
activity levels decreased between 8 and 12 months of age both in AβPP-PS1 
and wild-type mice, suggesting increased familiarity with the open field even 
after 4 months.   
 
In line with previous results from our lab, AβPP-PS1 mice also showed 
impaired performance in the MWM and rMWM both at 8 and 12 months of age  
as compared to wild-type littermates [38], which might suggest visuo-spatial 
learning and memory deficits. Noteworthy are the relatively low escape 
latencies of both AβPP-PS1 and wild-type mice during the initial trials of the 
rMWM training at 8 months. Although 8-month-old wild-type mice displayed 
good short-term spatial memory for the NE platform location during the probe 
of the MWM, it appears that this information might not have been sufficiently 
consolidated in the long-term memory since they displayed more “random” 
search during the initial rMWM trials (resulting in lower escape latencies) than 
expected if animals had good long-term memory for the former platform 
location. One possible explanation could be that the MWM task as used in the 
current study was slightly too difficult to optimally master within 4 days of 
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training. For mice, a MWM pool with a diameter of 120 cm and a platform of 
10-12 cm in diameter (or even larger) is commonly used, resulting in a search 
area to target size of 144:1 to 100:1 (or even lower). In the current study, we 
used a pool with a diameter of 104 cm and a platform of 8 cm in diameter, 
resulting in a search area to target size of 169:1, thereby increasing the MWM 
task difficulty [58, 59]. At 12 months of age, when the mice were exposed to 
the MWM for the second time, wild-type mice not only showed a higher 
preference for the NE target quadrant during the probe than at 8 months of age, 
they also persevered in searching the original platform location during the initial 
trials in the rMWM, suggesting that habituation to, and repetition of the MWM 
task resulted in enhanced short-term, and formation of long-term memory for 
the platform location in wild-type mice.  
 
Standard measures of performance in the MWM as used in the current study, 
such as escape latency during acquisition training, time spent in platform 
quadrant and the number of platform crossings during a probe trial, may depend 
on other factors than visuo-spatial learning ability and memory capacity alone. 
Longer escape latencies during spatial navigation may be caused by slower 
swim speed, although we do not expect this to be a confounding factor, since 
wild-type and AβPP-PS1 mice did not display any significant differences in 
swim speed during the probe trials at any age. Furthermore, several groups have 
reported no differences in swim speed during MWM training between 
C57BL/6J wild-type and AβPPswe-PS1dE9 mice at any age tested [60-63]. 
Longer escape latencies during spatial navigation may also be caused by the use 
of certain, less efficient, search strategies, such as a constant random search of 
the entire surface area of the pool, which would indicate a complete lack of 
spatial learning abilities, or by persistent performance of a less efficient than 
spatial (direct) search strategy, such as circling the pool at a certain distance 
from the wall to find the platform [64-67]. In this strategy, mice have not used 
the spatial cues to learn the location of the platform , although such a strategy 
would result in a successful location of the escape platform during training. To 
our knowledge, the search strategies used by AβPP-PS1 mice in the MWM have 
not be determined yet and should be addressed in future studies to further 
characterize the cognitive deficits in the AβPPswe-PS1dE9 mouse model. 
However, our results might imply that the AβPP-PS1 mice made use of a 
random or persistent non-spatial search strategy to locate the platform during 
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acquisition training, since AβPP-PS1 mice showed slightly longer escape 
latencies to find the hidden platform in the MWM at 8 months of age, searched 
the target quadrant during the probe trials at chance level (~25% or less) and 
they crossed the former platform location less often than wild-type mice. In 
contrast, wild-type mice performed well above chance level during the probe 
trials, indicating memorization of the platform location, which might imply that 
they made use of a more spatially precise search strategy. Furthermore, the high 
latency of the wild-type mice during the first 2 acquisition trials of the reversal 
task at 12 months of age might indicate that they learned and remembered the 
original NE platform location quite well, and persevered in searching the 
original platform location during those initial trials in the reversal MWM. The 
12-month-old AβPP-PS1 mice in contrast did not improve their performance 
over time in the reversal task, but seemed to perform better in the first 2 
acquisition trials compared to their wild-type littermates. Again this might 
imply that the AβPP-PS1 mice made use of a more random non-spatial search 
strategy and thereby coincidentally reaching the platform faster than their wild-
type littermates. 
 
This is in line with a study by  O’Leary and Brown, in which the search 
strategies used by 16-month-old AβPP-PS1and wild-type mice during visuo-
spatial navigation in the Barnes Maze were analyzed [68]. 16-month-old AβPP-
PS1 mice predominantly made use of a random search strategy to locate the 
escape hole in the Barnes Maze, whereas wild-type mice predominantly made 
use of a spatial (direct and accurate) search strategy. Similar results have been 
found for the search strategies used by the TgCRND8 transgenic AβPP mouse 
model in the MWM test [64, 65] . Moreover, it was shown that C57BL6 mice 
treated with Temozolomide (TMZ) to suppress adult hippocampal neurogenesis, 
displayed a delayed (or even absent) use of directed and place specific search 
patterns in the (reversal) MWM test compared to untreated mice, suggesting 
that hippocampal neurogenesis is necessary for adding flexibility to some 
hippocampus-dependent qualitative parameters of learning [67]. Although we 
did not observe a significant decrease in the amount of immature neurons in the 
12-month-old AβPP-PS1 mice in our current study, reduced hippocampal 
neurogenesis has been found previously in AβPP-PS1 mice [69-71] and in AD 
patients [72, 73], and might underlie some aspects of the cognitive deficits in 
AD.  
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Synaptic loss is a pathological hallmark of AD, and it is the best correlate of 
cognitive impairment [2, 74-76]. Synaptophysin is a widely used marker for 
quantification of presynaptic terminals, but conflicting results have been 
reported on synaptophysin immunoreactivity (SYN-IR) both in AD patients 
[77-80] and AD mouse models. SYN-IR in transgenic mice that develop Aβ 
plaques has been reported to decline, increase, or not change, apparently 
depending on the interplay of mouse strain, transgene, age, and disease 
progression [49, 81-86]. In the current study, no changes were found in the 
amount of presynaptic boutons at 12 months of age, similar to earlier reports of 
no changes in the amount of presynaptic boutons in 8-month-old AβPP-PS1 
mice [42], but in contrast to the increased amount of presynaptic boutons found  
in the hippocampus of 15-month-old AβPP-PS1 mice, which was suggested to 
reflect a synaptic compensatory response to maintain connectivity and preserve 
cognitive functioning [42]. However, we did find positive correlations between 
the levels of high-molecular weight Aβ40 and Aβ42 aggregates and the amount of 
SIPBs in the SR region of the hippocampus in the 12-month-old AβPP-PS1 
mice, which might suggest a possible involvement of Aβ aggregates in the 
initiation of this synaptic compensatory response. In contrast, a negative 
correlation was found between the TBS-T soluble Aβ42 levels and the amount of 
SIPBs in the PLA region, which might suggest a possible involvement of 
soluble Aβ oligomers in synaptic loss. However, these correlations between the 
amount of SIPBs and Aβ measures did no longer reach significance when 
Bonferroni’s correction for multiple comparisons was applied. Since the 
necessity of using the conservative Bonferroni’s adjustment for multiple 
correlations is still debated [87-89], these findings must be interpreted with 
caution.   
 
Recent studies suggest that synapse loss might not be an early event in the 
progression of AD, as a decrease in synapses is only seen in later stages of the 
disease, where especially tau pathology is more widespread [90-92]. It has been 
proposed that the pathogenesis of synaptic damage in AD can be divided into 
two phases: in the first phase, the disease is characterized by neuronal and 
synaptic dysfunction (loss of plasticity), which triggers a compensatory 
response to maintain connectivity by, first the formation of new synapses, and 
later on by increasing the size of remaining synapses [75, 86, 90, 93]. In the 
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second phase, cycles of aberrant sprouting and neuritic disorganization 
eventually result in synapse loss and neurodegeneration [94, 95].  It could be 
hypothesized that the decreased hippocampal neuronal viability found in our 12-
month-old AβPP-PS1 mice, together with increasing levels of Aβ40 and Aβ42 
oligomers and aggregates, contribute to synaptic and neuronal dysfunction, 
which might trigger a synaptic compensatory response that in time results in the 
increased amount of presynaptic terminals as seen in the hippocampus of 15-
month-old AβPP-PS1 mice [42].  
 
In vivo 
1
H MRS has been used to characterize cerebral metabolic alterations in 
mild cognitive impaired (MCI) individuals and AD patients [23, 25, 96-99], and 
in several transgenic AβPP animal models for AD [33, 100-107]. The most 
consistent finding is a decrease in NAA level, a biomarker for neuronal 
integrity, in the cortex and hippocampus with aging and disease progression. 
Clinically, reduction of NAA has been used as an indicator of the progression of 
neurodegenerative pathology in AD patients, and to differentiate stable MCI 
from progressive MCI [23, 96, 97, 108, 109]. Longitudinal changes in 
1
H MRS 
measures have also been evaluated in AD patients during therapeutic trials with 
cholinergic agents. Treatment with xanomeline, an M1-selective cholinergic 
agonist, increased the level of NAA and decreased the level of Cho compared to 
baseline values before treatment. Changes in Cho levels from baseline further 
correlated with improved or at least stable ADAS-Cog scores [110, 111].  These 
findings not only support the feasibility of MRS measures in AD clinical trials, 
but also indicate that AD-related changes detected by MRS may be reversible, 
and may reflect aspects of neuronal integrity or function. Furthermore, many 
previous 
1
H MRS studies have found increased levels of mI in the temporal, 
parietal and occipital lobes of AD patients [22, 25, 98, 99]. mI is a sugar alcohol 
that is thought to be a marker for osmotic stress, astrogliosis and microglial 
activation [27], and an increase in cerebral mI levels is therefore associated with 
inflammatory processes. Although we did not observe significant differences in 
hippocampal mI+Gly concentration between the 12-month-old wild-type and 
AβPP-PS1 mice in the current study, correlation analyses revealed a positive 
correlation between the levels of Aβ40 and Aβ42 aggregates and mI+Gly levels in 
the AβPP-PS1 animals, suggesting a possible involvement of Aβ in 
inflammatory processes. 
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In transgenic animals models, significant reduction of NAA levels and elevation 
of mI levels were found to occur at different ages in different transgenic species 
apparently depending on the interplay of mouse strain, transgene and disease 
progression. The AβPPswe (Tg2576) model and the AβPPswe-PS2N1411 
(PS2APP) model display significantly decreased NAA level in the frontal 
cortex at 19-24 months of age, when Aβ deposits are widespread, but on the 
other hand no change in mI levels compared to age-matched wild-type mice 
[100, 102]. In the case of the AβPPswe-PS1M146L model, a significant 
reduction in the NAA/tCre ratio in the frontal hippocampus was observed at 16 
month of age in one study [101], but already at 6.5 months in another study 
[104], while the most profound increase in mI level was observed after 20 
months of age [101, 103, 104]. In contrast to our findings of a lower NAA 
concentration in the hippocampus of 12-month-old AβPPswe-PS1dE9 mice, Xu 
and colleagues did not observe significantly decreased hippocampal NAA/total 
creatine (tCre) levels until 16 months of age, which was associated with 
progressive degeneration of CA3 pyramidal neurons [107]. Chen and colleagues 
on the other hand observed a significantly lower concentration of NAA in the 
frontal cortex and hippocampus already at 5 months of age in the AβPP-
PS1mouse model, which coincided with neuronal loss and neuronal shrinkage. 
Furthermore, compared to age-matched wild-type animals the concentration of 
mI was significantly higher in 3-month-old AβPP-PS1 mice, and pathology 
showed activation and proliferation of astrocytes in the frontal cortex and 
hippocampus [112, 113]. The discrepancy between the results found in the latter 
two studies and our findings at 8 and 12 months of age are most likely due to 
differences in methodology, e.g. the field strength of the MR system, the 
acquisition parameters used, the exact position of the spectroscopic volume of 
interest, and the amount of animals measured.  
 
It has been demonstrated that AβPPswe-PS1dE9 mice may exhibit various 
neurobiological abnormalities in the hippocampus before 8 months of age. Such 
abnormalities include inflammatory processes involving clusters of activated 
microglia and astrocytes, and TNF-α expression [114], functional pre- and 
postsynaptic cholinergic deficits [115], impaired survival of newborn neuronal 
cells [116], and increasing levels of insoluble and soluble Aβ40 and Aβ42 in 
parenchyma and vessel walls [36, 53, 117]. These neurobiological alterations 
might underlie the mild behavioral changes and cognitive decline observed in 
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our 8-month-old AβPP-PS1 mice in the open field and (r)MWM, since 
cholinergic neurotransmission and the integration of newborn neuronal cells 
into the circuitry of the hippocampus are important for learning and memory 
[67, 118, 119]. Although we did not observe a decrease in the amount of 
immature neurons in our 12-month-old AβPP-PS1mice, reduced hippocampal 
neurogenesis has been found previously in AβPP-PS1 mice beyond 8 months of 
age [69-71], as well as expression of IL-1β, IL-6 and MCP-1, suggesting 
chronic inflammatory processes [114], decreased cerebral blood volume (CBV) 
[34] and gray and white matter degeneration [120]. Increasing levels of Aβ 
together with chronic inflammation and decreased delivery of oxygen and 
nutrients (due to cerebral hypoperfusion) can cause neuronal dysfunction and 
suppress hippocampal neurogenesis [17, 19, 121], thereby contributing to the 
more severe cognitive and behavioral dysfunction observed in our 12-month-old 
AβPP-PS1 mice alongside with a reduction in NAA levels measured with 1H 
MRS. Furthermore, beyond 12 months of age AβPP-PS1 mice display more 
progressive AD-like pathology including increased brain-derived neurotrophic 
factor (BDNF) levels and lower norepinephrine, serotonin and acetylcholine 
levels [122, 123], hippocampal atrophy and a reduced amount of glucose 
transporter type 1 [124],  increased amount of presynaptic boutons [42], and a 
decrease in CBV [125]. However, it should be noted that AβPP-PS1 mice do 
not develop the widespread neurofibrillary tangle pathology or extensive 
neurodegeneration as seen in AD patients. Thus it is important to use caution in 
interpreting results found in AβPP-PS1 (and other transgenic) mice and 
translating them to the human AD situation. 
 
To summarize, in this paper we characterized the neurochemical profile of the 
hippocampus, measured by 
1
H MRS at 7 Tesla, in the brains of 8- and 12-
month-old AβPPswe-PS1dE9 mice as compared to age-matched wild-type 
animals. Our results show that at 8 months of age  no alterations in hippocampal 
metabolite levels could be detected, while behavioral changes and cognitive 
decline were present in the AβPP-PS1 mouse model. At 12 months of age, a 
decrease in hippocampal NAA levels, reflecting reduced neuronal integrity, 
correlated with more severe behavioral and cognitive impairment in AβPP-PS1 
mice as compared to wild-type animals. Furthermore, correlation analyses 
suggest a possible role of Aβ in inflammatory processes, synaptic dysfunction 
and impaired neurogenesis.   
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1
H MRS could potentially provide unique information about the underlying 
degenerative processes, because metabolite levels are sensitive to different in 
vivo pathological processes at the molecular or cellular level. Furthermore, 
1
H 
MRS has great potential for the early diagnosis of AD, monitoring disease 
progression and evaluating the efficacy of potential therapeutic agents, both in 
animals models and AD patients. However, to observe small changes related to 
the disease progression, 
1
H MRS data need to be acquired from a large number 
of mice. Furthermore, the sensitivity and specificity of 
1
H MRS depend on the 
field strength of the MR system, the acquisition parameters and the size and 
position of the spectroscopic volume of interest. Therefore, we cannot exclude 
the presence of subtle metabolic alterations at 8 months of age, since our 
1
H 
MRS methodology  may not have been sensitive enough to detect small but 
important functional or anatomical abnormalities in the AβPP-PS1mouse 
hippocampus. 
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Chapter 4 
 
 
 
Effects of specific multi-nutrient enriched 
diets on cerebral metabolism, cognition and 
neuropathology in AβPPswe-PS1dE9 mice 
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Abstract 
 
Recent studies have focused on the use of multi-nutrient dietary interventions in 
search of alternatives for the treatment and prevention of Alzheimer’s disease 
(AD). In this study we investigated to which extent long-term consumption of 
two specific multi-nutrient diets can modulate AD-related etiopathogenic 
mechanisms and behavior in 11-12-month-old AβPPswe-PS1dE9 mice. Starting 
from 2 months of age, male AβPP-PS1 mice and wild-type littermates were fed 
either a control diet, the DHA+EPA+UMP (DEU) diet enriched with uridine 
monophosphate (UMP) and the omega-3 fatty acids docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA), or the Fortasyn
®
 Connect (FC) diet 
enriched with the DEU diet plus phospholipids, choline, folic acid, vitamins and 
antioxidants. We performed behavioral testing, proton magnetic resonance 
spectroscopy, immunohistochemistry, biochemical analyses and quantitative 
real-time PCR to gain a better understanding of the potential mechanisms by 
which these multi-nutrient diets exert protective properties against AD. Our 
results show that both diets were equally effective in changing brain fatty acid 
and cholesterol profiles. However, the diets differentially affected AD-related 
pathologies and behavioral measures, suggesting that the effectiveness of 
specific nutrients may depend on the dietary context in which they are provided. 
The FC diet was more effective than the DEU diet in counteracting 
neurodegenerative aspects of AD and enhancing processes involved in neuronal 
maintenance and repair. Both diets elevated interleukin-1β mRNA levels in 
AβPP-PS1 and wild-type mice. The FC diet additionally restored neurogenesis 
in AβPP-PS1 mice, decreased hippocampal levels of unbound choline-
containing compounds in wild-type and AβPP-PS1 animals, suggesting 
diminished membrane turnover, and decreased anxiety-related behavior in the 
open field behavior. In conclusion, the current data indicate that specific multi-
nutrient diets can influence AD-related etiopathogenic processes. Intervention 
with the FC diet might be of interest for several other neurodegenerative and 
neurological disorders.  
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Introduction 
 
Alzheimer’s disease (AD) is a complex neurodegenerative disorder that affects 
over 36 million people worldwide. The exact cause of AD is still largely 
unknown despite over 100 years of extensive research, and still no curative 
treatments are available. Aging is recognized as the main risk factor for the late-
onset sporadic form of AD (SAD), while early-onset familial AD (FAD) has 
been linked to autosomal dominant mutations in the gene for the amyloid-β 
precursor protein (AβPP) and the genes for the presenilin 1 (PS1) and presenilin 
2 (PS2) proteins [1, 2]. Both SAD and FAD share specific neuropathologic 
features, including neurofibrillary tangles, amyloid-β (Aβ) plaques, neuronal 
loss, white matter lesions and synaptic changes in vulnerable brain regions such 
as the hippocampus and neocortex [3, 4]. For decades, the production and 
accumulation of the Aβ peptide has been proposed to be the primary trigger of 
the pathological cascade leading to neurodegeneration and the development of 
AD. Besides Aβ, several other (risk) factors have been proposed to play an 
important role in the development of AD.  
 
Many large epidemiological studies have demonstrated that vascular disorders, 
such as hypercholesterolemia and atherosclerosis, are important risk factors for 
AD [5-7]. Furthermore, cardiovascular disease risk factors, such as a sedentary 
lifestyle, high saturated fatty acid (SFA)  intake, diabetes, smoking and obesity, 
are associated with a higher risk of developing AD and other dementias [8-11]. 
Many of these cardiovascular risk factors are modifiable. Modifying 
cardiovascular risk factors, for example by changing lifestyle, might ultimately 
also affect the risk of developing AD. 
 
Due to the limited and short-lasting efficacy of the current drugs available [12], 
recent work has focused on the use of dietary interventions for the treatment and 
prevention of AD. Omega-3 long-chain poly-unsaturated fatty acids (n3 lc-
PUFAs), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA), have shown protective properties with regard to risk of age-related 
cognitive decline and AD [13-16]. The mechanisms by which these dietary 
nutrients exert protective properties against AD are still under investigation, but 
several lines of evidence have shown beneficial effects of n3 lc-PUFAs on the 
cardiovascular system [17, 18] and on neuronal membrane properties [19, 20].  
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These beneficial effects on the cardiovascular system have been explained by 
the capacity to decrease blood pressure [21], lower plasma triacylglycerols [22, 
23], prevent arrhythmias [24], improve vascular reactivity [25, 26], decrease 
atherosclerosis [27], and suppress inflammatory processes [28]. Furthermore, 
high levels of n3 lc-PUFAs replace omega-6 fatty acids (n6 FAs) and 
cholesterol from cell membranes, leading to increased membrane fluidity, 
increased number of receptors, enhanced receptor binding and affinity, better 
ion channel functionality, and modulation of gene expression of many enzyme 
proteins involved in signal transduction processes [29-31]. As a result, this will 
lead to improved neurotransmission and signaling [32], which is important for 
optimal cognitive functioning [33]. Other dietary components, like B vitamins 
and antioxidants, have also been shown to protect the brain from oxidative and 
inflammatory damage [34-36], and synaptic and neuronal loss [37, 38]. 
However, when tested in a clinical setting supplementation with single nutrients 
is marginally effective in improving disease status [39-42]. It has been 
suggested that approaches with multiple nutritional components might be more 
promising, since not individual nutrients but dietary patterns were identified as 
a factor influencing the risk of developing AD [43].   
 
Combined administration of different nutrients has shown increased 
effectiveness in altering specific parameters involved in AD. Supplementation 
with DHA or uridine monophosphate (UMP) improved water maze 
performance of environmentally impoverished rats. However, the combined 
administration of DHA and UMP was more effective in improving learning 
abilities [44]. Furthermore, performance on the four-arm radial maze, T-maze 
and Y-maze tests by normal adult gerbils was improved by supplementation of 
DHA and choline, and was even further enhanced by coadministering UMP 
[45]. In addition to enhancing cognitive performance, combinations of nutrients 
were shown to be more effective than single nutrients in counteracting 
neurodegenerative aspects of AD [38, 46, 47] and enhancing processes involved 
in neuronal regeneration and function [48-50]. Moreover, clinical trials with 
combinations of nutrients have shown beneficial effects on memory 
performance in patients with mild AD [51-53]. 
 
In the current study, we wanted to investigate the extent to which long-term 
consumption of two specific multi-nutrients diets can modulate behavior, 
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cognition, hippocampal metabolite levels, neurogenesis and inflammation in 11-
12-month-old AβPP-PS1 mice. Starting from 2 months of age, animals were fed 
either a control diet, a multi-nutrient diet enriched with DHA, EPA and UMP 
(DEU), or a multi-nutrient diet enriched with DHA, EPA, UMP, phospholipids, 
choline, folic acid, vitamins B6, B12, C ,E and selenium (Fortasyn
®
 Connect). 
We performed behavioral testing, proton magnetic resonance spectroscopy (
1
H 
MRS), immunohistochemistry, biochemical analyses and quantitative real-time 
PCR to gain a better understanding of the potential mechanisms by which these 
multi-nutrient diets may exert protective properties against AD.  
 
Animals, materials and methods 
 
Ethics statement, animals and housing conditions 
The experiments were performed according to Dutch federal regulations for 
animal protection and were approved by the Veterinary Authority of the 
Radboud University Nijmegen Medical Centre (Permit Number: RU-DEC 
2008-126h). All efforts were made to minimize suffering of the animals. 
 
The AβPPswe-PS1dE9 founders were originally obtained from Johns Hopkins 
University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of 
Pathology) and a colony was established at the Radboud University Nijmegen 
Medical Centre, The Netherlands. In short, mice were created by co-injection of 
chimeric mouse/human AβPPswe (mouse AβPP695 harboring a human Aβ 
domain and mutations K595N and M596L linked to Swedish familial AD 
pedigrees) and human PS1dE9 (deletion of exon 9) vectors controlled by 
independent mouse prion protein promoter elements. The two transfected genes 
co-integrate and co-segregate as a single locus [54, 55]. This line (line 85) was 
originally maintained on a hybrid background by backcrossing to C3HeJ × 
C57BL6/J F1 mice (so-called pseudo F2 stage). For the present work, the 
breeder mice were backcrossed to C57BL6/J for 13 generations to obtain mice 
for the current study. Throughout the experiment, animals were housed in 
groups of 2-6 mice per cage in a controlled environment, homogenously 
illuminated by normal fluorescent room light at 60 lux, with room temperature 
at 21ºC, and an artificial 12:12h light:dark cycle (lights on at 7 a.m.). Food and 
water were available ad libitum.  
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Table 1. Compositions of the experimental diets used, based on AIN-93M [56] with 
minor revisions. 
 Dietary groups 
Source Control 
(CO) 
DHA, EPA, UMP 
(DEU) 
Fortasyn
® 
Connect 
(FC) 
 g/100g of 
diet 
g/100g of diet g/100g of diet 
Corn Starch 35.57 34.57 33.12 
Casein (>85% protein) 14.00 14.00 14.00 
Corn dextrin 15.50 15.50 15.50 
Sucrose 10.00 10.00 10.00 
Dextrose 10.00 10.00 10.00 
Fibers 5.00 5.00 5.00 
Mineral mix (AIN-93M-MX) 3.50 3.50 3.50 
Vitamin mix (AIN-93-VX) 1.00 1.00 1.00 
Fats    
Soy oil 1.900 - - 
Coconut oil 0.900 0.100 0.100 
Corn oil 2.200 1.870 1.870 
Fish oil - 3.030 3.030 
Additions    
L-cysteine  0.180 0.180 0.180 
Choline bitartrate (41.1% 
choline) 0.250 
0.250 
0.250 
Tert-butylhydroquinone 0.0008 0.0008 0.0008 
Pyridoxine-HCl - - 0.00328 
Folic acid (90%) - - 0.00067 
Cyanocobalamin (0.1% in 
mannitol) - 
- 
0.00350 
Ascorbic acid (100% pure) - - 0.160 
dl-α-tocopheryl acetate (500 
IU/g) - 
- 
0.4650 
UMP disodium (24% H2O) - 1.0 1.0 
Choline chloride (74.576%) - - 0.402 
Soy lecithin - - 0.402 
Sodium selenite (46% min)  - - 0.00023 
Energy (kcal/100g chow) 376.9 372.9 367.1 
All diets were isoenergetic, contained 5% fat and standard vitamin and mineral 
premix, providing recommended daily amounts of these nutrients. 
DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid;  
UMP = uridine monophosphate 
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Male transgenic AβPP-PS1 mice and their wild-type littermates were fed either 
1] a standard Control diet (CO diet), 2] a multi-nutrient diet enriched with 
DHA, EPA and UMP (DEU diet), or 3] a multi-nutrient diet, called Fortasyn
®
 
Connect (FC diet), containing precursors and cofactors in membrane synthesis 
and maintenance via the Kennedy cycle [57], such as DHA, EPA, UMP, 
phospholipids, choline, vitamins B6, B9, B12, C and E, folic acid and selenium. 
The diets differed in composition with regard to the fat blends used, as well as a 
number of supplemented nutrients as indicated in Table 1. Diets were isocaloric 
and were manufactured by Research Diet Services (Wijk bij Duurstede, The 
Netherlands). In order to minimize oxidation of the n3 lc-PUFAs, the 
experimental diets were stored at -20°C in 2-day supply aliquots. Feeding the 
diets started when the mice reached the age of 2 months and was maintained for 
the remainder of the experiment. Animals underwent behavioral testing at 11 
months of age and subsequently MRI measurements at 12 months of age (Fig. 
1). In total, 85 mice were used in the current study. Table 2 describes the 
number of mice used in each experimental group. The body weight of the mice 
was determined one week before the start of the behavioral tests at 11 months of 
age, and again on the day of the MRI measurements at 12 months of age.  
 
Table 2. Overview of the number of mice used in each experimental group. 
Genotype Diet Total OF (r)MWM MRS  IHC BCH 
Wild-type  CO 20 20 20 13-15 15 9 
 DEU 17 17 17 13-15 8 8 
 FC 16 16 16 14-15 16 7 
AβPP-PS1 CO 14 14 13 10 5-7 5 
 DEU 8 8 8 7 4-5 3 
 FC 10 10 10 7 4-6 4 
CO = Control diet; DEU= DHA, EPA, UMP diet; FC = Fortasyn
® 
Connect diet; 
OF=open field; (r)MWM = (reverse) Morris water maze; MRS = magnetic resonance 
spectroscopy; IHC = immunohistochemistry;  
BCH = biochemistry. 
 
Behavioral analyses 
Behavioral testing was performed in the following order (Fig. 1): First open 
field, followed by the Morris water maze (MWM), and finally the reversal 
MWM (rMWM). All testing sessions were performed during the light phase 
(between 9 a.m. and 5 p.m.) and were recorded for computer-assisted analysis 
using Ethovision XT 7.0 software (Noldus Information Technology B.V., 
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Wageningen, The Netherlands). All behavioral testing was performed in the 
same room, homogenously illuminated by normal fluorescent room light at 60 
lux.   
 
 
Fig. 1. Time line of experimental design. At 2 months of age, AβPP-PS1 mice and their 
wild-type littermates were put on either a control diet (CO), a DHA, EPA and UMP 
diet (DEU) or a Fortasyn
®
 Connect diet (FC) for the remainder of the experiment. 
Behavioral testing was performed at 11 months of age. Animals were weighed one week 
before starting the behavioral testing battery. In the first week of behavioral testing, 
animals were exposed to the open field once for 30 minutes. In the second week, 
animals were trained in the Morris water maze (MWM) for 4 days. In the third week, 
animals were trained in the reverse Morris water maze (rMWM) for 2 days. MR 
imaging was performed at 12 months of age. Mice were weighed before MR scanning 
and sacrificed immediately after MR imaging.   
 
Open field 
To analyze explorative and anxiety-related behavior, mice were placed 
individually in the center of a square open field (50×50×40 cm) with white 
Plexiglas walls. Animals were observed for 30 minutes, and the durations 
(seconds) of walking, wall leaning, rearing, sitting and grooming were scored 
and analyzed. These open field parameters were defined as described previously 
[58, 59]. In addition, total walking distance, mean velocity, and the time spent 
in the corners and in the center of the open field were obtained from the 
recorded sessions. The center of the open field was defined as a square 
measuring 20×20 cm, and the corners of the open field were defined as the sum 
of all four 10×10 cm squared corners.  
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Morris water maze (MWM) 
To investigate spatial learning abilities, mice were tested in the Morris water 
maze (MWM). In short, mice were placed in a pool (104 cm diameter) at 
different starting positions and were trained to find a submerged platform by 
using distant visual cues in the room. The water was made opaque by the 
addition of milk powder, and was kept at a constant temperature of 21-22°C. 
The maze was surrounded by white curtains at a distance of 0.5 meter, which 
were marked by four spatial cues varying in shape, size and color. The 8 cm 
diameter round platform was submerged 1 cm below the water surface and was 
placed in the middle of the northeast (NE) quadrant at a distance of 
approximately 26 cm from the wall. The researcher was always present at the 
same location in the room during all trials (close to the southwest quadrant. 
 
Acquisition (spatial learning): Mice were trained to find the location of the 
submerged escape platform in 4 acquisition trials per day (maximal swimming 
time 120 s; 30 s on the platform; inter-trial interval 60 min) during 4 
consecutive days. The latency time (s) to find the hidden platform was scored. 
Starting positions during the 4 trails/day were: south (S), north (N), east (E), 
west (W). After each trial, mice were placed back in their home cage, and a 
paper towel was available inside the cage for additional drying.  
 
Probe (spatial memory): All mice performed a single probe trial 60 min after the 
last trial on day 4. The platform was removed from the swimming pool and 
mice were allowed to swim for 120 s. The time spent swimming and searching 
in the NE quadrant (former platform quadrant), the total swimming distance, the 
mean velocity and the time spent swimming at the exact former platform 
location were measured.  
 
Reverse Morris water maze (rMWM) 
Four days after the standard MWM probe trial, a simplified reversal MWM [59, 
60] was performed in which the platform was relocated to a new position in the 
southwest (SW) quadrant of the pool. In this procedure, memory retrieval needs 
to be selective for the most recently learned location, introducing an episodic 
like component in the spatial memory task [61]. Acquisition and probe sessions 
were performed similarly to the standard MWM sessions, except that starting 
positions were E, W, S, and N, the target quadrant was SW, and training lasted 
only 2 days (4 trials/day).  
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Magnetic resonance imaging (MRI) 
MRI measurements were performed on a 11.7T BioSpec Avance III small 
animal MR system (Bruker Biospin, Ettlingen, Germany) equipped with an 
actively shielded gradient set of 600 mT/m. A circular polarized volume 
resonator was used for signal transmission and an actively decoupled mouse 
brain quadrature surface coil was used for signal detection (Bruker BioSpin). 
During the experiments, mice were anesthetized with 3.5% isoflurane (Nicholas 
Primal (I) limited, London, United Kingdom) for induction and 2% isoflurane 
for maintenance in a mixture of N2O and oxygen (1:2) through a nose cone. The 
anesthetic concentration was adjusted during the experiment in order to 
maintain the breathing frequency at 70-100 per minute. Respiration of the 
animal was monitored using a pneumatic cushion respiratory monitoring system 
(Small Animal Instruments Inc., NY, USA). Body temperature was measured 
using a rectal thermometer and maintained at 37°C using a heated air flow 
device. Mice were placed in a stereotactic holder in order to immobilize the 
head and prevent unwanted movement during the scanning. Gradient echo (GE) 
images in the axial, sagittal and coronal orientation were acquired to visualize 
the anatomy of the mouse brain structures. Imaging parameters were: echo time 
(TE) = 5 ms, repetition time (TR) = 630 ms, flip angle = 12 deg, field of view 
(FOV) = 40×40 mm, matrix size = 512×512, slice thickness = 0.345 mm.  
 
Magnetic resonance spectroscopy (MRS) 
Metabolite concentrations in the hippocampus were determined using 
1
H MRS 
with single voxel technique. The spectroscopic volume of interest (VOI) of 
1.0×1.0×2.0 mm was positioned unilaterally in the right hippocampus based on 
the acquired anatomical images. Water-suppressed 
1
H-MRS spectra were 
acquired with a point-resolved spectroscopy sequence (PRESS) with a short 
echo time with imaging parameters: TE = 10.905 ms, TR = 2500 ms, T1 = 6.31 
ms, T2 = 4.59 ms, and 800 signal averages. Total acquisition time for 
1
H MRS 
was 27 min per animal.  
 
Quantification of the metabolite concentration was performed using a the Linear 
Combination (LC) model software package (LCModel
TM
, S. Provencher, 
Oakville, Canada). The quantification algorithm of LCModel
TM 
applies linear 
combinations of model spectra to calculate the best fit of the experimental 
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spectrum. The model spectra (dataset of prior knowledge) were calibrated to 
match the magnetic field strength, sequence type and sequence parameters used 
for data acquisition.  
 
The criteria to select reliable metabolite tissue concentrations were based on the 
Cramér-Rao lower bounds (CRLB), which are estimates of the S.D. of the fit 
for each metabolite [62] as determined by LCModel
TM. Only CRLB ≤ 20% 
were included in the analysis. Concentrations with CRLB > 20% were classified 
as not detected. Six metabolites fulfilled the criteria: choline + 
glycerophosphocholine + phosphocholine (tCho; choline-containing 
compounds), creatine + phosphocreatine (tCre), glutamine + glutamate (Glx), 
myo-Inositol + glycine (mI+Gly), N-acetylaspartate + N-acetylaspartylglutamate 
(tNAA) and taurine (Tau). Although the exact functions of these metabolites are 
not fully known, tNAA is considered to be a marker of neuronal viability, tCre 
is involved in energy metabolism, mI is a putative marker for microglia and 
astrogliosis, and tCho is required for the synthesis of the neurotransmitter 
acetylcholine, and of phosphatidylcholine, a major constituent of membranes, 
and is therefore associated with membrane turnover [63].  
 
Tissue sampling 
Directly following the MR measurements at 12 months of age, half of the 
number of mice was sacrificed by cervical dislocation to collect blood samples 
and brain tissue for biochemical analyses, and the other half was sacrificed by 
transcardial perfusion fixation with 4% paraformaldehyde (4% 
paraformaldehyde in 0.1M phosphate buffered saline (PBS; pH=7.3) to collect 
brains for immunohistochemical stainings. Blood samples were collected via 
eye extraction, and subsequently processed to obtain blood serum. Blood serum 
was stored at -80°C, before further biochemical processing. Non-perfused 
brains were snap frozen in liquid nitrogen and then stored at -80°C, before 
further biochemical processing. Perfused brains were collected and postfixed for 
15h at 4°C in 4% paraformaldehyde fixative and subsequently stored in 0.1M 
PBS with 0.01% sodium azide at 4°C before further immunohistochemical 
processing. 
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Immunohistochemistry 
Before cutting, the brain tissue was cryoprotected by immersion in 30% sucrose 
in 0.1M PBS. Six series of 40 µm coronal sections were cut through the brain 
using a sliding microtome (Microm HM 440 E, Walldorf, Germany) equipped 
with an object table for freeze sectioning at -60°C. Immunohistochemistry was 
performed using standard free-floating labeling procedures, and was carried out 
on a shaker table at room temperature.  
 
Doublecortin staining 
Immature neurons were visualized with anti-doublecortin antibody (polyclonal 
goat anti-doublecortin (C18): sc-8066, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) using one complete subseries of brain sections per animal with 
240 µm distance between the sections. Doublecortin is a microtubule-associated 
protein that is exclusively found in somata and processes of migrating and 
differentiating neurons [64, 65]. In short, after blocking the brain sections 
against endogenous peroxidase with 0.3% H2O2 in 0.1M PBS for 30 minutes, 
the sections were pre-incubated with PBS-BT (0.1M PBS with 0.1% Bovine 
Serum Albumin and 0.3% Triton-X-100) for 30 minutes. Brain sections were 
incubated overnight with polyclonal goat anti-doublecortin (1:3000 diluted in 
PBS-BT) as primary antibody. After incubating for 90 minutes with donkey 
anti-goat biotin secondary antibody (1:1500 diluted in PBS-BT, Jackson 
ImmunoResearch, West Grove, PA, USA), sections were transferred to a 
solution containing Vector ABC-elite (1:800 in PBS-BT; Vector Laboratories, 
Burlingame, CA, USA) for another 90 minutes. Visualization of doublecortin-
positive cells was achieved by incubation with 0.02%  3-3’diaminobenzidin 
tetra hydrochloride with 0.3% ammonium nickel sulphate as an intensifier in 
0.05M Tris buffer (DAB-Ni solution, pH=7.6) with 0.006% H2O2 for 10 min. 
After washing with 0.1M PBS, all stained sections were mounted on gelatin-
coated slides (0.5% gelatin and 0.05% chrome-alum), dried overnight in a stove 
at 37°C, dehydrated in alcohol series, cleared with xylol and mounted in 
Entellan. 
 
Quantification 
Quantification of the doublecortin-positive newly formed immature neurons in 
the subgranular zone of the hippocampus was performed using a Zeiss 
Axioskop microscope equipped with hardware and software from 
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Microbrightfield (Williston, VT, USA). Appropriate sections were digitized 
using a computer-assisted analysis system (Stereo Investigator). Three sections 
per animals were used at -.70, -2.18 and -2.46 posterior to bregma, based on the 
mouse brain atlas of Franklin and Paxinos [66]. Contours were drawn along the 
borders of the hippocampus at 2.5× magnification and doublecortin-positive 
(Dcx+) cells were counted at 20× magnification. All quantifications were 
performed by two independent raters who were blind to the experiment groups. 
Measurements were averaged to obtain a single value per animal.    
 
Biochemical analyses 
Serum and brain sterol analysis 
Serum cholesterol levels and the cholesterol precursor lathosterol and its 
oxidative brain specific  metabolites, 24S-hydroxycholesterol and 27-
hydroxycholesterol, were measured by gas-chromatography-mass-spectrometry-
selected ionmonitoring (GC-MS-SIM) as described in detail previously [67-69]. 
Brains were homogenized and sterols were extracted overnight by 
chloroform/methanol trimethylsilylated prior to GC-MS-SIM analysis [67, 68].   
 
Brain fatty acid analysis 
Fatty acid analyses were performed with a part of the brain homogenate 
(described above). Total lipid was extracted from brain homogenates by 
methanol and chloroform. Subsequently, samples were centrifuged at 3000 rpm 
for 10 min and the lower phase (chloroform and lipids) was removed. 
Chloroform was added to the upper phase, samples were centrifuged again at 
3000 rpm for 10 min and the lower phase was combined with the first one. The 
chloroform fractions were dried in a SpeedVac® and 2 ml methanol and 40 μl 
concentrated sulfuric acid were added to the dried extract. The samples were 
heated at 100°C for 60 min, and 2 ml hexane and 0.5 ml 2.5M sodium 
hydroxide solution were added. After vortexing and centrifuging the samples 
for 5 min at 3000 rpm, the upper layer was collected and evaporated in a 
SpeedVac®. The fatty acids (FAs) were dissolved in 125 μl iso-octane and 
analyzed on a GC-FID with a CP-SIL88 column (50 m × 0.25 mm id. 0.22 film 
thickness). The n6/n3 ratio was calculated as the sum of analyzed n6 FAs 
divided by the sum of n3 FA.  
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Quantitative real-time PCR (qRT-PCR) 
A part of the frozen brain tissue, including both hippocampi, were collected in 1 
ml cold Trizol (Invitrogen, Paisley, UK) and homogenized by sonification. 
After chloroform extraction and isopropyl alcohol precipitation, RNA was 
dissolved in 25 μl RNase-free DEPC-treated water. The RNA concentrations 
were measured with a Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific Inc, Wilmington, DE, USA). cDNA synthesis was performed using 1 
μg RNA dissolved in 10 μl RNase-free DEPC-treated water containing 2 μl 5× 
iScript reaction mix and 0.5 μl iScript reverse transcriptase (iScript cDNA 
synthesis kit, Bio-Rad Laboratories B.V., Veenendaal, The Netherlands) at 
25°C for 5 min, at 42°C for 30 min and at 85°C for 5 min (Eppendorf 
Thermoblock Mastercycler 5330).  
 
Quantitative real-time PCR (qRT-PCR) was performed in a total volume of 10 
μl buffer solution containing 2 μl of template cDNA, 5 μl 2× SYBR Green 
Master mix (Applied Biosystems, Foster City, CA, USA), 2.92 μl RNase-free 
DEPC-treated water and 0.04 μl of each primer (100 μM). Primers for cluster of 
differentiation 36 (CD36), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), interleukin-1β (IL-1β), interleukin-6 (IL-6), monocyte 
chemoattractant protein 1 (MCP-1) and tumor necrosis factor-α (TNF-α) were 
designed using Vector Primer Express software (Applied Biosystems).  
 
Primer pairs were as follows:  
CD36:  5’- ATGGGCTGTGATCGGAACTG-3’ and  
5’-GTCTTCCCAATAAGCATGTCTCC-3’;  
GAPDH: 5’-AGGTCGGTGTGAACGGATTTG-3’ and  
 5’-TGTAGACCATGTAGTTGAGGTCA-3’; 
IL-1β:  5’-GCAACTGTTCCTGAACTCAACT-3’ and  
 5’-ATCTTTTGGGGTCCGTCAACT-3’;  
IL-6:  5’-CAAGTCGGAGGCTTAATTACACATG-3’ and  
 5’-ATTGCCATTGCACAACTCTTTTCT-3’;  
MCP-1: 5’-CCCAATGAGTAGGCTGGAGA-3’ and  
 5’-TCTGGACCCATTCCTTCTTG-3’;  
TNF-α: 5’-CAGACCCTCACACTCAGATCATCT-3’ and  
 5’-CCTCCACTTGGTCCTTTGCTA-3’.  
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The optimal temperature cycling protocol was determined to be 95°C for 10 
min followed by 40 reaction cycles at  90°C for 15 s and at 60°C for 1 min, 
using a StepOnePlus real time PCR system (Applied Biosystems, Foster City, 
CA, USA). The absolute quantities were determined using standard curves, and 
the validity of the results was checked by running appropriate negative controls. 
The quantity of cDNA was calculated for each sample with StepOne Software 
version 2.2.2. Relative gene expression ratios, calculated according to the 
comparative CT method (also referred to as the 2
-ΔCT 
method) [70], were used to 
evaluate differences. Relative CT (ΔCT) values were calculated by subtracting 
the CT
 
value of the housekeeping gene GADPH from the CT values of CD36, 
IL-1β, IL-6, MCP-1 or TNF-α. For each primer, two independent qRT-PCR 
runs were performed, and the means of their relative values were used for 
statistical analysis.  
 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed with SPSS for windows 
18.0 software (SPSS Inc. Chicago, IL, USA). The repeated measures ANOVA 
was used for the acquisition phase of the MWM and rMWM (with the repeated 
measure: trial block), followed by a Bonferroni post hoc to analyze possible 
interactions between trial block, genotype and/or diet. If interactions between 
trial block, genotype and/or diet (between-group-factors) were present, the data 
were split for the concerning factor and thereafter analyzed again with the 
repeated measures ANOVA. Multivariate ANOVA’s (MANOVAs) were 
conducted with between group factors: genotype and diet, to analyze possible 
differences between wild-type and AβPP-PS1 mice and the different diet groups 
in the open field test, the probe trials of the MWM and rMWM, the body weight 
and brain weight, hippocampal metabolite concentrations, the amount of 
immature neurons, and the biochemical analyses. If interactions between 
genotype and diet (between-group-factors) were present, the data were split for 
the concerning factor and thereafter analyzed again with the MANOVA. If no 
interactions between the genotype and diet were present and overall analysis 
revealed a significant effect of diet, the separate diet groups were analyzed post 
hoc by using Tukey’s HSD test. For clarity reasons, F-values are not displayed. 
Furthermore, only between-group interactions that reached statistical 
significance are specified in detail. Statistical significance was set at p<0.05.  
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Results 
 
Body and brain weight 
All mice were weighed one week before starting the behavioral test battery and 
again on the day of the MR measurements (1-2 months later). Since body 
weights within the groups did not change significantly between those two time 
points (ANOVA, p>0.50), the mean weight was used for further statistical 
analyses. Body weight was affected by genotype (ANOVA, p<0.001), but not 
by dietary intake (ANOVA, p=0.913). No significant genotype×diet interaction 
was observed (ANOVA, p=0.164). Overall mean body weight was 39.6±0.7 g 
in the AβPP-PS1 mice and 35.2±0.6 g in the wild-type mice. Absolute brain 
weight was not affected by genotype (ANOVA, p=0.733) or by diet (ANOVA, 
p=0.543). No significant genotype×diet interaction was observed (ANOVA, 
p=0.078). Overall mean brain weight was 0.53±0.00 g in AβPP-PS1 animals 
and 0.53±0.01 g in wild-type mice.  
 
Behavioral analyses 
Open field 
In the open field, locomotor activity and active exploration parameters 
(walking, sitting, wall leaning, rearing) and grooming were scored for 30 
minutes. In addition, total walking distance, mean walking velocity, and the 
time spent in the corners respectively the center of the open field were obtained 
from the recorded sessions.  
 
AβPP-PS1 mice were more active in the open field than wild-type mice, 
independent of diet (genotype×diet interaction, walking p=0.777; sitting 
p=0.857; distance moved p=0.926; velocity p=0.927). AβPP-PS1 mice walked 
more (Fig. 2A; ANOVA p=0.015) and sat less (Fig. 2B; ANOVA p<0.001) than 
wild-type mice. This resulted in an increased distance moved (Fig. 2F; ANOVA 
p<0.001) and higher mean walking speed in AβPP-PS1 mice compared to wild-
type animals (ANOVA p<0.001; wild-type 4.2±0.1 cm/s, AβPP-PS1 5.1±0.3 
cm/s). Dietary intake affected the time spent sitting (ANOVA, p=0.015), the 
distance moved (ANOVA, p=0.006) and the mean velocity (ANOVA, 
p=0.006). Dietary intervention with the FC diet had no effect on these 
parameters (post hoc, p>0.05). However, animals fed the DEU diet sat less than 
animals fed the CO diet (Fig. 2B; post hoc p=0.025), but did not differ from the 
 
4 
117 
 
mice fed the FC diet (post hoc, p=0.322). Furthermore, mice fed the DEU diet 
also traveled a greater distance (Fig. 2F; post hoc p=0.009) with a higher mean 
velocity (post hoc, p=0.009; CO diet 4.2±0.2 cm/s, DEU diet 5.1±0.3 cm/s, FC 
diet 4.5±0.2 cm/s) than animals fed the CO diet, but again did not differ from 
the animals fed the FC diet (post hoc, p=0.098). Overall analysis revealed a 
tendency for a diet effect on the time spent walking (p=0.053), but since this did 
not reach statistical significance, no additional post hoc tests were performed to 
compare the different diet groups.  
 
Moreover, AβPP-PS1 mice displayed less explorative behavior away from the 
walls of the open field, e.g. rearing (Fig. 2C; ANOVA p=0.030) compared to 
wild-type animals, but more explorative behavior against the walls of the open 
field, e.g. wall leaning (Fig. 2D; ANOVA p<0.001), independent of diet 
(genotype×diet interaction, rearing p=0.468; wall leaning p=0.513). Rearing 
behavior was not affected by dietary intervention with the DEU and FC diets 
(ANOVA, p=0.355). Wall leaning behavior however was affected by diet 
(ANOVA, p=0.001). Animals fed the DEU diet leaned more against the walls of 
the open field than mice fed the FC diet (Fig. 2D; post hoc p=0.007), and also 
slightly more than animals fed the CO diet (post hoc, p=0.070), although this 
did not reach statistical significance. No significant differences between wild-
type and AβPP-PS1 mice (Fig. 2E; ANOVA p=0.744) nor between the dietary 
groups (ANOVA, p=0.620) were observed for grooming behavior 
(genotype×diet interaction, p=0.172). 
 
Furthermore, AβPP-PS1 mice spent slightly less time in the center of the open 
field than wild-type mice (Fig. 2G; ANOVA p=0.064), although it did not reach 
statistical significance. No differences were observed between the dietary 
groups in the time spent in the center of the open field (ANOVA, p=0.116). No 
genotype×diet interaction was observed for the time spent in the center of the 
open field (p=0.356). AβPP-PS1 mice did however spent significantly more 
time in the corners of the open field compared to wild-type animals (Fig. 2H; 
ANOVA p=0.001), independent of diet (genotype×diet interaction, p=0.085). 
Dietary intake affected the time spent in the corners of the open field (ANOVA, 
p=0.007), such that animals fed the FC diet spent significantly less time in the 
corners of the open field than mice fed the CO diet (post hoc, p=0.038) and the 
DEU diet (post hoc, p=0.033).  
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Fig. 2. Open field behavior of 11-month-old AβPP-PS1 and wild-type mice on control 
and specific multi-nutrient diets. Open field parameters were measured within a 30 
min period. (A) AβPP-PS1 mice spent more time walking than wild-type mice 
(*p=0.015). Walking was not affected by dietary intake. (B) AβPP-PS1 mice spent less 
time sitting than wild-type mice (*p<0.001). Animals on the DHA, EPA and UMP 
(DEU) diet sat let than animals on control (CO) diet (a* p=0.025), but did not differ 
from the mice on the Fortasyn
® 
Connect (FC) diet. (C) AβPP-PS1 mice spent less time 
rearing than wild-type mice (*p=0.030). Rearing behavior was not affected by dietary 
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intake. (D) AβPP-PS1 mice spent more time wall leaning than wild-type mice 
(*p<0.001). Animals fed the DEU diet leaned more against the walls than mice fed the 
FC diet (c* p=0.007), and also slightly more than animals fed the CO diet (a
#
 p=0.070), 
although this did not reach statistical significance. (E) Grooming behavior was similar 
among wild-type and AβPP-PS1 mice, and was not affected by dietary intake. (F) 
AβPP-PS1 mice traveled a longer distance than wild-type mice (*p<0.001). Mice fed the 
DEU diet traveled a greater distance than animals fed the CO diet (a* p=0.009), but did 
not differ from the animals fed the FC diet. (G) AβPP-PS1 mice spent slightly less time 
in the center of the open field than wild-type mice (
#
p=0.064), although this did not 
reach statistical significance. The time spent in the center of the open field was not 
affected by dietary intake. (H) AβPP-PS1 mice spent more time in the corners of the 
open field compared to wild-type mice (*p=0.001). Animals fed the FC diet spent less 
time in the corners of the open field than mice fed the CO diet (a* p=0.038) and animals 
fed the DEU diet (b* p=0.033).          
 
Altogether these data show increased activity, but decreased explorative 
behavior in AβPP-PS1 mice. Furthermore, AβPP-PS1 mice also display 
increased anxiety-related behavior, as indicated by the increased time spent wall 
leaning and increased time spent in the corners of the open field [59, 71]. 
Dietary intervention with the DEU diet increased general locomotor activity and 
anxiety-related exploration (e.g. wall leaning) in wild-type and AβPP-PS1 mice. 
Our results might suggest that the FC diet could have an anxiolytic effect, since 
it decreased the time spent in the corners of the open field in both wild-type and 
AβPP-PS1 mice.   
 
Morris water maze (MWM) 
The Morris water maze is designed to test spatial learning by training the mice 
to find a hidden platform (acquisition phase) in a pool. Spatial memory is tested 
in a trial in which the platform is removed from the maze (probe trial) following 
the last trial of the acquisition phase. 
 
Both AβPP-PS1 and wild-type mice showed a decrease in escape latency during 
training (Fig. 3A; ANOVA p<0.001). No significant time×genotype, time×diet 
or time×genotype×diet interactions were observed (p>0.05), indicating that all 
animals learned the position of the hidden platform equally well.  
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Fig. 3. Morris water maze performance of 11-month-old AβPP-PS1 and wild-type mice 
on control and multi-nutrient diets. Spatial learning was measured in a 4-day 
acquisition phase, by determining the latency to find a hidden platform in the NE 
quadrant. Spatial memory was tested in the probe phase in which the percentage of 
time spent in the target NE quadrant, the time spent in the former platform area, the 
latency to the former platform area and the total distance moved were measured. (A) 
Both AβPP-PS1 and wild-type mice showed a decrease in latency during training. 
Overall escape latencies were higher in AβPP-PS1 mice (*p<0.001), independent of 
dietary intake. (B) Animals on control (CO), the DHA, EPA and UMP (DEU) and 
Fortasyn
®
 Connect (FC) diets showed a similar decrease in latency during training, 
independent of genotype. Overall escape latencies were not affected by dietary intake. 
(C) AβPP-PS1 mice spent less time in the target NE quadrant than wild-type mice, 
independent of dietary intake (*p=0.033). Time spent in the NE quadrant was 
unaffected by dietary intake. (D) AβPP-PS1 mice spent less time in the former platform 
area than wild-type mice (*p=0.010), independent of dietary 
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However, escape latencies were significantly higher in AβPP-PS1 mice 
compared to wild-type animals (Fig. 3A; ANOVA p<0.001), independent of 
dietary intake (genotype×diet interaction, p=0.097), indicating that spatial 
learning was affected by genotype. Escape latencies did not differ between the 
animals fed the CO diet, DEU diet or FC diet (Fig. 3B; ANOVA p=0.203). 
During acquisition training, swim speed decreased in both AβPP-PS1 and wild-
type mice over time (data not shown; ANOVA p<0.001). No significant 
time×genotype, time×diet or time×genotype×diet interactions were observed 
(p>0.05). However, the average swim speed was significantly higher in AβPP-
PS1 mice compared to wild-type animals during training (ANOVA p=0.001; 
wild-type 10.5±0.3 cm/s; AβPP-PS1 12.5±0.5 cm/s), independent of dietary 
intake (genotype×diet interaction p=0.652). The mean swim speed did not differ 
(ANOVA, p=0.341) between the animals fed the CO diet (11.5±0.4 cm/s), DEU 
diet (10.6±0.4 cm/s) or FC diet (11.5±0.6 cm/s).  
 
During the probe trial, AβPP-PS1 mice spent less time in the target NE quadrant 
(Fig. 3C, ANOVA p=0.033) than wild-type mice, independent of diet 
(genotype×diet interaction, p=0.688), indicating impaired spatial memory. 
Furthermore, AβPP-PS1 mice also spent less time in the exact area where the 
platform had been located (Fig. 3D; ANOVA p=0.010)  and had a higher 
latency to reach the former platform location (Fig. 3E; ANOVA p=0.003) than 
wild-type animals, independent of diet, again reflecting impaired spatial 
memory. Dietary intervention with DEU and FC had no effect on these 
parameters of spatial memory (ANOVA, p>0.05). Overall statistical analysis 
indicated significant genotype×diet interactions for the swim distance (p=0.004) 
and mean velocity (p=0.004). Dietary intake affected the swim distance 
(ANOVA, p=0.014) and mean velocity (ANOVA, p=0.015) in AβPP-PS1 mice, 
such that AβPP-PS1 mice on the FC diet displayed a shorter swim distance (Fig. 
3F; post hoc p=0.013) and lower mean swim velocity than the AβPP-PS1 
animals on CO diet (post hoc, p=0.015; AβPP-PS1-CO diet 17.3±0.4 cm/s, 
AβPP-PS1-FC diet 13.8±1.2 cm/s), and compared to the wild-type animals on 
FC diet (ANOVA, p=0.009; wild-type-FC diet 16.9±0.4 cm/s), but not 
compared to the AβPP-PS1 animals on DEU diet (post hoc, p=0.079; AβPP-
PS1-DEU diet 16.8±0.9 cm/s).  
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Fig. 4. Reverse Morris water maze in 11-month-old AβPP-PS1 and wild-type mice on 
control and multi-nutrient diets. Spatial learning with an extra episodic memory 
component was measured in a 2-day acquisition phase, by determining the latency to 
find a hidden platform in the SW quadrant. Spatial memory was tested in the probe 
phase in which the percentage of time spent in the target SW quadrant, the time spent 
in the former platform area, the latency to the former platform area and the total 
distance moved were measured. (A) Both AβPP-PS1 and wild-type mice showed a 
decrease in latency during training, independent of dietary intake. Overall escape 
latencies did not differ between AβPP-PS1 and wild-type mice. (B) Animals on control 
(CO), the DHA, EPA and UMP (DEU) and Fortasyn
®
 Connect (FC) diets showed a 
similar decrease in latency during training, independent of genotype. Overall escape 
latencies were unaffected by dietary intake. (C) AβPP-PS1 mice spent less time in the 
target SW quadrant than wild-type mice, independent of dietary intake (*p=0.006), 
although all animals performed well above 25% chance level. Time spent in the SW 
quadrant was unaffected by dietary intake. (D) AβPP-PS1 mice spent less time in the 
former platform area than wild-type mice (*p<0.001), independent of dietary intake. 
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Time spent in the exact former platform area was unaffected by dietary intake. (E) 
AβPP-PS1 mice had a slightly higher latency to reach the former platform location 
than wild-type mice (
#
p=0.054), although this did not reach statistical significance. 
Latency to reach the former platform location was unaffected by dietary intake. (F) No 
differences were observed between AβPP-PS1 and wild-type animals in the swim 
distance. Overall statistical analysis indicated a significant diet effect on the swim 
distance (p=0.030). However, Tukey’s post hoc analysis revealed no significant 
differences between any of the diet groups.    
 
Reverse Morris water maze (rMWM) 
In the reverse Morris water maze (rMWM), mice have to learn to find a novel 
position for the hidden platform. This task is considered to be a test for new 
learning abilities, in which a previous successful strategy must be inhibited and 
a new strategy should be developed.  
 
Both AβPP-PS1 and wild-type mice showed a decrease in escape latency during 
training (Fig. 4A; ANOVA p=0.016). No significant time×genotype, time×diet 
or time×genotype×diet interactions were observed (p>0.05), indicating that all 
animals learned the new platform position equally well. Escape latencies did not 
differ between AβPP-PS1 and wild-type mice (Fig. 4A; ANOVA p=0.160), nor 
did they differ between the animals on CO diet, DEU diet and FC diet (Fig. 4B; 
ANOVA p=0.274). No genotype×diet interaction was observed for the escape 
latencies (p=0.922). During acquisition training with a new platform location, 
swim speed decreased in both AβPP-PS1 and wild-type mice over time (data 
not shown; ANOVA p<0.001). No significant time×genotype, time×diet or 
time×genotype×diet interactions were observed (p>0.05). However, the average 
swim speed was significantly higher in AβPP-PS1 mice compared to wild-type 
animals during revere MWM training (ANOVA p=0.008; wild-type 5.7±0.2 
cm/s; AβPP-PS1 6.8±0.4 cm/s), independent of dietary intake (genotype×diet 
interaction p=0.827). The mean swim speed did not differ (ANOVA, p=0.511) 
between the animals fed the CO diet (5.9±0.3 cm/s), DEU diet (6.5±0.4 cm/s) or 
FC diet (6.0±0.4 cm/s). 
 
During the probe trail, AβPP-PS1 mice spent less time in the target SW 
quadrant (Fig. 4C; ANOVA p=0.006) than wild-type mice, independent of diet 
(genotype×diet interaction, p=0.120), although all animals performed well 
above 25% chance level, indicating good memorization of the platform 
quadrant. However, AβPP-PS1 mice also spent less time in the exact area where 
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the platform had been located after relocation (Fig. 4D; ANOVA p<0.001), 
indicating impaired spatial memory. Furthermore, they displayed a slightly 
higher latency to reach the former platform location than wild-type animals 
(Fig. 4E; ANOVA p=0.054), although this did not reach statistical significance. 
Dietary intervention with DEU and FC had no effect on these parameters of 
spatial memory (ANOVA, p>0.05). No differences were observed between 
AβPP-PS1 and wild-type animals in the swim distance (Fig. 4F; ANOVA 
p=0.909) or in the mean swim velocity (ANOVA p=0.918; wild-type 16.3±0.2 
cm/s, AβPP-PS1 16.2±0.4 cm/s). Overall statistical analysis indicated a 
significant effect of diet on swim distance (ANOVA, p=0.030) and mean swim 
velocity (ANOVA p=0.031; CO diet 16.6±0.3 cm/s, DEU diet 16.5±0.3 cm/s, 
FC diet 15.6±0.5 cm/s). However, Tukey’s post hoc analysis revealed no 
significant differences between any of the diet groups (post hoc, p>0.1).  
 
Magnetic resonance imaging (MRI) 
Magnetic resonance spectroscopy (MRS) 
To determine hippocampal metabolite concentrations, single voxel 
1
H MRS at 
11.7 T was used (Fig. 5). No differences were observed between wild-type and 
AβPP-PS1 mice (Fig. 5A) , nor between the different diet groups (Fig. 5B) in 
the levels of creatine and phosphocreatine (tCre; ANOVA p>0.05). Therefore, 
tissue concentrations of metabolites are given relative to tCre as applied by 
others [72, 73].  
 
AβPP-PS1 mice had significantly lower levels of N-acetylaspartate and N-
acetylaspartylglutamate (tNAA; ANOVA p=0.030) than wild-type mice, 
independent of diet (genotype×diet interaction, p=0.513), indicating decreased 
neuronal integrity (Fig. 5A). Wild-type and AβPP-PS1 mice had similar levels 
of choline-containing compounds (tCho; ANOVA p=0.079), glutamine and 
glutamate (Glx; ANVOA p=0.963), myo-Inositol and glycine (mI+Gly; 
ANOVA p=0.196) and taurine (Tau; ANOVA p=0.475).  
 
Statistical analysis indicated a significant effect of dietary intake on tCho levels, 
independent of genotype (Fig. 5B; ANOVA p=0.035). Post hoc analysis 
revealed that animals fed the FC diet had significant lower tCho levels than 
animals fed the CO diet (post hoc, p=0.039), but no difference compared to the 
animals fed the DEU diet (post hoc, p=0.228). No differences were observed 
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between the different diets in relative concentrations of Glx (ANOVA, 
p=0.627), mI+Gly (ANOVA, p=0.400), tNAA (ANOVA, p=0.156) and Tau 
(ANOVA, p=0.523).  
 
 
Fig. 5. Hippocampal neurochemical profile of 12-month-old AβPP-PS1 and wild-type 
mice on control and specific multi-nutrient diets. The neurochemical profile of the 
hippocampus was determined with single voxel 
1
H MRS at 11.7 Tesla. (A) AβPP-PS1 
mice showed a significant decrease in tNAA/tCre compared to wild-type mice 
(*p=0.030), independent of dietary intake. AβPP-PS1 and wild-type mice displayed 
similar levels of tCho/tCre, tCre, Glx/tCre, mI+Gly/tCre and Tau/tCre. (B) Both wild-
type and AβPP-PS1 mice fed the Fortasyn
®
 Connect (FC) diet showed a significant 
decrease in tCho/tCre levels compared to animals fed the control (CO) diet (*p=0.039), 
but no difference compared to mice fed the DHA, EPA and UMP (DEU) diet. Dietary 
intake did not affect the levels of tCre, Glx/tCre, mI+Gly/tCre, tNAA/tCre and 
Tau/tCre. Values represent the mean and SEM. tCho=choline-containing compounds; 
tCre=creatine and phosphocreatine; Glx=glutamine and glutamate; mI+Gly=myo-
Inositol and glycine; tNAA=N-acetylaspartate and N-acetylaspartylglutamate; 
Tau=taurine.    
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Immunohistochemistry 
Doublecortin staining 
Immature neurons were visualized with a polyclonal antibody against 
doublecortin. Doublecortin-positive (Dcx+) cells were counted in three 
alternating hippocampal sections as a measure for neurogenesis.  
 
Overall statistical analysis indicated a significant genotype×diet interaction  
(ANOVA, p=0.004) for the relative amount of Dcx+ cells. In wild-type animals, 
the relative amount of Dcx+ cells were similar for all diet groups (ANOVA, 
p=0.530). However, in AβPP-PS1 mice, the relative amount of Dcx+ cells was 
affected by dietary intake (ANOVA, p=0.017).  
 
 
Fig. 6. Neurogenesis in 12-month-old AβPP-PS1 and wild-type mice on control and 
specific multi-nutrient diets. From 2 months of age, mice were fed either a control 
(CO), a DHA, EPA and UMP (DEU) or a Fortasyn
®
 Connect (FC) diet. The amount of 
immature neurons in the subgranular zone of the hippocampus were visualized 
immunohistochemically with a polyclonal goat anti-doublecortin antibody (1:3000) as a 
measure for neurogenesis. Values represent the mean and SEM and are relative (%) 
compared to wild-type mice on CO diet. In wild-type animals, the relative amount of 
doublecortin-positive (Dcx+) immature neurons was similar for all diet groups. 
However, in AβPP-PS1 mice the relative amount of Dcx+ immature neurons was 
affected by dietary intake (p=0.017). Post hoc analysis revealed that AβPP-PS1 mice fed 
the CO diet displayed a significantly decreased relative amount of Dcx+ immature 
neurons compared to wild-type mice on the CO diet (*p=0.004). The FC diet 
significantly increased the relative amount of Dcx+ immature neurons in AβPP-PS1 
mice as compared to AβPP-PS1 mice on CO diet (*p=0.015). Furthermore, AβPP-PS1 
mice on the FC diet had slightly higher relative amount of Dcx+ immature neurons 
than wild-type animals on the FC diet (
#
p=0.053), although this did not reach statistical 
significance.  
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Post hoc analysis revealed that AβPP-PS1 mice on CO diet showed a decreased 
amount of Dcx+ cells compared to wild-type mice on CO diet (Fig. 6; ANOVA, 
p=0.004), indicating decreased neurogenesis in AβPP-PS1 mice on a normal 
control diet.  
 
Moreover, AβPP-PS1 mice fed the FC diet had a significantly higher relative 
amount of Dcx+ cells than AβPP-PS1 animals fed the CO diet (post hoc, 
p=0.015), suggesting that the FC diet restored neurogenesis in AβPP-PS1 mice. 
Furthermore, AβPP-PS1 mice on FC diet also had a slightly higher relative 
amount of Dcx+ cells than wild-type animals on FC diet (ANOVA, p=0.053), 
although this did not reach statistical significance.  
 
Biochemical analyses 
Serum and brain sterol analysis 
Brain cholesterol levels (Fig. 7A) were similar between wild-type and AβPP-
PS1 mice (ANOVA, p=0.369), and between the diet groups (ANOVA, 
p=0.637). However, dietary intervention significantly affected serum 
cholesterol levels (Fig. 7B) in wild-type mice (ANOVA, p<0.001), but not in 
AβPP-PS1 mice (ANOVA, p=0.314), as indicated by a significant 
genotype×diet interaction (p=0.009). Post hoc analysis revealed that in wild-
type mice the DEU diet decreased serum cholesterol levels compared to the CO 
diet (post hoc, p=0.014), and the FC diet decreased serum cholesterol levels 
further (post hoc, p<0.001 compared to CO diet and p=0.026 compared to DEU 
diet). No genotype effects on serum cholesterol levels were observed between 
the wild-type and AβPP-PS1 mice on CO (ANOVA, p=0.101) and DEU diets 
(ANOVA, p=0.353), but AβPP-PS1 mice on FC diet had significantly higher 
serum cholesterol levels than wild-type mice on FC diet (ANOVA, p=0.007).  
 
In addition, brain levels of lathosterol (Fig. 7C), a main cholesterol precursor in 
the “de novo” synthesis pathway, were similar between wild-type and AβPP-
PS1 mice (ANOVA, p=0.800). Dietary intake did affect the brain levels of 
lathosterol (ANOVA, p=0.003), such that animals fed the DEU (post hoc, 
p=0.003) and FC diets (post hoc, p=0.010) displayed significantly decreased 
levels of brain lathosterol compared to animals fed the CO diet, independent of 
genotype (genotype×diet interaction, p=0.888). Serum lathosterol levels (Fig. 
7D) were similar between wild-type and AβPP-PS1 mice (ANOVA, p=0.069),  
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Fig. 7. Sterol levels in 12-month-old AβPP-PS1 and wild-type mice on control and 
specific multi-nutrient diets. Sterol levels were determined in brain homogenates and 
blood serum by gas-chromatography-mass-spectrometry-selected ionmonitoring. (A-B) 
Cholesterol levels were similar in the brains of AβPP-PS1 and wild-type mice and were 
unaffected by dietary intake. In blood sera of wild-type mice, the Fortasyn
®
 Connect 
(FC) diet decreased cholesterol levels as compared to the control (CO) and the DHA, 
EPA and UMP (DEU) diets (**), whereas the DEU diet led to intermediate cholesterol 
levels as compared to the CO and FC diets. Only wild-type mice on FC diet displayed 
decreased levels of serum cholesterol compared to AβPP-PS1 mice, *p<0.05. (C-D): 
Lathosterol levels were similar in the brains and blood sera of AβPP-PS1 and wild-type 
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mice. Serum lathosterol levels were unaffected by dietary intake, but brain lathosterol 
levels were decreased in AβPP-PS1 and wild-type mice on the DEU and FC diets as 
compared to the CO diet (a* p<0.05). (E-F) 24-hydroxycholesterol levels were similar in 
the brains and blood sera of AβPP-PS1 and wild-type mice. Brain 24-
hydroxycholesterol levels were increased in AβPP-PS1 and wild-type mice on the DEU 
and FC diets as compared to the CO diet (a*), whereas serum 24-hydroxycholesterol 
levels were decreased in AβPP-PS1 and wild-type mice on the DEU and FC diets as 
compared to the CO diet (a*), a*p<0.05. (G-H) Brain 27-hydroxycholesterol levels were 
decreased in AβPP-PS1 mice compared to wild-type mice (*p=0.040), but were 
unaffected by dietary intake. Serum 27-hydroxycholesterol levels were similar between 
AβPP-PS1 and wild-type mice, independent of dietary intake. Overall analysis revealed 
a tendency for an effect of dietary intake (p=0.054), but no post hoc analyses were 
performed since it did not reach statistical significance.  
 
and between the diet groups (ANOVA, p=0.709). 
 
Furthermore, the levels of cholesterol’s brain specific oxidative metabolite 24S-
hydroxycholesterol did not differ significantly in the brains (ANOVA, p=0.072) 
and sera (ANOVA, p=0.510) of wild-type and AβPP-PS1 mice. Dietary intake 
did affect both brain (ANOVA, p<0.001) and serum (ANOVA, p=0.001) 24S-
hydroxycholesterol levels, such that animals fed the DEU (post hoc, p=0.004) 
and FC diets (post hoc, p<0.001) had significantly higher levels of 24S-
hydroxycholesterol in the brain compared to animals fed the CO diet (Fig. 7E), 
independent of genotype (genotype×diet interaction, p=0.054), indicating 
increased conversion of cholesterol in the brain due to dietary intervention. In 
contrast, serum 24S-hydroxycholesterol levels (Fig. 7F) were decreased in 
animals fed the DEU (post hoc, p=0.028) and FC diets (post hoc, p<0.001) 
compared to animals fed the CO diet, independent of genotype (genotype×diet 
interaction, p=0.477).  
 
Another oxidative metabolite of cholesterol, 27-hydroxycholesterol (Fig. 7G), 
was significantly decreased in the brains of AβPP-PS1 mice compared to wild-
type animals (ANOVA, p=0.040), independent of diet (genotype×diet 
interaction, p=0.817), suggesting a decreased flux of cholesterol from the 
periphery into the brain [74-76]. No significant differences could be observed in 
the levels of brain 27-hydroxycholesterol between the diet groups (ANOVA, 
p=0.073). Serum 27-hydroxycholesterol levels (Fig. 7H) were similar between 
wild-type and AβPP-PS1 mice (ANOVA, p=0.256). Overall analysis revealed a 
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tendency for an effect of diet intervention (ANOVA, p=0.054) on serum 27-
hydroxycholesterol levels, but this did not reach statistical significance. 
 
 
Fig. 8. Brain fatty acids in 12-month-old AβPP-PS1 and wild-type mice on control and 
specific multi-nutrient diets. The relative concentrations of different fatty acids were 
determined in the lipid fraction of brain homogenates, and were similar between 
AβPP-PS1 and wild-type mice. Dietary intake affected the relative concentrations of 
different fatty acids similarly in AβPP-PS1 and wild-type mice. Both the DHA, EPA 
and UMP (DEU) diet and the Fortasyn
®
 Connect (FC) diet increased the relative 
concentrations of omega-3 fatty acids (n3) and decreased the relative concentrations of 
omega-6 fatty acids (n6), resulting in a pronounced shift in n3/n6 ratio in favor of the 
n3 fatty acids as compared to the control(CO) diet, *p<0.001. The reduction of the 
relative n6 content was mainly caused by a decrease in arachidonic acid (AA; 
C20:4n6), while the higher n3 content was mainly caused by an increase in 
docosahexaenoic acid (DHA; C22:6n3), *p<0.001. The relative concentration of oleic 
acid (OA; C18:1n9) was increased due to intake of the DEU diet *p=0.005), while it was 
only slightly, but not significantly, increased due to intake of the FC diet (
#
p=0.066). 
The relative amount of palmitic acid (C16:0); stearic acid (C18:0), saturated fatty 
acids, mono-unsaturated fatty acids and poly-unsaturated fatty acids were unaffected 
by dietary intake (data not shown).     
 
Brain fatty acid analysis 
Dietary intake affected the relative concentrations of oleic acid (ANOVA, 
p=0.011), arachidonic acid (ANOVA, p<0.001), docosahexaenoic acid 
(ANOVA, p<0.001), omega-3 fatty acids (n3 FAs; ANOVA p<0.001), and 
omega-6 FAs (ANOVA; p<0.001) in both wild-type and AβPP-PS1 mice (Fig. 
8). Animals fed the DEU and FC diets (post hoc p<0.001) showed a shift in the 
balance between n3 and n6 fatty acids as compared to animals fed the CO diet 
(main ANOVA diet effect, p<0.001). The relative amount of n3 FA in DEU and 
FC fed mice increased compared to the CO diet (post hoc, p<0.001), whereas 
the relative amount of n6 decreased (post hoc, p<0.001), resulting in a 
pronounced shift in the n3/n6 ratio in DEU and FC fed mice in favor of the n3 
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FA. The reduction of the relative n6 content was mainly caused by a relative 
decrease in arachidonic acid (AA; C20:4n6; post hoc p<0.001), while the higher 
n3 content originated from a relative increase in DHA (C22:6n3; post hoc 
p<0.001) in both the DEU and FC fed animals as compared to the CO fed 
animals. Furthermore, the relative concentration of oleic acid (OA; C18:1n9) 
was significantly increased in the DEU fed mice (post hoc, p=0.005), and also 
slightly increased in the FC fed animals (post hoc, p=0.066) as compared to the 
CO diet, although it did not reach statistical significance. No significant 
differences were observed between the DEU and FC diets in any fatty acid 
analyzed (post hoc, p>0.05). The relative amounts of palmitic acid (C16:0; 
ANOVA p=0.714), stearic acid (C18:0; ANOVA p=0.841), total saturated fatty 
acids (SFA; ANOVA p=0.793), total mono-unsaturated fatty acids (MUFA; 
ANOVA p=0.316) and total poly-unsaturated fatty acids (PUFA; ANOVA 
p=0.459) were unaffected by the diets (data not shown). No significant 
genotype effects or genotype×diet interactions were found for any of the fatty 
acids analyzed (ANOVA, p>0.05).  
 
Quantitative real-time PCR (qRT-PCR) 
Wild-type and AβPP-PS1 mice displayed similar levels of MCP-1 (ANOVA, 
p=0.927), IL-6 (ANOVA, p=0.081), TNF-α (ANOVA, p=0.701) and CD36 
(ANOVA, p=0.180). However, IL-1β levels were significantly increased in 
AβPP-PS1 mice compared to wild-type animals (Fig. 9A; ANOVA, p<0.001), 
independent of dietary intake (genotype×diet interaction, p=0.272). 
Furthermore, overall statistical analysis indicated a significant effect of dietary 
intake on the levels of IL-1β (ANOVA, p=0.005). Post hoc analysis revealed 
that both wild-type and AβPP-PS1 animals fed the DEU (post hoc, p=0.034) 
and FC diets (post hoc, p=0.013) had significantly higher levels of IL-1β than 
animals fed the CO diet (Fig. 9B). No differences were observed between the 
different diets in the levels of MCP-1 (ANOVA, p=0.349), IL-6 (ANOVA, 
p=0.232), TNF-α (ANOVA, p=0.707) and CD36 (ANOVA, p=0.157). 
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Fig. 9. Inflammatory markers in 12-month-old AβPP-PS1 and wild-type mice on 
control and specific multi-nutrient diets. Inflammatory markers were determined by 
quantitative real-time PCR in a part of the snap-frozen brain tissue, which included 
both hippocampi, using primers for monocyte chemoattractant protein 1 (MCP-1), 
interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), cluster of 
differentiation 36 (CD36), and glyceralehyde-3-phospate dehydrogenase (GADPH). 
Relative gene expression ratios were calculated according to the comparative CT 
method (2
-ΔCT
 method), by subtracting the CT value of the housekeeping gene GADPH 
from the CT values of the inflammatory markers(ΔCT). (A) AβPP-PS1 and wild-type 
mice displayed similar levels of MCP-1, IL-6, TNF-α and CD36. However, IL-1β levels 
were increased in AβPP-PS1 mice compared to wild-type animals, independent of 
dietary intake (*p<0.001). (B) Levels of MCP-1, IL-6, TNF-α and CD36 were 
unaffected by dietary intake. However, the levels of IL-1β were affected by dietary 
intake, independent of genotype (p=0.005). Both the DHA, EPA and UMP (DEU) diet 
(p=0.034) and  the Fortasyn
® 
Connect (FC) diet (p=0.013) increased the levels of IL-1β 
as compared to the control (CO) diet in AβPP-PS1 and wild-type mice. 
 
Discussion 
 
In the present study, we investigated the extent to which long-term consumption 
of two specific multi-nutrient enriched diets, developed to support membrane 
synthesis and maintenance, can modulate behavior, cognition, hippocampal 
metabolite levels, neurogenesis and inflammation in 11-12-month-old AβPP-
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PS1 mice. An overview of the main results found in the current study is shown 
in Table 3.  
 
In agreement with previous results from our lab [59, 77], 11-month-old AβPP-
PS1 mice displayed increased activity and anxiety-related behavior, and 
decreased explorative behavior in the open field as compared to age-matched 
wild-type mice. Hyperactivity and decreased explorative behavior are specific 
characteristics of many AβPP transgenic mice [78-80] and may be explained as 
a result of elevated anxiety levels [81, 82]. Curiosity motivates mice to explore 
a novel environment, but this exploratory drive is in conflict with fear of the 
unknown. Hyperactivity and anxiety-related behavior in AβPP transgenic mice 
resemble anxiety symptoms and restlessness, which occur in up to 70% of AD 
patients during the course of their illness and are significantly correlated with 
impairments in activities of daily living [83-85]. Dietary intervention with the 
DEU and FC diets differentially affected open field behavior in both AβPP-PS1 
and wild-type mice. While the DEU diet increased general locomotor activity 
(restlessness) and anxiety-related exploration (e.g. wall leaning), our results 
suggest that the FC diet could have an anxiolytic effect, since it decreased the 
time spent in the corners of the open field as compared to the animals on CO 
and DEU diets. Previous studies have shown that rats fed an n3 lc-PUFA 
deficient diet display increased anxiety-related behavior in the open field and 
elevated plus maze tasks as compared to animals fed an n3 lc-PUFA adequate 
diet [86, 87]. Supplementation with n3 lc-PUFAs led to substantial reduction in 
the anxiety levels of n3 lc-PUFA deficient rats [87, 88] and mice [89]. 
Moreover, n3 fatty acid deficiency has been linked to increased vulnerability to 
stress, elevated aggression, and increased depressive-like symptoms in rodents 
[90]. Supplementation with n3 lc-PUFAs has also shown beneficial effects on 
depressive symptoms and agitation in patients with mild to moderate AD [91]. 
However, it should be noted that both the DEU diet and the FC diet contained 
equal amounts of n3 lc-PUFAs, suggesting that the combination of additional 
nutrients in the FC diet was important for the efficacy on anxiety-related 
behavior. Interestingly, Schipper et al. showed that a combination of n3 lc-
PUFAs, phospholipids and B-vitamins (which are also part of the current FC 
diet) completely abolished anxiety-related behavioral responses, increased 
social behavior and facilitated fear extinction recall in serotonin transporter 
knockout (SERT-ko) rats [92]. 
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Furthermore, the FC diet also reduced anxiety-related behavior in the open field 
in 12-month-old  apolipoprotein E (apoE)-ε4/ε4 and apoE knockout mice [93]. 
Combined, these results suggest that supplementation with the FC diet could 
potentially be beneficial for several neurodegenerative and neurological 
disorders in which patients exhibit symptoms of agitation, anxiety and 
depression. 
 
In line with our previous results [59, 77], 11-month-old AβPP-PS1 mice also 
showed impaired performance in the MWM and rMWM as compared to age-
matched wild-type animals. Although both AβPP-PS1 and wild-type mice 
showed a similar decrease in escape latency during training in the MWM, 
overall escape latencies were significantly higher in AβPP-PS1 mice, 
independent of dietary intake. Longer escape latencies during spatial navigation 
can be caused by slower swim speed, although this is not a confounding factor 
in the current study, since AβPP-PS1 mice displayed higher swim speeds during 
the task acquisition trials. Longer escape latencies during spatial navigation may 
also be caused by the use of certain, less efficient, search strategies, such as a 
constant random search of the entire surface area of the pool, which would 
indicate a complete lack of spatial learning abilities, or by persistent 
performance of a less efficient than spatial (direct) search strategy, such as 
circling the pool at a certain distance from the wall to find the platform [94, 95]. 
In this strategy, mice have not used the spatial cues to learn the location of the 
platform, although such a strategy would result in a successful location of the 
escape platform during training. Since AβPP-PS1 mice searched the target NE 
quadrant during the probe trial at chance level (25% or less), our results might 
imply that the AβPP-PS1 mice made use of a random or a persistent non-spatial 
search strategy to locate the platform during acquisition training. This is in line 
with a study by O’Leary and Brown, in which the search strategies used by 16-
month-old AβPP-PS1and wild-type mice during visuo-spatial navigation in the 
Barnes Maze were analyzed [96]. 16-month-old AβPP-PS1 mice predominantly 
made use of a random search strategy to locate the escape hole in the Barnes 
Maze, whereas wild-type mice predominantly made use of a spatial (direct and 
accurate) search strategy. Similar results have been found for the search 
strategies used by the TgCRND8 transgenic AβPP mouse model in the MWM 
test [97, 98]. Moreover, it was shown that C57BL6 mice, treated with 
Temozolomide (TMZ) to suppress adult hippocampal neurogenesis, displayed a 
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delayed (or even absent) use of directed and place specific search patterns in the 
(reversal) MWM test compared to untreated mice, suggesting that hippocampal 
neurogenesis is necessary for adding flexibility to some hippocampus-
dependent qualitative parameters of learning [94]. Consistent with our current 
findings, reduced hippocampal neurogenesis has been found previously in 
AβPP-PS1 mice [99-101] and in AD patients [102, 103], and might underlie 
some aspects of the cognitive deficits in AD.  
 
In line with our previous findings [77], AβPP-PS1 and wild-type mice showed a 
similar decrease in escape latency during training in the reversal MWM. The 
reversal task requires selective memory retrieval of the newly learned location 
of the platform, and contains therefore an extra episodic component [61, 104]. 
Since episodic memory impairment is a major characteristic in early AD [105-
107], our results in AβPP-PS1 mice resemble the problems that are present in 
early AD patients. Noteworthy are the relatively low escape latencies of both 
AβPP-PS1 and wild-type mice during the initial trials of the rMWM acquisition 
training. Although wild-type mice displayed good short-term spatial memory 
for the NE platform location during the probe trial of the MWM, it appears that 
this information might not have been sufficiently consolidated in the long-term 
memory since they displayed more “random” search behavior during the initial 
rMWM trials (resulting in lower escape latencies) than expected if animals had 
good long-term memory for the former platform location. One possible 
explanation could be that the MWM task as used in the current study was 
slightly too difficult to optimally master within 4 days of training. For mice, a 
MWM pool with a diameter of 120 cm and a platform of 10-12 cm in diameter 
(or even larger) is commonly used, resulting in a search area to target size of 
144:1 to 100:1 (or even lower). In the current study, we used a pool with a 
diameter of 104 cm and a platform of 8 cm in diameter, resulting in a search 
area to target size of 169:1, thereby increasing the MWM task difficulty [108, 
109].  
 
Previous studies have shown that n3 lc-PUFA intake may improve cognition in 
both mice and rats [59, 110, 111]. Besides n3 lc-PUFAs, other nutrients can also 
affect spatial memory performance. Supplementing CDP-choline or UMP and 
choline to rats improved spatial memory in the water maze [112, 113]. In 
addition, transgenic mice fed vitamin E [114] or vitamin B3 [115] showed 
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normalized escape latency in the water maze. Furthermore, a combination of 
vitamin E and folic acid prevented human Aβ1-40-induced impairment of water 
maze learning in 3-month-old male Swiss mice [116]. However, in agreement 
with our current results, there are also some reports showing no effect of n3 lc-
PUFA intake on learning and memory performance [90, 117, 118]. Moreover, 
most intervention studies based on single nutrient supplementation with n3 lc-
PUFAs, B-vitamins or vitamin E have failed to show any protective effect on 
AD [39-41, 119] or cognitive decline [120-122], except in some patients with 
mild AD [123, 124]. Interestingly, clinical studies with the multi-nutrient FC 
supplementation have shown beneficial effects on memory performance in 
patients with mild AD [51-53], although we could not replicate these findings in 
our AβPP-PS1 mouse model when using the standard conventional measures of 
performance in the MWM. However, the FC diet did recently improve  the 
search strategy of AβPP-PS1 mice in the acquisition of the MWM, by switching 
from  predominantly random search strategies towards a more efficient search 
strategy, suggesting some beneficial effects of the FC diet on the ability to cope 
with cognitive impairment in the AβPP-PS1 mouse model [125].   
 
1
H MR spectroscopy revealed decreased tNAA/tCre levels in the hippocampus 
of 12-month-old AβPP-PS1 mice as compared to wild-type mice, in accordance 
with our previous results [77]. The reduction of tNAA levels is one of the most 
consistent findings using 
1
H MRS in AD patients [126-129] and in several 
transgenic AβPP animals models for AD [130-134], and is commonly 
interpreted as a result of neuronal dysfunction or neuronal loss [135, 136]. 
Furthermore, many previous 
1
H MRS studies have found elevated levels of 
myo-Inositol (mI) in the temporal, parietal and occipital lobes of AD patients 
[127, 129], which has been associated with enhanced inflammatory processes. 
Reports on mI levels in transgenic animals models are highly inconsistent, since 
disturbances in mI levels were found to occur at different ages in different 
transgenic species apparently depending on the interplay of mouse strain, 
transgene and disease progression [137]. For example, the AβPPswe (Tg2576) 
model and the AβPP-PS2N1411 (PS2APP) model do not show any change in 
mI levels throughout life compared to age-matched wild-type mice, even though 
these animal models display decreased NAA levels in the frontal cortex at 19-24 
months of age, when Aβ deposits are widespread [130, 138]. In the case of the 
AβPPswe-PS1M146L model, one study reported the most profound increase in 
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mI levels after 20 months of age [131], whereas another study reported a 
decrease in mI levels at 2.5 months of age as compared to age-matched wild-
type mice [132]. In the current and in our previous study [77], we did not 
observe any differences in the levels of mI+Gly between AβPP-PS1 and wild-
type mice. In contrast, Chen and colleagues observed significantly increased 
levels of mI in 3-, 5- and 8-month-old AβPPswe-PS1dE9 mice, when pathology 
showed activation and proliferation of astrocytes in the frontal cortex and 
hippocampus [139, 140]. The discrepancy between the results found by Chen et 
al. and our own findings are most likely due to differences in methodology, e.g. 
the field strength of the MR system, the acquisition parameters used, the exact 
position of the spectroscopic volume of interest, the age of the animals, and the 
amount of animals used.  
 
Disturbances of several other metabolites have been found in AD patients as 
well, although the reports are inconsistent. Some studies identified elevated 
choline-containing compounds (tCho) and creatine (Cre) in AD patients [141-
143], whereas others did not [126, 144]. One possible explanation for the 
elevation of tCho in AD is increased membrane turnover due to 
neurodegenerative processes [145, 146]. It has also been postulated that the 
elevation of the tCho peak is the consequence of membrane phosphatidylcholine 
catabolism in order to provide free choline for the chronically deficient 
acetylcholine production in AD [147, 148]. In agreement with our current 
findings, no differences were observed between AβPP-PS1 and wild-type mice 
at any age tested in the levels of tCho [77, 134, 139]. Dietary intake with the FC 
diet significantly decreased the levels of tCho in AβPP-PS1 and wild-type mice, 
suggesting diminished membrane turnover. Since the FC diet provides 
precursor and cofactors in membrane synthesis and maintenance that are not 
supplemented in the CO and DEU diets, such as choline chloride and soy 
lecithin, these additional nutrients might underlie the decreased levels of tCho. 
1
H MRS studies to investigate the effect of the multi-nutrient FC diet on brain 
metabolism in mild AD patients are currently ongoing.     
 
Dietary intervention with the FC diet, but not with the DEU diet, restored 
neurogenesis in AβPP-PS1 mice. Reduced hippocampal neurogenesis has been 
found previously in AβPP-PS1 mice beyond 8 months of age [100, 101, 149] 
and in AD patients [103, 150, 151]. In line with our results, previous studies 
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have shown that n3 lc-PUFAs [152, 153], folic acid [154, 155], and vitamins 
and antioxidants [156, 157] may promote neurogenesis. Since the FC diet did 
not affect neurogenesis in wild-type mice, our results could imply that this 
dietary intervention may especially be beneficial when neurogenesis is severely 
compromised. Dietary intervention with the FC diet might therefore be of 
interest for several other neurodegenerative and neurological disorders in which 
neurogenesis is impaired, such as Parkinson’s disease and major depression.  
 
Quantitative real-time PCR revealed increased IL-1β mRNA levels in 12-
month-old AβPP-PS1 mice as compared to age-matched wild-type mice. In 
response to brain injury or infection, IL-1β is both expressed by and targeted to 
many different cell types within the brain, such as microglia, astrocytes, 
endothelial cells, infiltrating leukocytes, neurons and oligodendrocytes [158-
160]. IL-1β has been implicated to be at or near the top of the cytokine 
signaling cascade that initiates the neuroinflammatory changes seen in AD 
(reviewed in [161, 162]). It has been suggested that the initial burst of IL-1β 
production might actually have a beneficial role in AD, by enhancing the 
microglial clearance of amyloid plaques [162-164]. However, chronic elevation 
of IL-1β is detrimental, since IL-1β is capable of propagating inflammatory 
responses by increasing its own expression [162, 163, 165] and inducing the 
expression of several other pro-inflammatory cytokines, such as TNF-α and IL-
6 [166], and chemokines, such as MCP-1 [167, 168]. Our results of increased 
IL-1β mRNA levels in 12-month-old AβPP-PS1 mice, but no changes (yet) in 
the mRNA levels of MCP-1, IL-6, TNF-α and CD36, might reflect the initial 
burst of IL-1β production in response to brain injury or toxic agents such as Aβ.  
 
Surprisingly, IL-1β mRNA levels were also elevated in both AβPP-PS1 and 
wild-type mice in response to dietary intervention with the DEU and FC diets. 
This seems contradictory to the anti-inflammatory and immunosuppressive 
properties ascribed to n3 lc-PUFAs, B vitamins and antioxidants [28, 34, 169]. 
However, IL-1β signaling has also been associated with neuroprotective 
mechanisms, including mediating the production of survival signals such as 
nerve growth factor [170, 171] and mediating re-myelination of the central 
nervous system by stimulating oligodendrocytes proliferation [160, 172]. 
Interestingly, results from our own lab indicate that both the DEU and FC diets 
prevent axonal disconnection and myelin degradation, determined by diffusion 
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tensor MR imaging, in the 12-month-old AβPP-PS1 and wild-type mice used in 
the current study (Zerbi et al., submitted data). However, since prolonged 
elevation of IL-1β can initiate chronic neuroinflammatory processes, the 
question remains whether the effects of these multi-nutrient diets on IL-1β 
production are ultimately beneficial or detrimental in the AβPP-PS1 mouse 
model.  
 
In conclusion, we showed that specific multi-nutrient diets can ameliorate some 
AD-related pathologies in 11-12-month-old AβPPswe-PS1dE9 mice. Although 
both diets were equally effective in changing brain fatty acid profiles and 
cholesterol metabolism, the diets differentially affected open field behavior, 
hippocampal metabolite levels and neurogenesis, suggesting that the 
effectiveness of specific nutrients may depend on the dietary context in which 
they are provided. The multi-nutrient enriched FC diet with DHA, EPA, UMP, 
phospholipids, choline, folic acid, vitamins B6, B12, C, E and selenium 
(Fortasyn
®
 Connect; FC diet) was more effective than the DEU diet enriched 
with DHA, EPA and UMP in counteracting neurodegenerative aspects of AD 
and enhancing processes involved in neuronal maintenance and repair. 
Intervention with the FC diet might therefore be of interest for several other 
neurodegenerative and neurological disorders.  
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Chapter 5 
 
 
 
Impact of a multi-nutrient diet on cognition,  
brain metabolism, hemodynamics, and  
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Abstract 
 
Lipid metabolism and genetic background together strongly influence the 
development of both cardiovascular and neurodegenerative diseases like 
Alzheimer’s disease (AD). A non-pharmacological way to prevent the 
genotype-induced occurrence of these pathologies is given by dietary behavior. 
In the present study, we tested the effects of long term consumption of a 
specific multi-nutrient diet in two models for atherosclerosis and vascular risk 
factors in AD: the apolipoprotein ε4 (apoE4) and the apoE knockout (apoE ko) 
mice. This specific multi-nutrient diet was developed to support neuronal 
membrane synthesis and was expected to contribute to the maintenance of 
vascular health. At 12 month of age, both genotypes showed behavioral changes 
compared to control mice and we found increased neurogenesis in apoE ko 
mice. The specific multi-nutrient diet decreased anxiety-related behavior in the 
open field, influenced sterol composition in serum and brain tissue, and 
increased the concentration of omega-3 fatty acids in the brain. Furthermore, we 
found that wild-type and apoE ko mice fed this multi-nutrient diet showed 
locally increased cerebral blood volume and decreased hippocampal glutamate 
levels. Taken together, these data suggest that a specific dietary intervention has 
beneficial effects on early pathological consequences of hypercholesterolemia 
and vascular risk factors for AD.  
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Introduction 
 
Diseases related to a sedentary lifestyle with high-fat dietary intake become a 
major problem in our aging western society. For example cardiovascular 
diseases, like coronary heart disease (CHD), and neurodegenerative disorders, 
like Alzheimer’s disease (AD), are the most described in the current literature 
and share many risk factors such as obesity, diabetes mellitus and 
hypercholesterolemia [1-5]. Despite the growing awareness of the impact of a 
sedentary lifestyle and high-fat dietary intake, these risk factors are likely to 
increase in the future and extend to developing countries, which will have a 
huge impact on the global economy because of costs associated with screening, 
treatment and daily care services. These same risk factors are modifiable by the 
management of hypercholesterolemia; this reduces the risk of developing 
cardiovascular-related pathologies, including CHD [6]. Epidemiological studies 
have associated the use of cholesterol lowering agents (statins) with diminished 
prevalence of AD [7, 8] and with preserved cognitive functions [9], although 
more recent studies have shown no beneficial effects of statins on dementia or 
AD [10-12].  
 
To which extent a compromised cholesterol homeostasis in the vascular system 
and in the brain is able to trigger cerebrovascular and neurodegenerative 
pathologies is still under debate. A potential key-factor in the relationship 
between lipid metabolism and vascular and neurodegenerative disorders is the 
cholesterol transporter apolipoprotein ε4 (apoE-ε4), which is a major genetic 
risk factor for hypercholesterolemia, vascular dementia and sporadic AD [13-
15]. ApoE is the most prevalent brain lipoprotein and plays a fundamental role 
in neuronal maintenance and repair. In the human population three common 
isoforms termed apoEε2, apoEε3, and apoEε4 are expressed, which differ from 
each other in one to two amino acids [16]. ApoE has several functions in the 
body and in the brain, including anti-inflammation and antioxidation [17-19], 
but especially functions as a ligand in receptor-mediated endocytosis of 
lipoprotein particles, such as cholesterol. Cholesterol released from apoE-
containing lipoprotein particles is used to support synaptogenesis and the 
maintenance of synaptic connections [20, 21]. Compared to the apoEε2 and 
apoEε3 isoforms, apoEε4 is a less functioning cholesterol transporter 
contributing to hypercholesterolemia and atherosclerosis [22, 23]. Interestingly, 
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while in the general population 10-15% carries one ε4 allele, the occurrence in 
AD patients is 40-65%. In addition, ε4 allele carriers develop AD at a younger 
age than non- ε4 allele carriers [24], and ε4-positive AD patients display higher 
levels of AD pathological hallmarks, such as amyloid-β (Aβ) plaques and 
neurofibrillary tangles (NFTs), than do corresponding non-ε4 AD patients [25-
27]. 
 
The non-pharmacological management of cholesterol levels by means of 
specific diets containing fish oil has been recently proposed to prevent and treat 
the negative effects of the apoE4 genotype in AD [28, 29]. Recent experiments 
on young apoE4- target replacement mice suggest a positive influence of fish-
oil containing diets on behavioral and cognitive performances [30]. These 
beneficial effects have been explained by the capacity to prevent arrhythmias 
[31], lowering plasma triacylglycerols [32-34], decreasing blood pressure [35], 
improving vascular reactivity [32, 36] and decreasing atherosclerosis [37] and 
inflammation [38]. Furthermore, high levels of omega-3 (n-3) long-chain 
polyunsaturated fatty acids (lc-PUFAs) replace omega-6 (n-6) fatty acids and 
cholesterol from cell membranes leading to increased fluidity of the membrane, 
increased number of receptors, enhanced receptor binding and affinity, and 
better ion channel functionality [39-41]. As a result, this leads to improved 
neurotransmission and signalling [40], which is important for optimal cognitive 
functioning [42]. Other dietary components like B-vitamins and antioxidants 
have been shown to protect the brain from oxidative and inflammatory damage 
[43-46], and synaptic and neuronal loss [47, 48].  
 
Based on these findings, a specific multi-nutrient diet has been developed for 
the dietary management of AD’s risk factors [49]. To date, two randomized, 
double-blind controlled clinical trials demonstrated improved memory 
performance in patients with mild AD, taking this multi-nutrient component diet 
supplementation on a daily base [49-51]. The mechanisms by which these 
dietary nutrients influence the cholesterol metabolism and have protective 
properties against AD traits yet need to be elucidated. In this study, we 
investigate the extent to which a specific multi-nutrient diet, containing 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), phospholipids, 
uridine monophosphate (UMP), choline, B-vitamins and antioxidants, which are 
precursors and co-factors for membrane synthesis and maintenance [52] and 
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may help to support vascular health, may inhibit cerebrovascular flaws and 
neuronal and synaptic loss in apoE4-carrier and apoE knockout mice. ApoE4-
carrier and apoE knockout mice represent relevant models to study the effects of 
compromised cholesterol homeostasis on the development of CHD and AD. 
While apoE4 carrier mice exhibit an increased risk of vascular disorders due to 
altered cholesterol metabolism, apoE knockout mice spontaneously develop 
severe hypercholesterolemia and atherosclerosis [53, 54].   
 
Animals, materials and methods 
 
Animals, dietary intervention and housing conditions 
The apoE4 founder mice were originally obtained from Taconic Transgenic 
Models (Hudson, NY, USA) and a colony was established at the Radboud 
University Nijmegen Medical Centre (RUNMC), the Netherlands. In short, 
mice were created by targeting the murine APOE gene for replacement with the 
human APOE4 alleles (4/4) in 129P2/OlaHsd-derived E14TG2a ES cells and 
injecting the targeted cells into blastocysts. Resultant chimeras were 
backcrossed to C57BL/6J for 8 generations. The line was derived by embryo 
transfer and is maintained by incrossing homozygous mice. For the present 
study, male and female apoE4 breeder mice were used to generate homozygous 
apoE4 offspring (1
st
 generation at the RUNMC).  
 
The apoE-deficient (B6,129P2-Apoe
tm1Unc
/J) founders were originally obtained 
from Jackson Laboratories (Bar Harbor, ME, USA) and a colony was 
established at the RUNMC. In short, mice were created by targeting the apoE 
gene in 129P2/OlaHsd-derived E14TG2a ES cells and injecting the targeted 
cells into C57BL/6J blastocysts. Resultant chimeras were backcrossed to 
C57BL/6J for 11 generations. The line was derived by embryo transfer and is 
maintained by incrossing homozygous mice [55].  For the present work, male 
and female apoE knockout (apoE ko) breeder mice were used to generate 
homozygous apoE ko offspring (1
st
 generation at the RUNMC).  
 
C57BL/6J wild-type mice, which were the non-transgenic wild-type littermates 
of our colony of AβPPswe-PS1dE9 mice, were used as controls. In short, the 
AβPP-PS1swe-PS1dE9 founders were originally obtained from John Hopkins 
University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of 
 
5 
164 
 
Pathology) and a colony was established at the RUNMC [56, 57]. The 
AβPPswe-PS1dE9 line (line 85) was originally maintained on a hybrid 
background by backcrossing to C3HEJ×C57BL/6J F1 (so-called pseudo F2 
stage). For the present work, male AβPPswe-PS1dE9 breeder mice were 
backcrossed to female C57BL/6JOlaHsd (Harlan Laboratories, Inc., Horst, the 
Netherlands) for 10 generations, and the non-transgenic C57BL/6J wild-type 
offspring were used for the current study.  
 
Throughout the experiments animals were housed in groups of 2-7 mice per 
cage in a controlled environment, homogenously illuminated by normal 
fluorescent room light at 60 lux, with room temperature at 21ºC, and an 
artificial 12:12h light:dark cycle (lights on at 7 a.m.). Food and water were 
available ad libitum.  
 
Male apoE ko, apoE4 and wild-type mice were fed either a standard Control 
diet (CO diet), or a specific multi-nutrient diet, called Fortasyn
®
 Connect (FC 
diet). The diets differed in composition with regard to the fat blends used, as 
well as the number of supplemented nutrients as indicated in Table 1. Diets 
were isocaloric and were manufactured by Research Diet Services (Wijk bij 
Duurstede, the Netherlands). In order to minimize oxidation of the lc-PUFAs, 
the experimental diets were stored at -20°C in 2-day supply aliquots. At 2 
months of age the mice were put on the diets for the remainder of the 
experiment. Animals underwent behavioral testing at 9 ± 1 month of age and 
MRI measurements at 11 ± 1 month of age (Fig. 1). In total 84 mice were used. 
Table 2 describes the number of mice in each experimental group. The 
experiments were performed according to Dutch federal regulations for animal 
protection and were approved by the Veterinary Authority of the Radboud 
University Nijmegen Medical Centre.  
 
Behavioral analyses 
Behavioral testing was performed at 9 ± 1 months of age, in the following 
order: First open field, followed by Morris water maze (MWM), and finally the 
reversal MWM (Fig. 1). All testing sessions were performed during the light 
phase (between 9 a.m. and 5 p.m.) and were recorded for computer-assisted 
analysis using Ethovision 7.0 software (Noldus Information Technology B.V., 
Wageningen, the Netherlands). All behavioral testing was performed in the 
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same room, homogenously illuminated by normal fluorescent room light at 60 
lux. 
 
Table 1. Compositions of the experimental diets used, based on AIN-93M [58] with 
minor revisions. All diets were isocaloric contained 5% fat and standard vitamin and 
mineral premix, providing recommended daily amounts of these nutrients. All amounts 
of nutrients are indicated in g/100 g of diet 
 Dietary groups 
Source Control (CO) 
Fortasyn
®
 Connect 
(FC) 
Corn starch 35.57 33.12 
Casein  14.00 14.00 
Corn dextrin 15.50 15.50 
Sucrose 10.00 10.00 
Dextrose 10.00 10.00 
Fibers 5.00 5.00 
Mineral mix (AIN-93M-MX) 3.50 3.50 
Vitamin mix (AIN-93-VX) 1.00 1.00 
Fats:   
Soy oil 1.900 - 
Coconut oil 0.900 0.100 
Corn oil 2.200 1.870 
Fish oil - 3.030 
Additions:   
L-cysteine 0.180 0.180 
Choline bitartrate (41.1% choline) 0.250 0.250 
Tert-butylhydroquinone 0.0008 0.0008 
Pyridoxine-HCL - 0.00328 
Folic acid (90%) - 0.00067 
Cyanocobalamin (0.1% in mannitol) - 0.00350 
Ascorbic acid (100% pure) - 0.160 
dl-α-tocopheryl acetate (500 IU/g) - 0.4650 
UMP disodium (24% H2O) - 1.0 
Choline chloride (74.576%) - 0.402 
Soy lecithin - 0.402 
Sodium selenite (46% min) - 0.00023 
   
Energy (kcal/100g chow): 376.9 367.1 
   
% Fatty acids:   
Total n3  2 22 
Total n6 44 22 
Ratio n6/n3 20.3 1.0 
SFA 27 24 
MUFA 21 24 
PUFA 46 44 
UMP = uridine monophosphate; SFA = saturated fatty acids;  
MUFA = mono unsaturated fatty acids; PUFA = poly unsaturated fatty acids. 
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Fig. 1. Time line of experimental design. At 2 months of age, the mice were put on 
either control or Fortasyn
® 
Connect diet for the remainder of the experiment. 
Behavioral testing was performed at 9±1 months of age. In the first week of behavioral 
testing, animals were exposed to the open field once for 30 minutes. In the second week, 
animals were trained in the Morris water maze (MWM) for 4 days. In the third week, 
animals were trained in the reverse Morris water maze (rMWM) for 2 days. MR 
imaging was performed at 11±1 months of age. Animals were sacrificed immediately 
after MR imaging. 
 
 
Table 2. Overview of the number of mice used in each experimental group 
Genotype Diet Total Open 
Field 
(r)MWM MRS  CBV IHC BCH 
Wild-type  CO 17 8 8 8 8 7-8 8 
 FC 16 8 8 8 10 8-9 7 
apoE4  CO 13 8 8 9 9 7 5-6 
 FC 13 8 6 8 7 7 5-6 
apoE ko  CO 13 8 8 8 9 5-7 6 
 FC 12 8 8 8 10 5-6 6 
CO = Control diet; FC = Fortasyn
®
 Connect diet; (r)MWM = (reverse) Morris water 
maze; MRS = magnetic resonance spectroscopy; CBV = cerebral blood volume; IHC = 
immunohistochemistry; BCH = biochemistry. 
 
Open field 
To analyze explorative and anxiety-related behavior mice were placed 
individually in the center of a square open field (50×50×50 cm) with white 
Plexiglas walls, and were observed for 30 min. The duration (seconds) of 
walking, wall leaning, rearing, sitting and grooming were scored and analyzed. 
 
5 
167 
 
These open field parameters were defined as described previously [59, 60]. In 
addition, total walking distance, mean velocity, and the time spent in the corners 
respectively the center of the open field were obtained from the recorded 
sessions. The center of the open field was defined as a square measuring 20×20 
cm, and the corners of the open field were defined as the sum of all four 10×10 
cm squared corners.  
 
Morris water maze (MWM) 
To investigate spatial learning abilities, mice were tested in the Morris water 
maze (MWM). Mice were placed in a pool (104 cm diameter) filled with water 
(21-22°C; made opaque by the addition of milk powder) at different starting 
positions and trained to find a submerged platform by using distant visual cues 
present on the four walls of the test room at a distance of 0.5 meter. The 8 cm 
diameter round platform was submerged 1 cm below the water surface and 
placed in the middle of the northeast (NE) quadrant at a distance of 26 cm from 
the wall. During all trials the researcher was present and always located at the 
same location in the room (close to the SW quadrant). 
 
Acquisition (spatial learning): Mice were trained to find the location of the 
submerged escape platform in 4 acquisition trials (maximal swimming time 120 
s; 30 s on the platform; inter-trial interval 60 min) per day during 4 consecutive 
days. The latency time (seconds) to find the hidden platform was scored. 
Starting positions during the 4 trails/day were: S, N, E, W. After the 2 min swim 
the mice were placed back in their home cage, and a paper towel was available 
inside the cage for additional drying.  
 
Probe (spatial memory): All mice performed a single probe trial 60 min after the 
last trial on day 4, in which the platform was removed from the swimming pool. 
Mice were allowed to swim for 60 s and the time spent swimming and 
searching in the former platform quadrant and former platform location), total 
swimming distance, and mean velocity were recorded.  
 
Reverse Morris water maze (rMWM) 
Four days after the standard MWM probe trial, a simplified reversal MWM [60] 
was performed in which the platform location was changed to the southwest 
(SW) quadrant. In this procedure, earlier platform location needs to be encoded 
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in the long-term memory. Memory retrieval needs to be selective for the most 
recently learned location, introducing an episodic like component in the spatial 
memory task [61]. Acquisition and probe sessions were performed similar to the 
standard MWM sessions, except that starting positions were E, W, S, and N, the 
target quadrant was SW, and training lasted only 2 days (4 trials/day).  
 
Magnetic resonance imaging (MRI) 
MRI measurements were performed at 11 ± 1 month of age on a 7T/300mm 
horizontal-bore magnet interfaced to a ClinScan console (Bruker Biospin, 
Ettlingen, Germany). An integrated circular polarized transmit 
1
H volume coil 
(200mm/154mm outer/inner diameter) was used for signal transmission and 
combined with a circular polarized mouse brain 
1
H surface coil for signal 
reception. Before the MR measurements, all mice received an intravenous tail 
vein catheter. During the experiments, mice were anesthetized with 2% 
isoflurane (Abott, Cham, Switzerland) in a mixture of oxygen and N2O (2:1) 
through a nose cone and placed in a stereotactic holder. Body temperature was 
maintained at physiological levels with heated airflow and monitored with a 
rectal optical temperature probe. Respiration of the animal was monitored using 
a pneumatic cushion respiratory monitoring system (Small Animal Instruments 
Inc, NY, USA). Initially, multislice turbo spin echo images in the coronal, 
transversal and longitudinal orientations were acquired to visualize the anatomy 
and the morphology of the mouse brain structures. Imaging parameters were: 
field of view (FOV) = 25×25 mm, matrix size = 256×256, slice thickness = 0.5 
mm, echo time (TE) = 46 ms, and repetition time (TR) = 3500 ms.  
 
Magnetic resonance spectroscopy (MRS) 
Metabolite concentrations in the hippocampus were determined using 
1
H MRS. 
A volume of interest (VOI) of 1.0×1.0×2.0 mm was positioned inside the left 
hippocampus between -2.18 and -2.46 posterior to bregma, according to the 
mouse brain atlas of Franklin and Paxinos [62]. 
1
H-MRS spectra were acquired 
with stimulated echo acquisition mode (STEAM) sequence with imaging 
parameters: TR = 1500 ms, TE = 13 ms, and 1024 signal averages. Water 
suppression was performed with variable pulse power and optimized relaxation 
delays (VAPOR). For each 
1
H MRS spectrum, a water reference spectrum was 
acquired without water suppression in the same VOI with the same imaging 
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parameters and 32 signal averages. Total acquisition time for 
1
H MRS was 27 
min per animal.  
 
Quantification of the metabolite concentration was performed using the Linear 
Combination model software package (LCModel
TM
, S. Provencher, Oakville, 
Canada). Model metabolite spectra were simulated to match the magnetic field 
strength, sequence type and sequence parameters used for data acquisition. 
Metabolite concentrations are given as absolute values using the water signal in 
non-water suppressed spectra as a reference. The criteria to select the reliable 
metabolite concentrations were based on the Cramér-Rao lower bounds 
(CRLB), which are measures of the minimum standard deviation of the fit for 
each metabolite [63] and are also determined by LCModel
TM
. Only metabolites 
that had a CRLB ≤ 20% in more than 80% of the spectra were included. Five 
metabolites or metabolite combinations fulfilled the criteria: creatine + 
phosphocreatine (tCre), glutamate (Glu), myo-Inositol + glycine (mI+Gly), N-
acetylaspartate (NAA) and taurine (Tau).  
 
Relative cerebral blood volume (rCBV) 
To assess differences in microvascular brain blood volume reserves, relative 
cerebral blood volume (rCBV) was determined with a susceptibility contrast 
enhanced MRI technique as described previously, with modifications [64]. In 
short, a multi GE FLASH sequence was performed prior to and 1 min after 
administration of an intravenous bolus injections of ultra small particles of iron 
oxide  (USPIO – AMI-277, Sinerem®, Guerbet Laboratories, France) at the 
dose of 140µg Fe/mouse. The USPIO is a contrast agent that provides a 
valuable tool to characterize tissue vascularity since it remains intravascular for 
a prolonged period of time and strongly enhances the transverse water proton 
MR relaxation rate (R2
*
). Previous studies have shown an approximately linear 
relationship between the increase of relaxation rate (ΔR2*) and rCBV fraction 
over the physiologically relevant range [65, 66]. This technique has been widely 
used to assess rCBV in mice [67, 68]. Imaging parameters were: FOV = 
303014 mm, matrix size = 19219288, total resolution = 0.16×0.16×0.16 
mm, TEs = 5.13 – 7.28 – 9.40 ms, TR = 50 ms, resulting in a total scan time of 
35 min per mouse.  
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Data pre-processing and cerebral blood volume calculation 
For spatial normalization, the GE images before and after USPIO of all mice 
were co-registered with a study-specific template created from the averaged GE 
images of all animals using Advanced Normalization Tools (ANTs. V1.9.x, 
http://picsl.upenn.edu/ANTS/). Spatial normalization was achieved by using 
mutual information as the initial affine similarity metric and cross-correlation as 
‘greedy SyN’ diffeomorphic transformation metric [69]. Spatially normalized 
and masked datasets were then imported in MatLab (R2008a, Mathworks, 
Natick, MA, USA) and, for each mouse, a pixel-by-pixel delta relaxation rate 
ΔR2
*
 map was obtained using the formula: 
 
   
  
 
  
    (
    
    
) 
where S is the signal amplitude before-USPIO (Sbef ) and after-USPIO (Saft). 
Image sets from the three TEs were used for the calculation of three ΔR2
*
 values 
and thereafter these values were averaged for ∆R2
*
 maps. Histogram analysis of 
the ΔR2* images was used to mask voxels containing pial and large perforating 
arteries and veins and focus on the microvasculature compartment (rCBVmicro) 
as described in detail elsewhere [64]. The analysis of genotype-wise and diet-
wise differences in rCBVmicro was performed with a voxel-based and regions of 
interest (ROIs)–based approaches. 
 
Voxel-based and ROI-based group comparisons 
Normalized rCBVmicro values were measured in several ROIs drawn based on 
the atlas of Franklin and Paxinos [62]. These ROIs include: hippocampus, 
cerebral cortex (all cortical areas above the corpus callosum), olfactory bulb, 
cerebellum and thalamus. For the ROI-based approach, we evaluated significant 
interactions between genotype and diet. Significant differences in rCBVmicro 
maps were additionally assessed voxel-wise using the SPMMouse toolbox 
within statistical parametric mapping 5 (SPM5, Wellcome Department of 
Clinical Neurology, London) [70]. Spatially normalized rCBVmicro datasets were 
smoothed with a 500μm isotropic Gaussian kernel to correct for imperfect 
registration and subsequently a two-group t test was performed to identify 
genotype-wise and diet-wise differences in the framework of the general linear 
model (GLM). Statistical significance for an individual voxel was established at 
p<0.01, uncorrected for multiple comparisons [71].  
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Tissue sampling 
Directly following the MR measurements at 11 ± 1 months of age, half of the 
number of mice was sacrificed by cervical dislocation to collect brain tissue for 
biochemical analyses, and the other half was sacrificed by transcardial perfusion 
fixation with Somogyi’s fixative (4% paraformaldehyde, 0.05% glutaraldehyde 
and 0.2% picric acid in 0.1M phosphate buffer, PB, pH=7.3). Blood samples 
were collected via eye extraction, and subsequently processed to obtain blood 
serum. Blood serum was stored at -80°C before further biochemical processing. 
Non-perfused brains were snap frozen in liquid nitrogen and then stored at -
80°C, before further biochemical processing. Perfused brains were collected and 
postfixed for 15h at 4°C in Somogyi’s fixative and subsequently stored in 0.1M 
PBS with 0.01% sodium azide at 4°C for immunohistochemical stainings.  
 
Immunohistochemistry 
Before cutting, the brain tissue was cryoprotected by immersion in 30% sucrose 
in PB. Six series of 40 µm coronal sections were cut through the brain using a 
sliding microtome (Microm HM 440 E, Walldorf, Germany) equipped with an 
object table for freeze sectioning at -60°C. Presynaptic boutons were visualized 
with anti-synaptophysin antibody (monoclonal rabbit anti-synaptophysin clone 
EP1098Y, Abcam Inc., Cambridge, UK). Synaptophysin is localized in small 
synaptic vesicles of the presynaptic terminal and functions in the regulation of 
exocytosis [72]. Newly formed immature neurons were visualized with anti-
doublecortin antibody (polyclonal goat anti-doublecortin (C18): sc-8066, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Doublecortin is a 
microtubule-associated protein that is exclusively found in somata and 
processes of migrating and differentiating neurons [73, 74]. 
Immunohistochemistry was performed using standard free-floating labeling 
procedures, and was carried out on a shaker table at room temperature as 
described in detail elsewhere [75]. One complete series of brain sections, with 
240 µm distance between the sections, was used for each staining. Brain 
sections were incubated overnight with either monoclonal rabbit anti-
synaptophysin (1:20,000), or polyclonal goat anti-doublecortin (1:3000) as 
primary antibody. Either donkey anti-rabbit biotin (1:1500) or donkey anti-goat 
biotin (1:1500) was used as a secondary antibody (Jackson ImmunoResearch, 
West Grove, PA, USA).  
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Quantification 
Quantification of presynaptic boutons and doublecortin-positive newly formed 
immature neurons was performed using a Zeiss Axioskop microscope, equipped 
with hardware and software from Microbrightfield (Williston, VT, USA). 
Appropriate sections were digitized and photomicrographed using a computer-
assisted analysis system (Stereo Investigator). Brain regions were based on the 
mouse brain atlas of Franklin and Paxinos [62]. All quantifications were 
performed by two independent raters who were blind to the experimental 
groups. Measurements were averaged to obtain a single value per animal for 
every region of interest (ROI).  
 
Quantification of synaptophysin-immunoreactive presynaptic boutons 
To determine the amount of synaptophysin-immunoreactive boutons (SIPBs), 
appropriate sections were digitized and photomicrographed at 100× 
magnification using an 100× oil immersion objective. SIPBs were analyzed in 
the hippocampus (cornu ammonis (CA)1, CA3 and dentate gyrus (DG) 
regions), and in the cortical regions prelimbic area (PLA) and anterior cingulate 
gyrus (ACg). These regions were chosen because of their large amyloid load in 
AD patients and transgenic mouse models for AD and their importance in 
learning and memory [76, 77]. In the hippocampus, SIPBs were analyzed in the 
stratum radiatum of the CA1 area (SR), stratum lucidum of the CA3 area (SL), 
and the inner molecular layer (IML) and outer molecular layer (OML) of the 
DG using one section per animal at -2.18 mm posterior to bregma. The ACg 
was quantified at level +0.98 mm anterior to bregma using one section per 
animal. The PLA was quantified at +1.94 mm anterior to bregma using one 
section per animal. For every ROI, two photomicrographs were taken at 100× 
magnification by each independent rater. Images were further processed using 
ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA) for 
the quantification of the amount of SIPBs. All settings were kept identical for 
all analyses and background levels were equalized using a threshold. Shading 
correction was performed before measurement to correct for irregularities in 
illumination in the microscopic field. A differential contrast enhancement filter 
was applied to selectively enhance weak differences in contrast. To eliminate 
noise signal and to differentiate between possible artifacts and specific SIPBs, 
particles were classified based on size. Particles ranging between 0.1-4.5 µm
2
 
were considered to be normal sized SIPBs [78], and were included for statistical 
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analyses. The amount of SIPBs was defined as the total number of SIPBs per 
µm
2
.  
 
Quantification of doublecortin-positive cells 
For the assessment of the amount of newly formed immature neurons in the 
subgranular zone of the hippocampus as a measure for neurogenesis, three 
sections per animal (at -1.70, -2.18 and -2.46 posterior to bregma) were 
digitized and contours were drawn along the borders of the hippocampus at 5× 
magnification using Stereo Investigator software. These three sections were 
selected as representative slices containing the subgranular zone of the 
hippocampus. Doublecortin-positive (Dcx+) cells were counted at 20× 
magnification, and the values of the three sections were averaged to obtain a 
single value per animal.  
 
Biochemical analyses 
Serum and brain sterol analysis 
Serum cholesterol levels and the cholesterol precursor lathosterol and its 
oxidative brain specific metabolite 24S-hydroxycholesterol were measured by 
gas-chromatography-mass-spectrometry-selected ionmonitoring (GC-MS-SIM) 
as described in detail previously [79-81]. Brains were homogenized and sterols 
were extracted overnight by chloroform/methanol trimethylsilylated prior to 
GC-MS-SIM analysis [79, 81]. 
 
Brain fatty acid analysis 
Fatty acid analyses were performed with a part of the homogenate (described 
above). Total lipid was extracted from brain homogenates by methanol and 
chloroform. Subsequently, samples were centrifuged at 3000 rpm for 10 min 
and the lower phase (chloroform and lipids) was removed. Chloroform was 
added to the upper phase, samples were centrifuged again at 3000 rpm for 10 
min and the lower phase was combined with the first one. The chloroform 
fractions were dried in a SpeedVac® and 2 ml methanol and 40 μl concentrated 
sulfuric acid were added to the dried extract. The samples were heated at 100°C 
for 60 min, and 2 ml hexane and 0.5 ml 2.5M sodium hydroxide solution were 
added. After vortexing and centrifuging the samples for 5 min at 3000 rpm, the 
upper layer was collected and evaporated in a SpeedVac®. The fatty acids 
(FAs) were dissolved in 125 μl iso-octane and analyzed on a GC-FID with a 
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CP-SIL88 column (50 m × 0.25 mm id. 0.22 film thickness). The n6/n3 ration 
was calculated as a sum of analyzed n6 FAs divided by the sum of n3 FA.  
 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed with SPSS for windows 
16.0 software (SPSS Inc. Chicago, IL, USA). Since the setup of the current 
study was designed to determine the effect of diets and the extent to which 
apoE4 and apoE ko mice develop behavioral and neuropathological traits of AD 
and not to study the effects of apoE itself, statistical analyses were performed 
separately for the apoE4 and apoE ko mice (apoE4 versus wild-type, and apoE 
ko versus wild-type). The repeated measures ANOVA was used for the 
acquisition phase of the MWM and rMWM (with the repeated measure: trial 
block), followed by a Bonferroni post hoc to analyze possible interactions 
between trial block, genotype and/or diet. If interactions between trial block, 
genotype or diet (between-group-factors) were present, the data were split for 
the concerning factor and thereafter analyzed again with the repeated measures 
ANOVA. Multivariate ANOVAs (MANOVA) were conducted with between-
group-factors genotype and diet, to analyze possible differences between wild-
type, apoE4 and apoE ko mice, and between the CO and FC diets in the open 
field parameters, the probe trials of the MWM and rMWM, the body weight, 
brain weight, metabolite concentrations, rCBV, immunohistochemical stainings 
and biochemical analyses. If the Bonferroni post hoc test indicated a significant 
interaction between genotype and diet (between-group-factors), the data were 
split for the concerning factor and thereafter analyzed again with the 
MANOVA. For clarity reasons, F-values are not displayed. Furthermore, only 
between-group interactions that reached statistical significance are specified in 
detail. Statistical significance was set at p≤0.05.  
 
Results 
 
Body and brain weight 
All mice were weighed one week before starting the behavioral tests at the age 
of 9 ± 1 months and again on the day of the MR measurements at the age of 11 
± 1 months. Body weight was not affected by genotype or diet when animals 
were measured one week before starting the behavioral tests (p>0.05). Overall 
mean body weight was 34.8 ± 0.8 g in the apoE ko mice, 33.8 ± 0.5 g in the 
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apoE4 mice and 32.6 ± 1.0 g in the wild-type mice. Body weight was affected 
by genotype, but not by diet when animals were measured on the day of the MR 
measurement. At scanning, ApoE ko mice were significantly heavier than wild-
type mice (p<0.001), independent of diet. Overall mean body weight was 36.5 ± 
0.7 g in the apoE ko mice, 33.3 ± 0.7 g in the apoE4 mice and 31.7 ± 0.8 g in 
the wild-type mice. Since absolute brain weight was not affected by genotype or 
diet (p>0.05), we expect no confounding effects of the increased body weights 
in ApoE ko mice on the MR parameters measured. Overall mean brain weight 
was 0.49 ± 0.01 g in apoE ko mice, 0.48 ± 0.01 g in both apoE4 and wild-type 
mice.  
 
Behavioral analyses 
Open Field 
In the open field, locomotion activity and active exploration parameters 
(walking, sitting, wall leaning, rearing) and grooming are scored for 30 minutes. 
In addition, total walking distance, mean walking velocity, and the time spent in 
the corners respectively the center of the open field were obtained from the 
recorded sessions.  
 
ApoE4 mice, but not apoE ko mice, were more active in the open field than 
wild-type mice. ApoE4 mice walked more (Fig. 2A; p=0.016) and sat less (Fig. 
2B; p=0.004), although the total distance moved (Fig. 2F; p=0.140) and mean 
walking speed (p=0.141; wild-type 6.1 ± 0.3 cm/s, apoE4 7.0 ± 0.5 cm/s, apoE 
ko 6.3 ± 0.4 cm/s) did not differ significantly between apoE4 and wild-type 
mice. Dietary intervention with the FC diet had no effect on these parameters 
(p>0.05). There was a significant genotype×diet interaction for the time spent 
grooming (p=0.032). ApoE4 mice on CO diet spent slightly less time grooming 
than wild-type mice on CO diet (Fig. 2E; p=0.062), whereas no difference was 
found between apoE4 and wild-type mice on the FC diet, or between apoE ko 
and wild-type mice (p=0.411). No differences were observed between the 
apoE4, apoE ko and wild-type mice in the time spent rearing (Fig. 2C) and wall 
leaning (Fig. 2D). ApoE ko animals spent significantly less time in the center 
(Fig. 2G; p=0.001) and significantly more time in the corners of the open field 
(Fig. 2H; p=0.025) than wild-type mice, independent of diet. Overall 
MANOVA analysis revealed significant genotype×diet interactions for the time 
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spent in the center (p=0.007) and corners (p=0.015) of the open field when 
comparing  apoE4 and wild-type mice.  
 
 
Fig. 2. Open Field behavior in 9 ± 1 months old apoE4, apoE ko and wild-type mice on 
control (CO) and Fortasyn (FC) diet. Different open field parameters were measured 
within a 30 min period. A) duration of walking, B) duration of sitting, C) duration of 
rearing; i.e. standing on the hind paws and exploring the environment, D) duration of 
wall leaning, E) duration of grooming, F) total distance moved, G) duration spent in 
the center of the open field, and H) duration spent in the corners of the open field. 
Values represent the mean and SEM. a * different from wild-type mice p<0.05; b # 
different from wild-type CO p=0.062; c * different from control (CO) diet p<0.05.  
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Only in wild-type mice, the FC diet increased the time spent in the center 
(p=0.001), and decreased the time spent in the corners (p=0.002) of the open 
field compared to the CO diet (Fig. 2G, H). The FC diet had no effect on these 
parameters in the apoE4 mice (p=0.360 and p=0.532 respectively). Furthermore, 
an overall effect of the FC diet on time spent in the center (p<0.001) and 
corners (p<0.001) was found comparing the apoE ko and wild-type mice. 
Again, the FC diet increased the time spent in the center and decreased the time 
spent in the corners of the open field compared to the CO diet (Fig. 2G, H). 
 
Altogether these data show increased activity in apoE4 mice, whereas the apoE 
ko mice did not differ from the wild-types on the parameters related to 
locomotion. Instead, apoE ko mice show increased anxiety-related behavior, 
indicated by the increased time spent in the corners and decreased time spent in 
the center of the open field [60, 82]. The FC diet decreased anxiety-related 
behavior in both apoE ko animals and wild-type mice. 
 
Morris water maze (MWM) 
The Morris water maze is designed to test spatial learning by training the mice 
to find a hidden platform (acquisition phase). Spatial memory is tested in a trial 
in which the platform is removed from the maze (probe trial) directly following 
the acquisition phase. 
 
ApoE4, apoE ko and wild-type mice showed a decrease in escape latency 
during training (Fig. 3A; p<0.001). No significant trial block×genotype, trial 
block×diet or trial block×genotype×diet interaction was observed, indicating 
that all animals learned the position of the hidden platform equally well. Escape 
latencies did not differ between apoE4, apoE ko and wild-type mice, nor did 
they differ between the CO and FC diet (p>0.05).  
 
During the probe trial, apoE4 mice spent less time in the target NE quadrant 
(Fig. 3C; p=0.020) than wild-type mice. Furthermore, both apoE ko and wild-
type mice performed well above 25% chance level, indicating good 
memorization of the platform quadrant, whereas the apoE4 mice did not 
significantly deviated from 25% chance performance (p=0.057). However, no 
differences were observed between apoE4, apoE ko and wild-type mice in the 
time spent in the exact platform area (Fig. 3D), reflecting good memorization of 
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the platform location. The FC diet had no effect on the spatial acquisition and 
the spatial memory parameters. Overall analysis comparing apoE4 and wild-
type mice indicated no effects of the FC diet on swim distance (p=0.402) and 
velocity (p=0.403). However, when comparing apoE ko and wild-type mice, the 
FC diet significantly decreased swim distance (Fig. 3B; p=0.049) and swim 
velocity (p=0.049; CO diet 18.2 ± 0.6 cm/s, FC diet 16.3 ± 0.8 cm/s), 
suggesting that the effects of the FC diet on those parameters are found mainly 
in the apoE ko mice. 
 
 
Fig. 3. Spatial learning and memory in the Morris water maze (MWM). Spatial 
learning was measured in a 4 day acquisition phase in 9 ± 1-month-old apoE4, apoE ko 
and wild-type mice on control (CO) and Fortasyn (FC) diet, by determining the latency 
to find a hidden platform (A). The spatial memory was tested in the probe phase in 
which the % of time spent in the north east (NE) target quadrant was measured (C), 
the % of time spent in the platform area (where formerly the platform had been 
located; D), and the total distance moved (B). Values represent the mean and SEM.  a * 
different from wild-type mice p<0.05.  
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Fig. 4. Spatial learning and memory with an extra episodic memory component in the 
reversal Morris water maze (rMWM). Spatial learning was measured in a 2 day 
acquisition phase in 9 ± 1-month-old apoE4, apoE ko and wild-type mice on control 
(CO) and Fortasyn (FC) diet, by determining the latency to find a hidden platform in 
the south west (SW) quadrant (A). The spatial memory was tested in the probe phase in 
which the % of time spent in the SW target quadrant was measured (C), the % of time 
spent in the platform area (where formerly the platform had been located; D), and the 
total distance moved (B). Values represent the mean and SEM.  No significant 
differences were observed.   
 
Reverse Morris water maze (rMWM) 
In the reverse Morris water maze, mice have to learn to find a novel position for 
the hidden platform. This task is considered to be a test for new learning 
abilities, in which a previous successful strategy must be discarded and a new 
strategy should be developed.  
 
ApoE4, apoE ko and wild-type mice showed a decrease in escape latency 
during training (Fig. 4A; p<0.001). No significant trial block×genotype, trial 
block×diet or trial block×genotype×diet interaction was observed, indicating 
that all animals learned the new position of the hidden platform equally well. 
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Escape latencies did not differ between apoE4, apoE ko and wild-type mice, nor 
did they differ between the CO and FC diet.  
 
During the probe trial, no differences were observed between the groups in the 
swim distance (Fig. 4B) or in the mean swim velocity (wild-type 18.5 ± 0.5 
cm/s, apoE4 18.5 ± 0.9 cm/s, apoE ko 17.9 ± 1.0 cm/s). No differences were 
observed between the groups in time spent in the exact platform area (Fig. 4D) 
or in the target SW quadrant (Fig. 4C). All animals spent well above 25% 
chance level in the SW target quadrant, indicating good memorization of the 
platform quadrant.  
 
 
 
Fig. 5. Hippocampal metabolite levels measured with 
1
H MRS. Multivariate ANOVA 
revealed an overall increase in taurine (Tau) in apoE4 mice compared to wild-type, 
independent of dietary intake. Compared to control (CO) diet, wild-type and apoE ko 
animals fed the Fortasyn (FC) diet showed an overall reduction in glutamate (Glu) 
levels. Values represent the mean and SEM. a* different from wild-type mice CO 
p<0.05, b* different from apoE ko CO p<0.05, c* different from wild-type FC p<0.05. 
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Magnetic resonance imaging (MRI) 
Magnetic resonance spectroscopy (MRS) 
To determine the effects of the FC diet on hippocampal metabolite 
concentrations, 
1
H MRS with a single voxel acquisition method (i.e. STEAM) 
was used in wild-type, apoE4 and apoE ko mice (Fig. 5). ApoE4 mice showed 
significantly higher levels of taurine (Tau) compared to wild-type animals, 
independent of diet (p=0.030). All the other metabolites levels showed no 
genotype differences or diet effects (p>0.05). In apoE ko and wild-type mice on 
FC diet, a significant decrease in glutamate (Glu) was observed compared to the 
same groups on CO (p=0.021). No genotype or diet effects were seen in other 
hippocampal metabolites levels (p>0.05). 
 
Relative cerebral blood volume (rCBV) 
To measure changes in rCBV, susceptibility-induced contrast MR imaging was 
used. Relaxation rate maps were obtained from T2
*
-weighted images before and 
after i.v. injection of USPIO. The contribution of large cerebral vessels was 
excluded by histogram analysis, to shift the sensitivity of ΔR2
*
 images towards 
the microvascular compartment (rCBVmicro) [64].   
 
ROI-based analyses. The analysis focused on the hippocampus, cerebral cortex, 
olfactory bulb, cerebellum and thalamus. No significant differences between 
genotypes or diet (p>0.05) were found in any ROIs between apoE4, apoE ko 
and wild-type mice (Fig. 6A). 
 
Voxel-based analyses. To determine the occurrence of rCBVmicro changes at 
higher spatial resolution, we applied a voxel-wise statistical approach to the co-
registered brains. No clear dissimilarities in rCBVmicro were seen between all the 
genotypes, with few voxels indicating significant positive or negative 
differences sparse throughout the brain (Fig. 6B,C). In wild-type and apoE ko 
mice on FC diet, several voxels in the midbrain – at the anatomical location of 
the first and second branches of the circle of Willis and of the posterior cerebral 
artery - revealed a significantly increased rCBVmicro compared to their 
respective control diet groups. A moderate increase in rCBVmicro was also seen 
in the parieto-temporal cortex for the same groups on FC diet (Fig. 7). No 
distinct effects of FC diet were detected for the apoE4 mice. 
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Fig. 6. Measurement of the microvascular cerebral blood volume (rCBVmicro) in several 
ROIs revealed no significant genotype differences between wild-type, apoE4 and apoE 
ko mice at 12 months of age. Values represent the mean and SEM (A). In (B) and (C), 
VBA results are shown superimposed on anatomical images. Voxels with 
decreased/increased rCBVmicro, corresponding to p<0.01for a two-tailed test, are 
highlighted in the t-maps. No relevant differences between the three genotypes were 
detected. 
 
Immunohistochemistry 
Immunohistochemical stainings were performed using standard free-floating 
labeling procedures on brain sections from 11 ± 1 month-old transgenic apoE4 
and apoE ko, and wild-type mice fed either the CO diet or the FC diet for 9 ± 1 
months.  
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Fig. 7. VBA was assessed between the two diet groups, split by genotypes, to reveal 
possible diet×genotype interactions not seen in the ROI analysis. No significant effects 
were seen in wild-type and apoE4 mice in response to dietary intervention (A). Instead, 
in wild-type and apoE ko the Fortasyn diet significantly increased the rCBVmicro in a 
relatively large area of the midbrain, in anatomical correspondence to the small 
branches of the circle of Willis, and in other cortical areas (B). Voxels showing 
decreased and increased rCBVmicro due to dietary treatment correspond to p<0.01 for a 
two-tailed test. 
 
Synaptophysin-immunoreactive presynaptic boutons (SIPBs) 
The amount of presynaptic boutons (size ranging from 0.1-4.5 µm
2
) was 
visualized using a monoclonal antibody against synaptophysin (Fig. 8A, B). 
Synaptophysin-immunoreactivity was determined in cortical regions prelimbic 
area (PLA) and anterior cingulate gyrus (ACg), and in hippocampal regions 
stratum radiatum of area CA1 (SR), stratum lucidum of area CA3 (SL), and 
inner (IML) and outer (OML) molecular layer of the dentate gyrus.   
 
Doublecortin-positive immature neurons 
 
Newly formed immature neurons were visualized with a polyclonal antibody 
against doublecortin (Fig. 9A). Doublecortin-positive (Dcx+) cells were 
counted in the subgranular zone of three alternating hippocampal sections as a 
measure for neurogenesis.  
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Fig. 8. Synaptophysin immunohistochemical staining performed on brain sections from 
11±1 month-old apoE4, apoE ko and wild-type mice on control (CO) and Fortasyn 
(FC) diet. A) Representative image of the synaptophysin-immunoreactive presynaptic 
boutons (SIPBs) in the hippocampus. Image taken using an 5× objective. Scale bar=100 
µm.  B) Representative image of the SIPBs in the stratum radiatum (SR). Image taken 
using an 40× objective. Scale bar=100 µm. C) Amount of SIPBs (between 0.1-4.5 µm
2
) 
per µm
2
 in hippocampal and cortical areas. Multivariate ANOVA did not reveal any 
significant differences between the different genotype and diet groups. Values 
represent the mean and SEM. IML=inner molecular layer, and OML=outer molecular 
layer (of the dentate gyrus); SR=stratum radiatum (CA1 area); SL=stratum lucidum 
(CA3 area); PLA=prelimbic area; ACg=anterior cingulate gyrus.  
 
ApoE ko mice showed increased amount of Dcx+ cells in the hippocampus 
compared to wild-type mice (Fig. 9B; p=0.045), independent of diet, suggesting 
increased neurogenesis in apoE ko animals. ApoE4 mice did not differ from 
wild-types (p=0.163). Furthermore, the FC diet had no significant effect on the 
amount of newly formed immature neurons (p>0.05). However, it appears that 
the FC diet increased the amount of Dcx+ cells in apoE4 animals, but due to the 
large variation within this group, it did not reach statistical significance in the 
overall analysis (p=0.087), and no genotype×diet interactions were found 
(p=0.106).  
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Fig. 9. Doublecortin immunohistochemical staining performed on brain sections from 
11±1 month-old apoE4, apoE ko and wild-type mice on control (CO) and Fortasyn 
(FC) diet. A) Representative image of the doublecortin-positive (Dcx+) cells in the 
subgranular zone of the hippocampus. Image taken using an 10× objective. Scale 
bar=100 µm. B) Amount of Dcx+ cells in the subgranular zone of the hippocampus. 
Multivariate ANOVA revealed an overall increase in the amount of newly formed 
immature neurons in apoE ko mice compared to wild-type animals. Values represent 
the mean and SEM. a* different from wild-type mice p<0.05. 
 
Biochemical analyses 
Serum and brain sterol analysis 
As shown in Table 3, brain cholesterol levels did not change due to genotype or 
the FC diet (p>0.05). However, serum cholesterol levels were approximately 
5.5× higher in apoE ko mice than in wild-type animals (p<0.001), whereas no 
differences were found between apoE4 and wild-type mice (p=0.917). 
Furthermore, serum cholesterol levels decreased due to the FC diet in wild-type 
and apoE4 animals (p=0.002). Overall analysis did not reveal such an effect of 
the FC diet comparing apoE ko and wild-type mice (p=0.112). In addition, 
serum lathosterol, a main cholesterol precursor in the “de novo” synthesis 
pathway, significantly decreased in FC fed wild-type and apoE4 mice 
(p=0.046). Again, overall analysis did not reveal such an effect of the FC diet 
comparing apoE ko and wild-type mice (p=0.833). Serum lathosterol levels 
were approximately 30× higher in apoE ko mice than in wild-type animals 
(p<0.001), and approximately 1.5× higher in apoE4 animals compared to wild-
type mice (p=0.005), independent of diet. In contrast, brain lathosterol levels 
were decreased in apoE ko animals (p=0.001), whereas no differences were 
observed between apoE4 and wild-type mice (p=0.771). The cholesterol 
elimination rate from the brain, measured by serum 24S-OH-cholesterol levels 
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decreased in FC fed wild-type and apoE4 mice (p=0.001). No diet effects were 
found on serum 24S-OH-cholesterol levels when comparing apoE ko and wild-
type mice (p=0.380). ApoE ko animals displayed a 5-fold increase in serum 
24S-OH-cholesterol levels (p<0.001), whereas no differences were observed 
between apoE4 and wild-type mice (p=0.304). In contrast, brain 24S-OH-
cholesterol levels did not change between apoE ko and wild-type mice 
(p=0.755), whereas apoE4 animals showed increased brain 24S-OH-cholesterol 
levels compared to wild-type mice (p=0.001), independent of dietary intake. 
 
Brain fatty acid analysis 
The relative concentrations of different fatty acids (FA) in brain tissue of 12-
month-old wild-type, apoE4 and apoE ko mice are shown in Table 4. Wild-type, 
apoE4 and ApoE ko mice fed the FC diet showed a shift in the balance between 
n3 and n6 fatty acids. The relative amount of n3 FA in FC fed mice increased 
compared to the CO diet (p<0.001), independent of genotype, whereas the 
relative amount of n6 decreased (p<0.001), resulting in a pronounced shift in 
the n3/n6 ratio in FC fed mice in favor of the n3 FA (p<0.001). The reduction of 
the relative n6 content was mainly caused by a decrease in arachidonic acid 
(20:4n6; p<0.001), while the higher n3 content originated from an increase in 
relative DHA (22:6n3; p<0.001) in all genotypes. Furthermore, the relative 
concentration of OA (18:1n9) was increased in the FC fed mice compared to the 
CO diet (p<0.001), independent of genotype. Overall analysis comparing apoE4 
and wild-type mice indicated that the FC diet decreased the relative 
concentration of PUFA (p=0.020), which was not observed when comparing 
apoE ko and wild-type mice (p=0.112), suggesting that this effect of the FC diet 
is found mainly in the apoE4 mice. 
 
Discussion 
 
The present study aimed to investigate the extent to which a specific multi-
nutrient diet can modulate cerebral hemodynamics, behavior, cognition, brain 
metabolism, and plasticity in the apoE4-carrier and apoE-knockout mice, which 
are models for risk factors in cardiovascular disorders and Alzheimer’s disease.  
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To this end, we performed behavioral testing, MRI and MRS approaches and 
immunohistochemical stainings to determine to which extent these transgenic 
animal models develop behavioral and neuropathological traits of AD and to 
determine the effect of dietary intervention. An overview of the main results 
found in the current study is shown in Table 5. 
 
 
 
ApoE4 mice were hyperactive in the open field, while apoE ko mice showed 
more anxiety-related behavior. The FC diet appears to have a general 
anxiolytic effect on open field behavior 
Our results show that while apoE4 mice are more active in the open field, apoE 
ko mice show more anxiety-related behavior, as indicated by the increased time 
spent in the corners (i.e. anxious mice prefer the borders of the open field) and 
decreased time spent in the center of the open field [60, 82, 83]. These findings 
are in line with previous studies in adult (6-13 months old) apoE4 and apoE ko 
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mice showing increased measures of anxiety in the elevated plus maze and 
higher acoustic startle responses to unavoidable anxiety-provoking stimuli 
compared to wild-type mice [84-86]. Furthermore, both apoE4 and apoE ko 
mice required more time to habituate to a novel environment compared to wild-
type mice, suggesting increased “emotional reactivity” [84, 85]. Consistent with 
their transgenic apoE mouse data, Robertson and colleagues also reported 
higher anxiety scores in probable AD patients with ε4/ε4 compared to those 
with ε3/ε3 [86]. Anxiety symptoms and restlessness may occur in up to 70% of 
AD patients during the course of their illness and are significantly correlated 
with impairments in activities of daily living [87-90].  
 
Furthermore, our results might suggest that the FC diet could have an anxiolytic 
effect, since it increased the time spent in the center and decreased the time 
spent in the corners of the open field in both apoE ko animals and wild-type 
mice. This is in line with studies showing that rats fed an n-3 PUFA deficient 
diet display increased anxiety-related behavior in the open field and elevated 
plus maze tasks as compared to animals fed an n-3 PUFA adequate diet [91, 
92]. Supplementation with n-3 PUFAs led to substantial reduction in the anxiety 
levels of n-3 PUFA deficient mice [93] and rats [92, 94]. Schipper et al. showed 
that the combination of n-3 lc-PUFAs, phospholipids and B-vitamins (similar to 
our FC diet) completely abolished anxiety-related behavioral responses, 
increased social behavior and facilitated fear extinction recall in serotonin 
transporter knockout (SERT-ko) rats [95]. Supplementation with n-3 lc-PUFAs 
has also shown beneficial effects on depressive symptoms and agitation in 
patients with mild to moderate AD [96, 97].  
 
Spatial learning in the MWM and rMWM was unaffected, although apoE4, 
but not apoE ko mice, showed impaired spatial memory in the MWM. The 
FC diet had no effect on spatial learning and memory performance 
In line with results from previous studies [98, 99], no differences were observed 
between apoE4, apoE ko and wild-type mice in their ability to learn the position 
of a submerged platform during acquisition training in the MWM and rMWM. 
However, the performance of the apoE4 mice during the MWM probe trial was 
worse than the performance of wild-type and apoE ko mice, independent of diet. 
The time apoE4 mice spent in the target quadrant did not exceed chance level, 
and was significantly shorter compared to wild-type mice, indicating spatial 
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memory impairment. These results are consistent with previous reports of 
impaired memory retention performance in apoE4 mice in several spatial 
memory tasks [85, 98-100]. Moreover, several studies have shown a direct 
correlation between the apoEε4 allele and cognitive decline in healthy elderly 
individuals [101-103].  
 
Contrary to expectations, no cognitive impairment could be observed in the 
apoE ko mice in the current study. Previous studies have shown that under basal 
naive conditions, apoE ko mice are severely impaired in water maze 
performance [104-107]. However, this cognitive deficit was abolished when 
apoE ko mice were repeatedly exposed to stressful stimuli. Stressed apoE ko 
mice performed the MWM tasks as good or even better than stressed wild-type 
mice, and this effect appeared to be mediated by corticosterone [108-111]. In 
the current study, animals were not experimentally exposed to repeated stressful 
stimuli. However, the normal daily care, like handling the animals, cleaning 
cages and transport for behavioral testing, can activate the stress responsive 
system especially in the apoE ko mice, and might have positively affected their 
performance in the MWM task [112-114].  
 
Previous studies have shown that n-3 lc-PUFA intake may improve cognition in 
both mice and rats [60, 115, 116]. Besides n-3 lc-PUFAs, other nutrients can 
also affect spatial memory performance. Supplementing CDP-choline or UMP 
and choline to rats improved spatial memory in the water maze [117, 118]. In 
addition, transgenic mice fed vitamin E [119] or vitamin B3 [120] showed 
normalized escape latency in the water maze. However, in agreement with our 
current results, there are also some reports showing no effect of n-3 PUFA 
intake and other nutrients on learning and memory performance [116, 121, 122]. 
Moreover, most intervention studies based on supplementation with n-3 PUFAs 
have failed to show any protective effect on AD [96, 123, 124] or cognitive 
decline [125-127], except in some AD patients with very mild cognitive 
impairment [123, 128, 129]. Furthermore, apoE4 carriers have been reported to 
lack risk reduction from n-3 PUFA consumption [130-133], and to be less 
sensitive to the protective effects of n-3 PUFA supplementation on cognition 
[124, 134], although the exact mechanisms underlying this gene-by-diet 
interaction remain unclear. Further research is needed to explain the differential 
effect of n-3 PUFA on AD according to apoE genotype.  
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The amount of presynaptic boutons was unaffected by genotype and 
dietary treatment. The amount of newly formed immature neurons was 
increased in apoE ko mice, which might reflect a compensatory mechanism 
in response to functional synaptic and neuronal failure or insults to the 
brain. Neurogenesis appeared unaffected by the FC diet 
Synaptic loss is a pathological hallmark of AD, and it is the best correlate of 
cognitive impairment [135-138]. However, synaptic loss does not appear to 
correlate with the APOE genotype (ε2, ε3, ε4) [139, 140]. Synaptophysin is a 
widely used marker for quantification of presynaptic terminals, but conflicting 
results have been reported on synaptophysin immunoreactivity (SYN-IR) both 
in AD patients [141-144] and AD mouse models. SYN-IR in transgenic mice 
that develop Aβ plaques has been reported to decline, increase, or not change, 
apparently depending on the interplay of mouse strain, transgene, age, and 
disease progression [75, 145-150]. In the current study, no changes were found 
between apoE4, apoE ko and wild-type mice in the amount of presynaptic 
boutons in hippocampal and cortical regions, which is in line with previous 
studies [151, 152], reporting no differences in presynaptic density in the 
hippocampus of male apoE4, apoE ko and wild-type mice. Veinbergs and 
colleagues did find a decrease in presynaptic density in the hippocampus and 
frontoparietal cortex of 12-month-old apoE ko mice as compared to wild-type 
mice, while presynaptic density was preserved in 12-month-old apoE4 mice 
[153]. Since cholesterol released from apoE-containing lipoprotein particles is 
used to support synaptogenesis and the maintenance of synaptic connections 
[20, 21, 154], a decrease in presynaptic density in apoE ko mice could be 
expected. However, no differences in brain cholesterol levels between wild-
type, apoE4 and apoE ko were observed in the current study, which might 
explain the lack of differences in amount of presynaptic boutons. It should be 
noted that we used female C57BL/6J breeder mice from Harlan Laboratories, 
Inc. (Horst, the Netherlands) to generate male wild-type offspring for the 
current study. It is known that these mice carry a gene mutation resulting in an 
alpha-synuclein gene deletion[155]. The alpha-synuclein deletion has some 
effects on synapse function related to neurotransmitter mobilization [156-158]. 
However, basal synaptic neurotransmission is unimpaired [156], and there are 
no indications of an altered number of (pre)synapses or neurogenesis in 
C57BL/6JOlaHsd mice. Furthermore, alpha-synuclein is not essential for spatial 
learning tasks, such as the Morris water maze [159]. Thus, although we should 
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keep this limitation in mind when interpreting our results, the use of the 
C57BL/6J wild-type offspring as control mice is not expected to significantly 
alter the outcomes of the experiments.  
 
In line with a previous study by Levi and Michaelson, [160], apoE ko mice 
displayed enhanced neurogenesis, which might reflect a compensatory 
mechanisms in response to functional synaptic failure or insults to the brain, 
like stroke or ischemia. [75, 161-165]. Both in AD patients and in AD and apoE 
mouse models, conflicting results have been found regarding neurogenesis. 
Most studies showed a decrease in neurogenesis in both AD patients [166-168] 
and in APP and PS1 mouse models [169-171]. In contrast, some studies found 
an increase in AD patients [161] and in AD transgenic animal models [172, 
173]. It has been suggested that neurogenesis, as well as synaptogenesis, may 
have a compensatory role in the early stages of AD which can counteract the 
effect of impaired synaptic and neuronal function, neurodegeneration and cell 
death [161, 163, 174, 175]. Accordingly, activation of apoptotic mechanisms 
and neuronal death during acute and chronic insults, such as ischemia, 
Huntington’s disease and AD, is indeed accompanied by compensatory 
increases in hippocampal neurogenesis [163-165, 176-181].  
 
In the current study, the FC diet had no significant effect on the amount of 
presynaptic boutons or the amount of newly formed immature neurons, 
although in the latter case one might notice the slight, but non-significant, 
increase in the amount of newly formed immature neurons in the apoE4 animals 
on the FC diet. In line with our results, previous studies failed to demonstrate an 
effect of n-3 PUFA diets on synaptophysin levels; instead, n-3 PUFAs seem to 
exert their beneficial effects more by improving synaptic function rather than by 
synaptogenesis [30, 182-184]. Other studies have shown that omega-3 fatty 
acids [185-188], folic acid [189, 190], and vitamins and antioxidants [191, 192] 
may promote neurogenesis. However, the majority of the studies reporting a 
positive effect of n-3 PUFAs, folic acid, and vitamins and antioxidants on 
neurogenesis were conducted in nutrient-deficient animals [186, 192]. These 
results could imply that beneficial effects of dietary interventions might become 
apparent only when neurogenesis is severely compromised in response to a 
dietary deficiency. Since our apoE4 and apoE ko mice were not nutrient-
deficient and did not show compromised neurogenesis at 11 ± 1 months of age, 
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this might explain the lack of differences due to dietary intervention in the 
current study.  
 
ApoE4 and apoE ko mice did not show differences in CBV compared to 
wild-type mice. The FC diet increased CBV in wild-type and apoE ko mice 
next to the brain feeding arteries 
Among other proprieties, apolipoprotein is very important in the maintenance of 
brain vascular health, and in the repair of blood brain barrier (BBB) after injury. 
A list of studies reported a number of neurovascular pathologies associated with 
apoE4 genotype, such as increased small vessel arteriolosclerosis and micro 
infarcts of the deep nuclei [193], cerebral amyloid angiopathy [194] and 
inflammation triggering blood brain barrier (BBB) breakdown [195]. These 
pathologies, together with gross cardiovascular problems, are present in higher 
extent in mice lacking apoE, and their conditions are worsened if the animals 
were fed a high fat / high cholesterol diet [196, 197]. Vascular defects in apoE4 
and apoE ko mice are shown to precede neuronal dysfunction and can initiate 
neurodegenerative processes [195]. We tested here if brain vascular pathology 
is detectable in apoE4 and apoE ko mice with MR imaging and if the specific 
multi-nutrient diet has beneficial effects on the neurovascular system. Our 
analysis revealed an increased rCBV due to the FC diet in apoE ko and wild-
type mice in the midbrain and in the parieto-temporal cortex.  
 
The lack of genotype differences is in contrast with our initial expectations of a 
diminished cerebral blood volume due to atherosclerosis in apoE4 and in apoE 
ko mice [198]. However, a micro-CT imaging study showed that apoE ko mice 
from 16 to 80 weeks develop atherosclerotic plaques in the aorta, pulmonary 
artery and carotid artery, but not in cerebral arteries [199]. The presence of 
atherosclerosis in the systemic circulation may have a detrimental effect on the 
cerebral perfusion, without directly compromising the brain vascular structure. 
The absence of genotype differences found in this study seems to confirm this 
hypothesis. Microcirculation deficits would then be triggered by a direct 
interaction between apoE and the neurovascular unit, rather than from the 
accumulation of atherosclerotic plaques in cerebral vessels. A recent study 
proposed the proinflammatory cyclophilin-a as a possible mediating factor 
between apoE genotype and brain microcirculation [195]. 
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In the mid-brain, adjacent to the circle of Willis and the posterior cerebral 
artery, we found voxels of increased rCBV in apoE ko and wild-type mice fed 
with the multi-nutrient FC diet, which may reflect an improvement in brain 
perfusion. Such improved cerebrovascular circulation is possibly influenced by 
both the n-3 PUFA components and by the B-vitamins in the FC diet and is 
consistent with other animal studies [60, 200]. The beneficial effects on the 
cardiovascular system by n-3 lc-PUFAs, important components in our FC diet, 
have been widely demonstrated in the last decade. Several epidemiological 
studies and controlled trials showed a correlation between n-3 PUFA and 
improvement in autonomic function, lowered blood pressure, reduced 
atherosclerosis and enhanced microvasculature endothelium-dependent 
vasodilation processes [201, 202]. All these factors may have contributed to 
improve the functionality of the brain vascular system, particularly in apoE ko 
mice, where these pathologies are accelerated. Furthermore, it has been shown 
that deficiency of folate and B-vitamins, which are  instead supplemented in the 
FC diet, reduced brain capillary density in mice [203]. Finally, all mice fed with 
FC diet showed significantly decreased serum total cholesterol levels, which 
may have an additional effect on the fluid dynamics of the blood, lowering 
plasma viscosity and facilitating blood perfusion [204-206]. A direct measure of 
the cerebral blood flow with other techniques (e.g. arterial spin labeling MRI) 
would help to quantitatively determine perfusion deficits in these mice and the 
effects of diets on brain hemodynamics. 
 
ApoE4 mice displayed increased levels of Tau in the hippocampus. The FC 
diet reduced the hippocampal Glu levels in all genotypes 
1
H hippocampal MR spectroscopy revealed increased Tau levels in the apoE4 
mice and a decrease in Glu levels in wild-type and apoE ko mice by 
supplementation with the FC diet. Tau is an amino acid that is reported to have 
a number of physiological and pharmacological functions, including 
osmoregulation, cell volume adjustment, antioxidation and modulation of the 
action of neurotransmitters [207]. Although the effects of taurine on brain 
metabolism are still unclear, some studies reported beneficial effects of taurine 
on brain function [208]. Moreover, it has been reported that taurine prevents the 
formation of atherosclerotic plaques in apoE ko mice [209]. Taurine is mainly 
obtained by dietary intake, but it can also be synthesized in the brain from other 
sulphur-containing amino acids in response to stressful events. Taurine levels 
 
5 
196 
 
increases in both rats and mice as a consequence of various cell-damaging 
conditions, including ischemia [210, 211]. The increase in taurine in the apoE4 
mice may therefore reflect a spontaneous response of the brain cells to an 
increased stress conditions / pathological status in these mice. The mechanism 
by which apoE4 genotype, and not the absence of apoE, induces excessive 
taurine production is however far from being clear and requires further studies.  
 
In our experiment, we found decreased levels of Glu due to the specific multi-
nutrient diet supplementation. Glutamate, and glutamate receptors, play a 
fundamental role in neuronal growth and differentiation, synaptic plasticity and 
in regulating neurotransmission, by being the major mediator of excitatory 
signals in the central nervous system. However, excess in glutamate production 
is potentially harmful due to its neurotoxic proprieties. In many 
neurodegenerative diseases, such as AD, glutamate levels are found to be higher 
than in normal aging. Amyloid-β peptides have been shown to increase 
glutamate release, inhibit clearance of glutamate by astrocytes and affect 
glutamate receptor activity [212]. Furthermore, glutamate is the major mediator 
of excitotoxic neuronal death following cerebral ischemia. Under hypoxic or 
ischemic conditions, glutamate transporters can functionally reverse to release 
glutamate, thereby inducing further neuronal injury [213-215]. Although the 
interpretation of these data needs to be made carefully, our results suggest that 
the FC diet can modulate the production / uptake of glutamate, and this is 
possibly linked to a better brain perfusion with an amelioration of neuronal 
function.  
 
Conclusion  
 
The  multi-nutrient Fortasyn Connect
® 
(FC) diet consists of nutrients which are 
precursors and co-factors for membrane synthesis and maintenance, and also 
contains various nutrients that may be expected to support cardio- and 
cerebrovascular health. In the present study, we showed that the 
supplementation of FC diet is able to change fatty acid composition in the 
brains of all our mice. We showed that 11 month-old apoE4 mice display 
increased activity and slightly reduced memory compared to wild-type mice, 
which may be a consequence of hypercholesterolemia and AD. The lack of 
substantial pathological status in these mice may explain why we could detect 
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only minor effects of the specific multi-nutrient diet. Instead, in the apoE ko 
mice, a more severe model for atherosclerosis and hypercholesterolemia, we 
measured several beneficial effects due to the FC diet: decreased anxiety-related 
behavior, a reduction in hippocampal glutamate levels, and increased rCBV. We 
hypothesize that these features reflect a better response from neuronal cells to 
sustain ischemic driven events, due to an amelioration of cardiovascular health 
and possibly due to improving the cell membrane properties. Taken together, 
these results suggest that this specific multi-nutrient diet has the potential to 
ameliorate AD-related and ischemia-related pathologies, by positively 
influencing both the vascular system and the cell membrane composition. 
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The degenerative processes underlying the development and progression of 
Alzheimer’s disease (AD) are complex and far from being completely 
understood. Rather than one single cause, it is much more likely that AD is a 
multifactorial disorder, caused by a combination of different (risk) factors 
which affect the integrity of the brain at multiple levels. Although ageing is 
recognized as the most important risk factor for AD, several other factors have 
been associated with an increased risk of developing AD as well. Recently, 
many epidemiological studies have shown that vascular disorders, such as 
hypertension, hypercholesterolemia, and atherosclerosis, are major risk factors 
for AD [1-4]. Modifying these vascular-based risk factors by means of changing 
lifestyle, such as physical exercise and nutrition, can thereby alter the risk of 
developing AD later in life [5-8]. While dietary intake of typical Western diets 
(TWD), high in saturated fatty acids such as cholesterol, increases the incidence 
of cardiovascular disease and AD [9-13], adherence to a Mediterrean diet, rich 
in omega-3 long-chain polyunsaturated fatty acids (n3 lc-PUFAs), vitamins and 
antioxidants, lowers the incidence of vascular disorders and reduces the risk of 
developing AD later in life [8, 14-16]. The possibility that the development of 
AD can be influenced by nutritional intake or lifestyle is a topic of increasing 
interest in the scientific community, and opens up new horizons in search of 
preventative strategies and alternatives for current AD medication. Although it 
is widely recognized that nutrition can affect the brain at many different levels 
[17-21], understanding the exact mechanisms by which dietary nutrients 
influence AD pathogenesis is necessary for the development of effective 
nutritional interventions. The aims of this thesis were to investigate by which 
mechanisms nutrition influences AD development and to determine the 
longitudinal etiopathogenic processes contributing to AD. To address these 
issues, we used three distinct transgenic mouse models: the AβPPswe-PS1dE9, 
the apoE knockout (B6, 129P-Apoe
tm1Unc/J) and the human apoEε4/ε4-carrier 
mouse models.  
 
AβPPswe-PS1dE9 mouse model 
 
The double transgenic AβPPswe-PS1dE9 mouse model used in studies 
described in chapter 2 to chapter 4 of this thesis represents a model for familial 
early-onset AD [22, 23]. This mouse line has rapid age-dependent production of 
amyloid-β (Aβ) and early cognitive decline, and differs from their wild-type 
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littermates in the presence of transfected human mutated genes encoding for the 
amyloid-β precursor protein (AβPP) and presenilin 1 (PS1). Throughout life, Aβ 
deposition in this mouse model is highest in the dentate gyrus (DG) of the 
hippocampus [24-26], which is similar to the human AD pathology where Aβ 
depositions appear first in the hippocampus and especially the DG [27-29]. In 
this thesis, we have studied the AβPP-PS1 mouse model at 8, 12 and 15 months 
of age to gain a better understanding of the order of etiopathogenic alterations 
contributing to AD development and progression.  
 
Genotype effects 
The most obvious and first appearing clinical sign of AD is memory 
impairment. In line with previous findings [24], we have shown that AβPP-PS1 
mice display mild cognitive impairment already at 8 months of age, in 
combination with hyperactivity and decreased explorative behavior (Chapter 
3). The increased activity and decreased explorative behavior are specific 
characteristics of many AβPP transgenic mice and are usually explained as a 
result of elevated anxiety levels [30-32]. Hyperactivity and anxiety-related 
behavior in AβPP transgenic mice resemble the anxiety symptoms and 
restlessness, which occur in up to 70% of AD patients during the course of their 
illness and are significantly correlated with impairments in activities of daily 
living [33-36]. As the disease progresses, cognitive decline and behavioral 
changes become more severe in the AβPP-PS1 mouse model at 12 (Chapter 3 
and Chapter 4) and 15 months of age [24]. Accordingly, cerebral blood volume 
(CBV) was slightly affected in some cortical regions and in the thalamus, but 
not in the hippocampus, of 8-month-old AβPP-PS1 mice [26]. In general, a 
decrease in CBV may be caused by vasoconstriction of the blood vessels or 
capillary loss. However, we have shown that capillary density, as determined by 
an immunohistochemical staining for glucose transporter type 1 (GLUT-1), 
which is primarily localized in brain vascular endothelial cells [37-39], was 
unaffected in the 8-month-old AβPP-PS1 model (Chapter 2). Although the 
Cavalieri’s grid-spacing method (Stereo Investigator, Microbrightfield, 
Williston, USA) used for quantification of the capillary density does allow us to 
exclude the possibility that a reduction in CBV is due to capillary loss, this 
method is not sensitive enough to detect minor changes in vessel diameter as 
would be expected in the case of vasoconstriction. Therefore, it is possible that 
the decrease in CBV is due to vasoconstriction of the blood vessels, which 
 
6 
223 
 
might have been triggered by the interaction of Aβ peptides with endothelial 
cells [40-42]. At this age, we have shown a preserved amount of presynaptic 
boutons and no alterations in hippocampal metabolite levels in the AβPP-PS1 
mouse model (Chapter 3), suggesting that the decrease in cerebral perfusion 
might not have been severe enough (yet) to affect neuropathological processes. 
At 12 months of age, AβPP-PS1 mice display a decreased CBV in several 
cortical and subcortical regions, including the hippocampus, while capillary 
density remained unaffected, again probably due to the insensitivity of the 
GLUT-1 quantification method [26]. Our follow-up study also showed 
decreased cerebral blood flow (CBF), measured by FAIR-ASL at 11.7T, in the 
hippocampus, cortex and thalamus of 12-month-old AβPP-PS1 mice (submitted 
data, [43]). Alongside these cerebrovascular alterations, we have shown several 
neuropathological changes in 12-month-old AβPP-PS1 mice, which might 
underlie the aggravation of AD-like behavioral and cognitive symptoms at this 
age. Although the amount of presynaptic boutons was still unaffected (Chapter 
3), 12-month-old AβPP-PS1 mice displayed decreased neuronal viability in the 
hippocampus (Chapter 3 and Chapter 4), as indicated by the decreased levels 
of N-acetylaspartate (NAA) measured with proton magnetic resonance 
spectroscopy (
1
H MRS). Furthermore, we have shown impaired neurogenesis 
(Chapter 4), although this did not reach statistical significance in the study 
described in chapter 3 probably due to the limited amount of animals used. 
Additional results from our lab show that 12-month-old AβPP-PS1 mice also 
display axonal disconnection, myelin degradation and hippocampal neuronal 
loss, as indicated respectively by diffusion tensor MRI (DT-MRI) and 
histological analysis with the Klüver-Barrera staining for myelin and nerve cells 
[44]. Moreover, we have shown increased mRNA levels of interleukin-1β (IL-
1β), reflecting an initial inflammatory response to counteract neurodegenerative 
processes (Chapter 4). At 15 months of age, decreased CBV and hippocampal 
atrophy were detected in the AβPP-PS1 mouse model, in combination with 
alterations in sterol and fatty acid profiles in the brain [24]. In this thesis, we 
have shown that 15-month-old AβPP-PS1 mice display increased amount of 
presynaptic boutons in several regions of the hippocampus (Chapter 2), 
suggesting a compensatory mechanism of enhanced synaptogenesis in an 
attempt to maintain connectivity and preserve cognitive function. These results 
are consistent with findings of increased amount of pre- and postsynaptic 
proteins in human AD brains [45-47], and support the notion that extensive 
 
6 
224 
 
synaptic loss might not be an early event in the progression of AD, as a marked 
decrease in synapses is only seen in later stages of the disease, when tau, Aβ 
and inflammatory pathology is more widespread [47-49]. However, in line with 
results from other studies [50, 51], we have shown that this synaptic 
compensatory response is unrelated to the deposition of Aβ plaques (Chapter 2 
and Chapter 3). Preliminary results from our lab indicate that also postsynapses 
are affected in the AβPP-PS1 mouse model (unpublished results). At 18 months 
of age, an increased density of postsynapses could be observed in the CA3 area 
of the hippocampus. In contrast, postsynaptic density was decreased in the CA1 
and dentate gyrus regions, suggesting failure of the compensatory mechanism 
due to severe neuropathology in these sensitive areas, resulting in synaptic loss 
(unpublished results).  
 
Diet effects 
Previous animal studies have shown that high cholesterol intake can influence 
AD development by increasing Aβ accumulation [52-54] and reducing CBV 
[24]. However, high cholesterol intake did not seem to worsen the behavioral 
changes and cognitive decline observed in 15-month-old AβPP-PS1 mice [24]. 
In Chapter 2, we investigated the effects of high dietary cholesterol intake and 
the cholesterol-lowering liver X receptor (LXR) agonist T0901317 on capillary 
density, Aβ plaque load, and the amount of presynaptic boutons in the 
hippocampus of adult (8 months) and aged (15 months) AβPPswe-PS1dE9 and 
wild-type mice. We have shown that high cholesterol intake increased the 
amount of presynaptic boutons in both 8- and 15-month-old AβPP-PS1 and 
wild-type mice, suggesting an accelerated need for enhanced synaptogenesis 
and fortifying the hypothesis of a synaptic compensatory response. Since high 
cholesterol intake did not affect Aβ plaque load, brain cholesterol levels [24] or 
capillary density (Chapter 2), we hypothesized that this effect of high 
cholesterol intake on synaptogenesis is most likely triggered by a reduction in 
CBV, as shown in our earlier study [24]. Neuronal and synaptic function is 
highly dependent on a sufficient blood flow for the delivery of essential 
nutrients and oxygen. Therefore, a diminished cerebral circulation, due to high 
cholesterol intake, might induce synaptic and neuronal dysfunction, thereby 
triggering the synaptic compensatory response to maintain connectivity and 
preserve cognitive function. We have further shown that the cholesterol-
lowering LXR agonist decreased the amount of presynaptic boutons in 15-
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month-old AβPP-PS1 mice, without affecting capillary density and Aβ plaque 
load (Chapter 2). Cholesterol-lowering agents may positively influence 
cerebral circulation, thereby maintaining or even improving synaptic function, 
and hence diminish or delay the need for synaptic compensation.  
 
In contrast to the promoting effects of cholesterol on AD pathogenesis, dietary 
components such as n3 lc-PUFAs, vitamins and antioxidants have been shown 
to exert protective properties with regard to risk of age-related cognitive decline 
and AD [55-57]. Several lines of evidence have shown beneficial effects of n3 
lc-PUFAs on the cardiovascular system [58, 59], on neuronal membrane 
properties [60, 61], and on inflammatory processes [62]. Nutrients such as B 
vitamins and antioxidants have also been shown to protect the brain from 
oxidative and inflammatory damage [63-66], and synaptic and neuronal loss 
[67, 68]. However, when tested in a clinical setting supplementation with single 
nutrients is marginally effective in improving disease status [69-76]. Therefore, 
it has been suggested that approaches with multiple nutritional components 
might be more promising [55, 77]. In Chapter 4, we tested two specific multi-
nutrient diets in 12-month-old AβPP-PS1 and wild-type mice. Both diets were 
enriched with the n3 lc-PUFAs docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) plus uridine monophosphate (UMP) (referred to as 
the DEU diet). The multi-nutrient Fortasyn
®
 Connect (FC) diet contained 
additional choline, vitamins B6, B9, B12, C and E, folic acid, selenium and 
phospholipids, in order to provide precursors and cofactors for neuronal 
membrane synthesis via the Kennedy cycle [78]. We have shown that that the 
FC diet, but not the DEU diet, was effective in diminishing anxiety-related 
behavior in the open field in both wild-type and AβPP-PS1 mice (Chapter 4). 
Furthermore, a detailed analysis of the search strategies used to acquire the 
MWM task indicated that the FC diet improved the search strategy of 12-
month-old AβPP-PS1 mice, by switching from predominantly random search 
strategies towards a more efficient search strategy, suggesting some beneficial 
effects of the FC diet on the ability to cope with cognitive impairment in the 
AβPP-PS1 mouse model [79]. These results indicate that the effectiveness of 
specific nutrients may depend on the dietary context in which they are provided, 
and suggest that these multi-nutrient diets may have a differential effect on the 
underlying etiopathogenic processes contributing to behavioral changes and 
cognitive decline. Indeed, it was shown that both diets were able to restore the 
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decreased hippocampal and thalamic CBF of the 12-month-old AβPP-PS1 mice 
to the CBF levels of their wild-type littermates. However, the FC diet was more 
effective than the DEU diet since it additionally restored CBF levels of AβPP-
PS1 mice in cortical regions and in the entire brain as well (submitted data, 
[43]). We have further shown that both the DEU and FC diets were equally 
effective in changing brain sterol and fatty acid profiles in wild-type and AβPP-
PS1 mice, by increasing the relative concentrations of n3 fatty acids and 24S-
hydroxycholesterol, and by decreasing the relative concentrations of n6 fatty 
acids and lathosterol (Chapter 4). These results might indicate a replacement of 
n6 fatty acids and cholesterol from cell membranes in favor of n3 lc-PUFAs, 
which has been shown to have a beneficial effect on membrane fluidity, 
neuronal transmission and signaling, and non-amyloidogenic AβPP processing 
[80-83]. Despite these potential beneficial effects of both diets on neuronal 
membrane properties, only the FC diet was able to diminish membrane turnover 
in wild-type and AβPP-PS1 mice, as indicated by decreased hippocampal levels 
of choline-containing compounds, and to completely restore hippocampal 
neurogenesis in AβPP-PS1 mice (Chapter 4). Since the FC diet provides 
precursors and cofactors for the Kennedy cycle that are not supplemented in the 
control and DEU diets, such as choline chloride and soy lecithin, these 
additional nutrients might underlie the beneficial effects of the FC diet in 
maintaining neuronal membranes, enhancing the formation of new neurons and 
diminishing AD-related behavioral measures. Clinical trials with a medical food 
containing Fortasyn
®
 Connect have also shown beneficial effect on memory 
performance and functional connectivity, as measured with EEG, in mild AD 
patients [84-86]. In addition, we have shown that these specific multi-nutrient 
diets were able to affect inflammatory processes (Chapter 4). Surprisingly, IL-
1β mRNA levels were elevated in both AβPP-PS1 and wild-type mice in 
response to dietary intervention with the DEU and FC diets. Since IL-1β 
signaling has been shown to mediate the production of survival signals such as 
nerve growth factor [87, 88] and to mediate re-myelination of the central 
nervous system by stimulating oligodendrocytes proliferation [89, 90], we 
hypothesize that the increase in IL-1β mRNA levels might reflect an initial 
response of the immune system against age-related degenerative processes. 
Indeed, both diets were able to prevent myelin degradation, and axonal and 
neuronal damage in several brain regions of 12-month-old wild-type and AβPP-
PS1 mice, although the differences were more striking in animals fed the FC 
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diet (submitted data, [43]). However, since prolonged elevation of IL-1β can 
initiate chronic neuroinflammatory processes, the question remains whether the 
effects of these multi-nutrient diets on IL-1β production are ultimately 
beneficial or detrimental in the AβPP-PS1 mouse model.  
 
Apolipoprotein E mouse models 
 
The human apolipoprotein E ε4/ε4-carrier (apoE4) and the apolipoprotein 
(apoE) knockout (B6, 129P-Apoe
tm1Unc
/J) mouse models used in chapter 5 of 
this thesis represent models for vascular risk factors in AD development. The 
apoE knockout mouse line has been shown to spontaneously develop severe 
hypercholesterolemia and atherosclerotic plaques [91, 92]. The apoE4 mouse 
line exhibits an increased risk of developing vascular disorders due to altered 
cholesterol metabolism [93]. In Chapter 5 of this thesis, we have studied the 
apoE knockout and apoE4 mouse models at 12 months of age to investigate to 
which extent these models for vascular disorders develop behavioral and 
neuropathological traits of AD. In addition, we determined the effects of long-
term dietary intervention with the specific multi-nutrient Fortasyn
®
 Connect 
(FC) diet in these mouse models.   
 
Genotype effects 
We have confirmed that apoE knockout mice develop severe 
hypercholesterolemia, since they displayed serum cholesterol levels up to 5.5× 
higher than in wild-type mice (Chapter 5). Although CBV was nearly 
unaffected in 12-month-old apoE knockout mice (Chapter 5), a follow-up 
study showed that CBF, measured by FAIR-ASL, was decreased in the 
hippocampus, cortex and thalamus of 12-month-old apoE knockout mice 
(submitted data, [94]). ApoE knockout mice develop atherosclerotic plaques in 
the aorta, pulmonary artery and carotid artery, but not in the cerebral arteries 
[91]. The presence of atherosclerosis in the systemic circulation can have a 
detrimental effect on the cerebral perfusion (CBF) without directly 
compromising the brain vascular structure (CBV). Alongside these 
cerebrovascular alterations, we have shown that apoE ko mice display enhanced 
neurogenesis, although the amount of presynaptic boutons and hippocampal 
metabolite levels were unaffected (Chapter 5). It has been suggested that 
neurogenesis, as well as synaptogenesis, may have a compensatory role in the 
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early stages of AD which can counteract the effects of impaired cerebral 
perfusion, and resulting impaired synaptic and neuronal function and 
connectivity, neurodegeneration and cell death [95-102]. Accordingly, a more 
recent study performed in our lab showed reduced functional connectivity, as 
measured with resting-state fMRI, between the hippocampus, thalamus and 
several cortical regions in 12-month-old apoE knockout mice (submitted data, 
[94]). In addition, 12-month-old apoE knockout mice also displayed reduced 
organization of axonal fibers in the hippocampus, as determined by DT-MRI 
(submitted data, [94]). Despite these neuropathological alterations, we have 
shown preserved cognition in the apoE knockout mouse model at 12 months of 
age (Chapter 5). This was contrary to our expectations, since previous studies 
reported that apoE knockout mice are severely impaired in water maze 
performance [103-106]. However, it was shown that this cognitive deficit was 
completely abolished when apoE knockout mice were repeatedly exposed to 
stressful stimuli. Stressed apoE ko mice performed the Morris water maze task 
as good or even better than stressed wild-type mice, and this effect appeared to 
be mediated by an increased emotional reactivity and an altered corticosterone 
response [107-110]. Due to the increased emotional reactivity of apoE knockout 
mice [111, 112], also confirmed by our results of increased anxiety-related 
behavior in the open field (Chapter 5), the normal daily care of the animals, 
like handling, cleaning cages and transport for behavioral testing, could have 
activated the stress response system in apoE knockout mice and might have 
positively affected their performance in the Morris water maze task [113-115].  
 
In contrast to the apoE knockout mouse model, the 12-month-old apoE4 mice 
described in this thesis did not display many differences compared to wild-type 
animals. Although we have shown some slight alterations in the sterol levels of 
12-month-old apoE4 mice, the CBV (Chapter 5) as well as the CBF were 
unaffected compared to wild-type animals (submitted data, [94]). Previous 
studies have shown that the apoE4 mouse line exhibits an increased risk of 
developing vascular disorders. However this effect was shown to be most 
pronounced when the animals were challenged with a high-fat diet [93]. The 
lack of cerebrovascular alterations at this age might explain the lack of 
differences in neurogenesis, amount of presynaptic boutons, and measures of 
neuronal viability in the apoE4 mouse model on a control diet (Chapter 5). 
However, we have shown impaired cognition in 12-month-old apoE4 mice 
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compared to wild-type controls (Chapter 5). These results are in line with 
previous studies showing that transgenic mice expressing human apoE4 develop 
an age-dependent decline in memory without pathological features of AD, 
implicating a direct detrimental effect of apoE4 itself on the maintenance of 
memory during normal senescence [116, 117]. A follow-up study performed in 
our lab showed that 12-month-old apoE4 mice display regional atrophy and 
disruption of white matter integrity within the medial temporal lobe, without 
affecting the functional connectivity or postsynaptic density of these regions 
(submitted data, [94]). These results suggest that apoE4 mice develop 
alterations in axonal caliber or density, as well as in the architecture of axonal 
membranes and myelin sheaths early in life, independent of cerebrovascular 
alterations, which might contribute to the cognitive deficits in this mouse 
model. These structural modifications may be linked to the isoform-specific role 
of apoE in synaptic development, dendrite formation, and axonal guidance, 
which may be impaired in apoE4 carriers [118]. Indeed, compared with apoE3 
transgenic mice, apoE4 transgenic mice had impaired compensatory sprouting 
and synaptogenesis after entorhinal cortex lesion [119] and were more severely 
impaired in learning and memory [112, 117]. At 18 months of age, regional 
atrophy and disruption of white matter integrity became more aggravated in the 
apoE4 mouse model, in combination with a decrease in CBF, a decrease in 
functional connectivity and a decrease in postsynaptic density (submitted data, 
[94]). 
 
Diet effects 
In Chapter 5, we tested the effects of the multi-nutrient Fortasyn
®
 Connect diet 
(FC diet) in the 12-month-old apoE4 and apoE knockout mice. We have shown 
that the FC diet was able to affect brain fatty acid profiles in wild-type, apoE 
knockout and apoE4 mice, by decreasing the relative concentrations of n6 fatty 
and by increasing the relative concentrations of n3 fatty acids (Chapter 5). 
These results might indicate a replacement of n6 fatty acids from cell 
membranes in favor of n3 lc-PUFAs, which has been shown to have a beneficial 
effect on membrane fluidity, and neuronal transmission and signaling [80-83]. 
Furthermore, we have shown that the FC diet affected serum sterol levels in 
apoE4 and wild-type mice, but not in apoE knockout mice. Serum cholesterol 
levels, lathosterol levels, and 24S-hydroxycholesterol levels were decreased in 
apoE4 and wild-type mice due to long-term dietary intervention, which could 
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contribute to a diminished risk for the development of hypercholesterolemia and 
other vascular disorders (Chapter 5). Despite the lack of alterations in serum 
sterol levels in the apoE knockout model, we have shown that the FC diet was 
able to increase the CBV in the midbrain feeding arteries and parietotemporal 
cortex of 12-month-old apoE knockout mice (Chapter 5). Several 
epidemiological studies and controlled trials showed a correlation between n3 
lc-PUFAs and improvement in autonomic function, lowered blood pressure, 
reduced atherosclerosis and enhanced microvasculature endothelium-dependent 
vasodilation processes [59, 120]. All these factors may have contributed to 
improve the functionality of the brain vascular system, particularly in apoE 
knockout mice, where these pathologies are accelerated. In addition, we have 
shown that the FC diet decreased the levels of glutamate, as measured by 
1
H 
MRS, in the hippocampus of apoE knockout mice (Chapter 5). Glutamate, and 
glutamate receptors, play a fundamental role in neuronal growth and 
differentiation, synaptic plasticity and in regulating neurotransmission, by being 
the major mediator of excitatory signals in the central nervous system. In many 
neurodegenerative diseases, such as AD, glutamate levels are found to be higher 
than in normal aging. Excess glutamate release is the major mediator of 
excitotoxic neuronal injury and neuronal death following cerebral ischemia. 
Therefore, the decrease in glutamate levels might possibly be linked to a better 
brain perfusion in the apoE knockout animals fed the FC diet, although the 
interpretation of these data needs to be made carefully because it should be kept 
in mind that the synaptic glutamate is just a small fraction of the total cellular 
glutamate, whereas the main pool being the metabolic glutamate. Finally, in 
agreement with the results obtained in the AβPPswe-PS1dE9 mouse model 
(Chapter 4), we have shown that the FC diet was effective in diminishing 
anxiety-related behavior in the open field in apoE knockout and wild-type mice 
(Chapter 5).  
 
Conclusions 
 
Taken together, the results described in this thesis support the CATCH 
hypothesis of de la Torre, positing that advanced age in combination with a 
vascular risk factor converges to create a Critical Attained Threshold of 
Cerebral Hypoperfusion (CATCH), triggering brain microcirculatory 
disturbances and hypoperfusion [121, 122]. We have shown that disturbances in 
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cerebral (capillary) blood circulation can be found already at an early age [26], 
and precede severe neuropathological alterations (Chapter 3 and Chapter 5). 
These results confirm that cerebral hypoperfusion and cerebrovascular 
pathology are among the earliest markers in AD development, and precede the 
clinical manifestation of this disease by many years [123-125]. In the AβPPswe-
PS1dE9 mouse model, a decrease in cerebral perfusion is most likely triggered 
by the interaction of (soluble) Aβ peptides with endothelial cells causing 
vasoconstriction, whereas in the apoE knockout model, a decrease in cerebral 
perfusion is the result of atherosclerotic plaques in the systemic circulation. 
Although ApoE4 mice exhibit an increased risk for developing vascular 
disorders (especially when challenged with a high-fat diet), they do not display 
alterations in cerebral perfusion until an advanced age (18 months) on a normal 
control diet (submitted data, [94]), which might explain the lack of substantial 
pathological status in these mice at 12 months of age. Microcirculatory 
disturbances diminish the delivery of essential nutrients and oxygen to the 
brain, leading to a suboptimal performance of neuronal cells in vulnerable 
regions such as the hippocampus, thereby causing mild cognitive impairment 
and behavioral changes as was shown in the 8-month-old AβPP-PS1 mice 
(Chapter 3). We hypothesize that these disturbances in cerebral (capillary) 
blood circulation might trigger a compensatory increase in neurogenesis in an 
attempt to maintain neuronal connectivity and preserve cognitive function, as 
was shown in the 12-month-old apoE knockout mice (Chapter 5), and in 9-
month-old AβPP-PS1 mice [126]. As cerebral hypoperfusion becomes more 
aggravated over time, processes contributing to a lowered cerebral energy 
metabolism (energy crisis), such as oxidative stress, mitochondrial dysfunction, 
glucose uptake deficiency and excess glutamate release, create a hostile 
environment for neuronal and glial cells, causing reduced neuronal viability, 
impaired capacity to produce new neurons, neuronal loss, and increased 
production of pro-inflammatory cytokines as was shown in the 12-month-old 
AβPP-PS1 mice (Chapter 4). 
The compensatory increase in synaptogenesis found in the 15-month-old AβPP-
PS1 mice reflects a final attempt to preserve the functional integrity of the brain 
(Chapter 2). However, due to the ongoing neurodegenerative and inflammatory 
processes, synaptogenesis will ultimately fail as well, resulting in extensive 
synaptic loss and severe cognitive impairment and behavioral alterations, 
consistent with the clinical manifestation of AD (Fig. 1).  
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Fig. 1. Schematic overview of the proposed sequence of events in the development of 
AD, and the mechanisms by which the Fortasyn® Connect (FC) diet prevents AD-
related processes.    
 
 
The role of nutrition 
This thesis shows that dietary intervention has a great impact on AD 
development through various pathways (Fig. 1). One of the major mechanisms 
by which nutrition affects AD development is by modifying cerebral 
circulation. Consistent with epidemiological findings indicating a link between 
high cholesterol intake and increased risk of AD [9-13], we have shown that 
 
6 
233 
 
dietary intake of a typical Western diet, enriched with cholesterol, causes 
hypercholesterolemia and reduces CBV [24], which in turn results in an 
accelerated onset of the compensatory increase in presynaptic boutons 
(Chapter 2). Therefore, AD prevention should focus on keeping serum 
cholesterol levels low and keeping hemodynamic parameters in a normal range 
already during early-life, for example by changing lifestyle factors such as 
physical exercise and dietary intervention. We have shown that multi-nutrient 
diets enriched with n3 lc-PUFAs and UMP lower serum cholesterol levels 
(Chapter 4 and Chapter 5) and improve cerebral perfusion (submitted data, 
[43]). The multi-nutrient Fortasyn
®
 Connect (FC) diet, containing additional 
choline, vitamins B6, B9, B12, C and E, folic acid, selenium and phospholipids 
was shown to be even more effective in preventing cerebral hypoperfusion than 
the DEU diet containing only n3 lc-PUFAs and UMP (submitted data, [43]), 
thereby offering a promising preventative nutritional approach. The increased 
effectiveness of the FC diet might be linked to the additional antioxidants 
provided in this diet that can reduce the levels of endothelial reactive oxygen 
species, which are believed to be an underlying factor in the development of 
vascular dysfunction in AD [127].   
Another mechanism by which nutrition can affect AD development is by 
altering neuronal membrane properties. AD membranes are subject to 
qualitative and quantitative changes in phospholipid content, which have a 
negative impact on neuronal functioning. Decreases in total PUFA content have 
been paralleled by increases in saturated fatty acids such as cholesterol [128], 
thereby influencing membrane fluidity. Finally, there is loss of membrane itself 
[129]. Therefore, nutritional interventions that support membrane synthesis and 
maintenance can be beneficial in preventing AD-related neurodegenerative 
processes. We have shown that both multi-nutrient diets increased the PUFA 
content in the brain (Chapter 4 and Chapter 5), which could have a beneficial 
effect on membrane fluidity, neuronal transmission and signaling, and non-
amyloidogenic AβPP processing [80-83]. The FC diet, which was specifically 
designed to support neuronal membrane synthesis and maintenance by 
providing precursor and cofactors for the Kennedy cycle [78], additionally 
diminished membrane turnover and restored neurogenesis (Chapter 4). Thus, 
the FC diet offers a promising nutritional approach to prevent AD-related 
neurodegenerative processes.   
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Concluding remarks 
 
Although chapter 1 to chapter 5 provide many novel insights in the 
etiopathogenic processes contributing to AD and the mechanisms by which 
nutrition can influence AD pathogenesis, it should be kept in mind that all 
experiments are performed in transgenic mouse models. It is becoming more 
and more clear that preclinical studies actually reflect the prodromal stage of 
human AD, and the results of interventional studies in transgenic mouse models 
should therefore be considered in the context of disease prevention [130, 131]. 
The AβPPswe-PS1dE9 mouse model for familial AD is a widely used model to 
study neurodegenerative processes in AD, since it develops cognitive 
impairment and Aβ pathology at a relatively young age. However, AβPP-PS1 
mice do not fully recapitulate all of the pathological features of the disease, 
since they do not develop the widespread neurofibrillary tangle pathology or 
extensive neurodegeneration as seen in AD patients. Moreover, the AβPP-PS1 
model is focused on a single aspect of AD, due to its enormous promotor driven 
production of Aβ. Thus it is important to use caution in interpreting results 
found in AβPP-PS1 mice and translating them to the human (late-onset) AD 
situation [132]. Regardless, we showed that disturbances in cerebral circulation 
are present already at an early age in the AβPP-PS1 mouse model [26], and 
precede any substantial neuropathological alterations except for Aβ pathology 
(Chapter 2 and Chapter 3). Therefore, we can already conclude that changes 
in hemodynamics play a major role in the progression and aggravation of AD. 
This is in line with a study reporting that cerebral blood flow is already 
diminished in hippocampal and parietofrontal regions of asymptomatic middle-
aged adults with a (maternal) family history of AD [133].  
In order to exclude the presence of human Aβ and give a more definitive answer 
to the question whether vascular disorders play a causal role in AD 
development, we used the apoE knockout and apoE4 mouse models. The apoE 
knockout mouse line is a widely used model to study hypercholesterolemia and 
atherosclerosis, which are major risk factors for AD development [92, 134]. 
However, this model is also often used to study the function of apoE and the 
effects of apoE deficiency. ApoE plays a fundamental role in neuronal 
maintenance and repair, anti-inflammation,  antioxidation, and Aβ clearance 
[135-137], and therefore apoE deficient mice might be impaired in these 
processes. Nonetheless, we showed hypercholesterolemia and cerebrovascular 
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alterations at 12 months of age in this mouse model, alongside with some 
neuropathological traits reflecting early stage AD (Chapter 5). Based on these 
results, we therefore propose that vascular disorders could play a major role in 
the development of AD. It would however be very interesting to study this 
mouse model longitudinally at various ages, to determine the order of 
etiopathogenic processes contributing to AD development in more detail. One 
limitation to the utility of apoE knockout mice as models for vascular disorders 
in AD development is the altered stress response system, which was shown to 
be a confounding factor when studying cognition and cognitive deficits in this 
mouse model (Chapter 5). Future studies should try to minimize exposure to 
stressful stimuli as much as possible in the apoE knockout mouse model, for 
example by limiting the amount of different animal care takers, reducing the 
frequency of cleaning cages, and let the animals habituate for a longer period of 
time after transporting them for behavioral testing [115].  
The apoE4 mouse line used in this thesis is a widely used model to study the 
effects of human apoE4 alleles in AD, since the presence of the apoE4 allele is 
the most important genetic risk factor for developing AD known today. 
Emerging data strongly suggest that apoE4 contributes to AD development by 
interacting with different factors through various pathways. Compared to the 
other apoE-isoforms it has been shown that apoE4 is less efficient in 
transporting cholesterol, thereby contributing to hypercholesterolemia and 
atherosclerosis [138, 139], less efficient in the repair and remodeling of 
damaged synapses [140], and less efficient in the clearance of Aβ across the 
blood brain barrier [141, 142]. Although it was suggested that the apoE4 mouse 
model exhibits an increased risk of developing hypercholesterolemia and 
atherosclerosis due to altered cholesterol metabolism, we could not detect 
cerebrovascular alterations until 18 months of age on a control diet (submitted 
data, [94]). Therefore, apoE4 mice are probably not the best model to study 
vascular risk factors in relation to AD development, unless these mice are fed a 
high-fat diet to accelerate the onset of vascular disorders. Despite the lack of 
alterations in cerebral circulation, we have shown cognitive deficits (Chapter 
5), regional atrophy and disruption of white matter integrity (submitted data, 
[94]) in 12-month-old apoE4 mice. These results imply a direct detrimental 
isoform-specific effect of the apoE4 allele on neuronal maintenance, repair and 
function [137, 143]. However, this should be confirmed using the more 
appropriate human apoE3 mouse model as control mice.  
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Despite their limitations, transgenic mouse models are valuable tools to unravel 
the mechanisms contributing to AD and to test novel therapeutic agents [144]. 
Although we have already used a wide array of different methodologies 
throughout this thesis, it would be interesting to include 
31
P MRS to get a 
greater insight in the cerebral energy metabolism in these animal models, which 
may help to confirm the importance of an energy crisis due to hypoperfusion in 
AD and to study the effects of nutritional intervention on energy and neuronal 
membrane metabolites. In addition, it would be valuable to use positron 
emission tomography (PET) imaging studies with [
18
F] flurodeoxyglucose to 
study in vivo the longitudinal changes in regional glucose metabolism. 
Furthermore, other parameters such as blood pressure could be informative as 
well, since many studies show a relation between dementia and high blood 
pressure in mid-life or low blood pressure in late-life [145], which can be 
modified by nutritional intake. We further suggest to use immunohistochemical 
stainings in combination with techniques such as ELISA, Western blotting and 
quantitative real-time PCR (qRT-PCR), to gain a more detailed understanding 
of how nutrition may affect protein distribution, protein levels and mRNA 
levels. Moreover, as mentioned in Chapter 3 and Chapter 4, the Morris water 
maze (MWM) is a widely used behavioral test to study spatial learning and 
memory. However, standard measures of performance in the MWM, such as 
escape latency during training, time spent in platform quadrant and the 
frequency of platform crossings, may depend on other factors than visuospatial 
learning ability and memory capacity alone. Future studies should therefore 
include the analysis of the search strategies used by the animals to locate the 
hidden platform in the MWM, to be able to discriminate between hippocampus-
dependent learning and hippocampus-independent learning [79, 146].  
 
Taken together, this thesis provides evidence on the importance of cerebral 
hemodynamics which implicates that AD prevention should focus more on 
keeping hemodynamic parameters in a normal range already during early-life. 
Lifestyle changes, such as psychical exercise and dietary intervention can be an 
important tool herein. We have shown that a typical Western diet, rich in 
cholesterol, can accelerate the onset of neurodegenerative processes 
contributing to AD (Chapter 2). Due to the limited exchange of cholesterol 
across the blood brain barrier [147, 148], we hypothesize that cholesterol exerts 
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its promoting effects on AD development mainly by affecting peripheral and 
cerebral circulation. We have further shown that a specific multi-nutrient diet, 
called Fortasyn
® 
Connect, containing many similar components like in typical 
Mediterrean-like diets, can prevent or delay the onset of neurodegenerative 
processes contributing to AD (Chapter 4 and Chapter 5). Besides a beneficial 
effect on the cardiovascular system, the components in this diet can also directly 
influence neuronal membrane properties and inflammatory processes, thereby 
protecting the integrity of the brain at multiple levels. Since we started the 
dietary interventions at a young adult age (2 months), prior to appearance of 
measurable cognitive deficits and pathological lesions, the work described in 
this thesis provides strong evidence that nutrition can affect the risk of 
developing AD later in life, but does not answer the question whether dietary 
intervention with a “healthy diet” could be an effective treatment for AD 
patients. Clinical trials with a medical food containing Fortasyn
®
 Connect have 
shown beneficial effects on memory performance and functional connectivity, 
measured with EEG, in mild AD patients [84-86]. Therefore, it would be 
valuable to test the mechanisms by which the Fortasyn
®
 Connect diet is still 
effective once extensive Aβ production becomes apparent in the AβPP-PS1 
model (4-6 months of age) and after the development of atherosclerotic plaques 
in the apoE knockout mouse model (> 4 months of age), to more closely mimic 
the situation in mild AD patients. 
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De ziekte van Alzheimer (AD) is de meest voorkomende oorzaak van dementie 
bij ouderen. In 2010 leden er ongeveer 36 miljoen mensen wereldwijd aan deze 
ziekte. Het grootste risico om AD te ontwikkelen is gevorderde leeftijd. Wegens 
de stijgende levensverwachting in onze westerse samenleving wordt verwacht 
dat er zo’n 115 miljoen mensen aan de ziekte van Alzheimer zullen lijden in 
2050.  
 
De ziekte heeft invloed op het vermogen van de patiënt om dagelijkse 
activiteiten uit te voeren, en  wordt gekenmerkt door een voortschrijdende 
achteruitgang van de cognitieve functies, zoals geheugenstoornissen (moeite 
met het opslaan van nieuwe informatie en later ook geheugenverlies), 
taalstoornissen, en visueel-ruimtelijke stoornissen (waardoor patiënten 
bijvoorbeeld verdwalen in een bekende omgeving). Bij een groot percentage 
patiënten komen ook persoonlijkheidsveranderingen en stemmingswisselingen 
voor, zoals apathie (onverschilligheid, verliest interesse in de omgeving), 
rusteloosheid, agressie, maar ook angststoornissen en depressie.  
 
Gedurende het verloop van deze ziekte sterven er geleidelijk zenuwcellen 
(neurodegeneratie) en synapsen (verbindingen tussen zenuwcellen) af in 
specifieke gebieden van het brein zoals de hippocampus, cortex en amygdala 
(gebieden die betrokken zijn bij geheugenprocessen, taalbegrip en emoties). 
Buiten de zenuwcellen (neuritic/senile plaques) en in de wand van de 
bloedvaten (cerebrale amyloid pathologie; CAA) worden er eiwitophopingen 
gevonden, voornamelijk bestaand uit het eiwit amyloid-β (Aβ). Tevens zijn er 
kluwens van draadvormige eiwitten (neurofibrillaire tangles) in de hersencellen 
aanwezig die het functioneren van de zenuwcel onmogelijk maken. Daarnaast 
zijn er ook actieve microglia (de immuuncellen van het centrale zenuwstelsel) 
en astrocyten te vinden in het brein van Alzheimer patiënten, wat duidt op een 
ontstekingsreactie.     
 
AD is een complexe ziekte, en de onderliggende mechanismen die AD 
veroorzaken zijn tot op heden nog grotendeels onbekend. In plaats van één 
specifieke oorzaak is het veel waarschijnlijker dat de ziekte van Alzheimer het 
gevolg is van een combinatie van verschillende (risico) factoren, die de 
integriteit van de hersenen op meerdere niveaus aantasten. Naast veroudering 
zijn er nog andere factoren geassocieerd met een verhoogd risico op het 
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ontwikkelen van AD. Onlangs hebben veel epidemiologische studies 
(populatiestudies) aangetoond dat vasculaire aandoeningen, zoals hoge 
bloeddruk (hypertensie), hoge cholesterolbloedspiegel (hypercholesterolemie) 
en aderverkalking (atherosclerose) belangrijke risicofactoren zijn voor het 
ontwikkelen van AD [1-4]. Het wordt gesuggereerd dat deze vasculaire 
aandoeningen de ontwikkeling van AD beïnvloeden door de doorbloeding van 
de hersenen te verminderen (cerebrale hypoperfusie), waardoor er minder 
zuurstof en voedingsstoffen via het bloed in de hersenen aankomen. Hierdoor 
worden hersencellen noodlijdend (energie crisis) waardoor ze minder goed of 
zelfs abnormaal gaan functioneren. Uiteindelijk zou dit alles dan leiden tot 
neurodegeneratie, cognitieve achteruitgang en de ziekte van Alzheimer.  
 
Steeds meer onderzoek laat zien dat ook levensstijl, zoals voeding en 
lichaamsbeweging, een belangrijke rol speelt bij het ontstaan en het beloop van 
de ziekte van Alzheimer [5-8]. Het is bijvoorbeeld gebleken dat mensen die een 
Westers dieet volgen, rijk aan verzadigde vetzuren zoals cholesterol, een grotere 
kans hebben om vasculaire aandoeningen te ontwikkelen, en uiteindelijk ook 
een hoger risico hebben op de ziekte van Alzheimer [9-13]. Daarnaast zijn er 
ook verschillende genen gevonden, betrokken bij het cholesterol metabolisme 
zoals apolipoprotein E (APOE), die geassocieerd worden met de ontwikkeling 
van AD [14]. Zo hebben mensen die het ε4 allel van het APOE gen dragen 
(apoE4) een verhoogd risico op het ontwikkelen van vasculaire aandoeningen 
en AD, en ze ontwikkelen AD vaak op een jongere leeftijd dan apoE-ε2 en 
apoE-ε3 dragers [15]. Daarentegen is gebleken dat het volgen van een 
Mediterraans dieet, rijk aan visolie (ofwel omega-3 meervoudig onverzadigde 
vetzuren), vitamines en antioxidanten, de incidentie (aantal nieuwe gevallen) 
van vasculaire aandoeningen verlaagt en het risico op de ontwikkeling van AD 
op latere leeftijd vermindert [8, 16-18].  
 
Vanuit de wetenschappelijke gemeenschap is er met toenemende mate 
belangstelling voor de rol van voeding en levensstijl in de ontwikkeling van 
AD, op zoek naar alternatieven voor de huidige medicatie die slechts beperkte 
en tijdelijke uitkomst biedt. Het is algemeen bekend dat voeding de werking van 
de hersenen op verschillende niveaus kan beïnvloeden (“je bent wat je eet”) [19-
23]. Het is echter belangrijk om de exacte mechanismen te ontrafelen waarop 
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voeding de ontwikkeling en progressie van AD kan beïnvloeden om een 
effectieve dieetinterventie te ontwikkelen.  
 
Het doel van dit proefschrift was om te onderzoeken op welke manieren 
voeding de ontwikkeling van AD kan beïnvloeden, en om te bepalen welke 
processen bijdragen aan het ontstaan en het verloop van AD. Om deze vragen te 
beantwoorden hebben we gebruik gemaakt van drie verschillende transgene 
muismodellen. De dubbele transgene AβPPswe-PS1dE9 muizen, beschreven in 
hoofdstuk 2 t/m hoofdstuk 4, werden gebruikt als model voor de familiale, 
vroege vorm van Alzheimer (< 65 jaar)  [24, 25]. Deze muislijn heeft een snelle 
en leeftijdsafhankelijke productie van het amyloid-β (Aβ) eiwit, resulterend in 
de karakteristieke eiwitophopingen die vanaf de leeftijd van 4-6 maanden oud 
kunnen worden waargenomen [26]. De AβPPswe-PS1dE9 muizen verschillen 
van hun wild-type nestgenoten in de aanwezigheid van gemuteerde humane 
genen die coderen voor het amyloid-β voorloper eiwit (Aβ precursor protein; 
AβPP) en presenilin 1 (PS1), die beiden bijdragen aan een verhoogde productie 
van het Aβ eiwit. De apoE knockout (B6, 129P-Apoetm1Unc/J) en humane 
apoEε4/ε4-dragende (apoE4) muismodellen, beschreven in hoofdstuk 5, werden 
gebruikt als model voor vasculaire risicofactoren voor AD. ApoE4 muizen 
hebben een verhoogd risico op het ontwikkelen van vasculaire aandoeningen 
wegens een afwijkend cholesterol metabolisme, en apoE knockout muizen 
ontwikkelen spontaan ernstige hypercholesterolemie en atherosclerose [27, 28].  
 
AβPPswe-PS1dE9 muismodel 
 
AβPPswe-PS1dE9 muizen vertonen cognitieve achteruitgang en vormen al op 
jonge leeftijd Aβ deposities. Gelijk aan de humane situatie [29-31] zijn deze Aβ 
deposities als eerste zichtbaar en het meest talrijk in de dentate gyrus (DG) van 
de hippocampus [32-34]. In dit proefschrift hebben we het AβPP-PS1 
muismodel bestudeerd op de leeftijd van 8, 12 en 15 maanden om nader te 
onderzoeken welke processen bijdragen aan het ontstaan en de progressie van 
AD.  
 
Effecten van genotype 
De meest voor de hand liggende en eerste klinische symptoom van AD is 
geheugenstoornis. In overeenstemming met eerdere bevindingen [32] hebben 
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we in hoofdstuk 3 laten zien dat AβPP-PS1 muizen al op de leeftijd van 8 
maanden milde leer- en geheugenproblemen hebben, gecombineerd met een 
verhoogde activiteit (hyperactiviteit) en verminderd exploratief gedrag 
(nieuwsgierig verkennen van de omgeving). Veel AβPP transgene 
muismodellen laten hyperactiviteit en verminderd exploratief gedrag zien, en 
het wordt gedacht dat deze specifieke gedragskenmerken het gevolg zijn van 
verhoogde angst reactiviteit [35-37]. Deze gedragsveranderingen in AβPP 
transgene muizen lijken sterk op de symptomen van angst en rusteloosheid, die 
voorkomen bij zo’n 70% van de Alzheimer patiënten gedurende het verloop van 
hun ziekte [38-41]. In 12 maanden (hoofdstuk 3 en hoofdstuk 4) en 15 
maanden oude AβPP-PS1 muizen [32] worden de gedragsveranderingen en 
cognitieve achteruitgang steeds erger naarmate de ziekte vordert.  
 
Om te onderzoeken of veranderingen in de cerebrale doorbloeding ten 
grondslag kunnen liggen aan de veranderingen in gedrag en cognitie in het 
AβPP-PS1 muismodel, hebben wij de cerebrale bloedvolume (CBV) bepaald 
met behulp van contrast-versterkte MRI scans. In vergelijking met wild-type 
muizen lieten 8 maanden oude AβPP-PS1 muizen een verlaagde CBV zien in 
een aantal cortex gebieden en in de thalamus, maar niet in de hippocampus [34]. 
Over het algemeen kan een afname in de CBV worden veroorzaakt door 
vasoconstrictie (samenknijpen van de bloedvaten) of door een afname van het 
aantal bloedvaten. In hoofdstuk 2 hebben wij echter aangetoond dat de 
bloedvat dichtheid onveranderd was in 8 maanden oude AβPP-PS1 muizen. De 
bloedvat dichtheid was bepaald door middel van een immunohistochemische 
kleuring voor glucose transporters (GLUT-1), die voornamelijk voorkomen in 
de endotheelcellen van de bloedvaten in het brein [42-44]. De Cavalieri’s 
rastermethode (Stereo Investigator, Microbrightfield, Williston, USA), die is 
gebruikt om de bloedvat dichtheid te kwantificeren, is echter niet gevoelig 
genoeg om kleine veranderingen in de diameter van de vaten te detecteren, 
zoals te verwachten is in het geval van vasoconstrictie. Daarom is het mogelijk 
dat de afname in CBV in de AβPP-PS1 muizen het gevolg is van vasoconstrictie 
van de bloedvaten, wat misschien veroorzaakt zou kunnen zijn door de 
interactie van Aβ eiwitten met de endotheelcellen [45-47]. Verder hebben wij in 
hoofdstuk 3 laten zien dat er in 8 maanden oude AβPP-PS1 muizen nog geen 
veranderingen te vinden zijn in de hoeveelheid synapsen of in de concentraties 
van verscheidene metabolieten in de hippocampus, die informatie kunnen geven 
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over (de “gezondheid” van) zenuwcellen of over de mate van ontsteking. Deze 
bevindingen suggereren dat de verminderde hersendoorbloeding in de 8 
maanden oude AβPP-PS1 muizen misschien (nog) niet ernstig genoeg is om 
grote pathologische veranderingen in het brein teweeg te kunnen brengen.  
 
Op de leeftijd van 12 maanden laten AβPP-PS1 muizen een verlaagde CBV 
zien in verschillende corticale en subcorticale gebieden, zoals de hippocampus 
[34]. Ook hier was er geen verandering in vaatdichtheid te ontdekken, maar 
kunnen we vasoconstrictie niet uitsluiten wegens de ongevoeligheid van de 
GLUT-1 kwantificatiemethode. Onze vervolgstudie toonde aan dat ook de 
cerebrale bloedstroming (CBF), gemeten door middel van FAIR-ASL in een 
11.7T MRI scanner, verlaagd was in de hippocampus, cortex en thalamus van 
12 maanden oude AβPP-PS1 muizen (ingediende artikel, [48]). Naast deze 
veranderingen in hersendoorbloeding hebben we laten zien dat er verschillende 
pathologische veranderingen hebben plaats gevonden in het brein van 12 
maanden oude AβPP-PS1 muizen, die ten grondslag kunnen liggen aan de 
verergering van de gedragsveranderingen en cognitieve achteruitgang op deze 
leeftijd. Zo is er een lagere concentratie van de metaboliet N-acetylaspartate 
(NAA) waarneembaar in de hippocampus van 12 maanden oude AβPP-PS1 
muizen, bepaald met behulp van proton magnetic resonance spectroscopy (
1
H 
MRS), wat er op duidt dat de gezondheid en integriteit van de zenuwcellen is 
aangetast (hoofdstuk 3 en hoofdstuk 4). Daarnaast hebben wij aangetoond dat 
de 12 maanden oude AβPP-PS1 muizen minder nieuwe zenuwcellen aanmaken 
(verminderde neurogenese) dan hun wild-type nestgenoten (hoofdstuk 4), 
terwijl de hoeveelheid synapsen nog steeds onveranderd is gebleven (hoofdstuk 
3). Aanvullende resultaten uit ons lab laten zien dat er ook axonale disconnectie, 
myeline afbraak en verlies van zenuwcellen in de hippocampus waarneembaar 
is in 12 maanden oude AβPP-PS1 muizen, zoals bepaald met behulp van 
respectievelijk diffusie tensor MRI (DT-MRI) en histologische analyse met de 
Klüver-Barrera kleuring voor myeline en zenuwcellen [49]. Bovendien is er een 
verhoogd niveau van interleukine-1β (IL-1β) mRNA te vinden in het brein van 
12 maanden oude AβPP-PS1 muizen, wat zou kunnen duiden op het begin van 
een ontstekingsreactie (hoofdstuk 4).   
 
Op de leeftijd van 15 maanden laten AβPP-PS1 muizen een verlaagde CBV en 
hippocampale atrofie zien, in combinatie met veranderingen in de niveaus van 
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bepaalde sterolen en vetzuren in het brein [32]. In dit proefschrift hebben we 
aangetoond dat 15 maanden oude AβPP-PS1 muizen een verhoogd aantal 
(pre)synapsen hebben in verschillende gebieden van de hippocampus 
(hoofdstuk 2). Wij suggereren dat deze verhoogde aantal presynapsen een 
compensatie mechanisme reflecteert waarbij er meer synapsen worden gevormd 
(synaptogenese) in een poging om verbindingen tussen zenuwcellen te 
handhaven en cognitieve functies te behouden. Deze resultaten komen overeen 
met bevindingen van verhoogde aantal pre en post synaptische eiwitten in het 
humane AD brein [50-52], en ondersteunen het idee dat het verlies van 
synapsen pas in een laat stadium van de ziekte van Alzheimer plaatsvindt [52-
54]. In overeenstemming met resultaten van andere studies [55, 56], hebben wij  
aangetoond dat dit synaptische compensatie mechanisme niet afhankelijk is van 
de hoeveelheid Aβ eiwitophopingen in het brein (hoofdstuk 2 en hoofdstuk 3). 
Voorlopige resultaten van ons lab wijzen erop dat ook de aantallen 
postsynapsen worden beïnvloed in het AβPP-PS1 muismodel (nog niet 
gepubliceerde resultaten). Op de leeftijd van 18 maanden laten AβPP-PS1 
muizen een verhoogde dichtheid van postsynapsen zien in het CA3 gebied van 
de hippocampus. Daarentegen is de dichtheid van postsynapsen verlaagd in de 
CA1 en DG gebieden van de hippocampus, wat suggereert dat het compensatie 
mechanisme niet meer in staat is om de verbindingen tussen zenuwcellen te 
handhaven als gevolg van de ernstige neuropathologische veranderingen, 
waardoor er uiteindelijk verlies van synapsen optreedt (ongepubliceerde 
resultaten).    
 
Effecten van dieet 
Eerdere dierexperimenten hebben laten zien dat een hoge cholesterol inname de 
ontwikkeling van AD kan beïnvloeden door het aantal Aβ eiwitophopingen te 
verhogen [57-59] en de CBV te verlagen [32]. Een hoge inname van cholesterol 
bleek echter de gedragsveranderingen en cognitieve achteruitgang niet te 
verergeren in 15 maanden oude AβPP-PS1 muizen [32]. In hoofdstuk 2 
onderzochten wij het effect van een cholesterol dieet en een cholesterol 
verlagend middel, de liver X receptor (LXR) agonist T0901317 (T09), op de 
bloedvat dichtheid, de dichtheid van Aβ eiwitophopingen, en het aantal 
presynapsen in de hippocampus van volwassen (8 maanden oud) en oude (15 
maanden oud) AβPPswe-PS1dE9 en wild-type muizen. We hebben aangetoond 
dat een hoge inname van cholesterol het aantal presynapsen verhoogt in zowel 
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de 8 en 15 maanden oude AβPP-PS1 en wild-type muizen. Deze resultaten 
ondersteunen de eerder genoemde hypothese van een synaptisch compensatie 
mechanisme in de ontwikkeling van AD, en suggereren dat een hoge inname 
van cholesterol de behoefte aan meer synapsen (synaptogenese) versnelt. 
Aangezien het cholesterol dieet geen effect had op de dichtheid van Aβ 
eiwitophopingen, de cholesterol niveaus in het brein [32] of op de bloedvat 
dichtheid (hoofdstuk 2), veronderstellen wij dat de verhoogde aantallen 
presynapsen door het cholesterol dieet waarschijnlijk wordt getriggerd door een 
verlaging in de CBV, zoals aangetoond in onze eerdere studie [32]. Een 
optimale werking van zenuwcellen en synapsen is sterk afhankelijk van een 
normale bloedtoevoer naar en in het brein, zodat er voldoende essentiële 
voedingsstoffen en zuurstof worden aangeleverd. Als de doorbloeding naar en 
in het brein is verminderd, zoals door een hoge inname van cholesterol, kunnen 
zenuwcellen en synapsen niet optimaal meer functioneren (dysfunctie), 
waardoor het synaptische compensatie mechanisme wordt getriggerd in een 
poging om verbindingen tussen zenuwcellen te handhaven en cognitieve 
functies te behouden. Daarnaast hebben wij aangetoond dat het cholesterol 
verlagende middel, T09, zorgt voor een verminderde hoeveelheid presynapsen 
in 15 maanden oude AβPP-PS1 muizen, terwijl het geen effect heeft op de 
bloedvat dichtheid en de dichtheid van Aβ eiwitophopingen (hoofdstuk 2). 
Cholesterol verlagende middelen kunnen een positieve invloed hebben op de 
cerebrale doorbloeding, waardoor de werking van synapsen kan worden 
gehandhaafd of zelfs verbeterd. Hierdoor zou er minder behoefte zijn aan 
synaptische compensatie.  
 
In tegenstelling tot de stimulerende effecten van cholesterol op de ontwikkeling 
van AD, kunnen voedingscomponenten zoals omega-3 meervoudig 
onverzadigde vetzuren (n3 lc-PUFAs), vitamines en antioxidanten beschermend 
werken met betrekking tot het risico op leeftijds-gerelateerde cognitieve 
achteruitgang en de ziekte van Alzheimer [60-62]. Verschillende studies hebben 
aangetoond dat n3 lc-PUFAs een positieve werking hebben op het 
cardiovasculaire systeem [63, 64], op de membraan eigenschappen van 
zenuwcellen [65, 66], en op ontstekingsreacties [67]. Voedingsstoffen zoals 
vitamines B en antioxidanten kunnen het brein beschermen tegen oxidatieve 
schade en schade door ontsteking [68-71], en tegen het verlies van synapsen en 
zenuwcellen [72, 73]. Inname van afzonderlijke voedingsstoffen heeft echter 
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een marginaal effect op het verbeteren van het ziekteverloop bij Alzheimer 
patiënten [74-81]. Er is daarom gesuggereerd dat een dieet met meerdere 
voedingscomponenten (samengesteld dieet) misschien wel veelbelovender zou 
kunnen zijn [60, 82]. 
 
In hoofdstuk 4 hebben we twee specifieke samengestelde diëten getest in 12 
maanden oude AβPP-PS1 muizen. Beide diëten waren verrijkt met 
uridinemonofosfaat (UMP) en de n3 lc-PUFAs doxosahexaeenzuur (DHA) en 
eicosapentaeenzuur (EPA) (aangeduid als het DEU dieet). Het samengestelde 
Fortasyn
® 
Connect (FC) dieet was daarnaast ook nog verrijkt met choline, 
vitamines B6, B9, B12, C en E, foliumzuur, selenium, en fosfolipiden. Deze 
voedingsstoffen zijn belangrijk in de Kennedy synthese cyclus [83], als 
voorloper eiwitten en cofactoren in de vorming van neuronale membranen.  
 
We hebben aangetoond dat het FC dieet, maar niet het DEU dieet, angst-
gerelateerd gedrag verminderde in zowel wild-type als AβPP-PS1 muizen 
(hoofdstuk 4). Daarnaast verbeterde het FC dieet de zoekstrategie van 12 
maanden oude AβP-PS1 muizen in de Morris water maze (MWM) taak, wat 
suggereert dat het FC dieet een gunstig effect heeft in het AβPP-PS1 muismodel 
op het vermogen om te gaan met cognitieve stoornissen [84]. Deze resultaten 
wijzen erop dat de effectiviteit van specifieke voedingsstoffen afhangt van de 
samenstelling van het dieet, en suggereren dat de processen die bijdragen tot 
gedragsveranderingen en cognitieve achteruitgang verschillend worden 
beïnvloed door de DEU en FC samengestelde diëten. We hebben inderdaad 
aangetoond dat beide diëten de verlaagde CBF in de hippocampus en thalamus 
van 12 maanden oude AβPP-PS1 muizen konden herstellen. Echter, het FC 
dieet was effectiever dan het DEU dieet, aangezien het FC dieet ook de 
verlaagde CBF in corticale gebieden en in het gehele brein kon herstellen in de 
AβPP-PS1 muizen (ingediende artikel, [48]. We hebben verder aangetoond dat 
de DEU en de FC diëten even effectief waren om de niveaus van bepaalde 
sterolen en vetzuren in het brein van wild-type en AβPP-PS1 muizen te 
veranderen (hoofdstuk 4). Beide diëten verhoogden de relatieve concentraties 
van omega-3 vetzuren en 24S-hydroxycholesterol (afbraakproduct van 
cholesterol), en verlaagden de relatieve concentraties van omega-6 vetzuren en 
lathosterol (voorloper van cholesterol). Deze resultaten kunnen er mogelijk op 
wijzen dat omega-6 vetzuren en cholesterol in de celmembranen zijn vervangen 
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door omega-3 vetzuren, wat weer een gunstig effect zou kunnen hebben op de 
vloeibaarheid van membranen, signaaloverdracht in en tussen zenuwcellen, en 
op een vermindering van de Aβ productie door middel van de niet-
amyloïdogene verwerking van het AβPP eiwit [85-88].  
 
Ondanks deze mogelijk gunstige effecten van beide diëten op neuronale 
membraan eigenschappen, was alleen het FC dieet in staat om het dynamische 
verloop van neuronale membranen (wat getriggerd kan worden door 
neurodegeneratieve processen) te verlagen, zoals aangetoond door lagere 
niveaus van choline-bevattende metabolieten in de hippocampus. Bovendien 
was alleen het FC dieet in staat om de neurogenese (aanmaak van nieuwe 
zenuwcellen) volledig te herstellen in de AβPP-PS1 muizen (hoofdstuk 4). De 
extra voedingsstoffen in het FC dieet, die niet voorkomen in het controle en 
DEU dieet zoals choline chloride en soja lecithine, kunnen mogelijk ten 
grondslag liggen aan de gunstige effecten van het FC dieet op het behoud van 
neuronale membranen en de vorming van nieuwe zenuwcellen (door middel van 
het leveren van voorloper eiwitten en cofactoren in de Kennedy synthese 
cyclus), en op AD-gerelateerde gedragsveranderingen. Klinische studies in 
patiënten met een milde vorm van Alzheimer lieten ook positieve effecten zien 
van een medisch voedingsmiddel, verrijkt met Fortasyn
®
 Connect, op leer- en 
geheugen prestaties en op de functionele connectiviteit van het brein, gemeten 
met EEG [89-91]. 
 
We hebben verder aangetoond dat de specifieke samengestelde diëten 
ontstekingsprocessen in het brein kunnen beïnvloeden (hoofdstuk 4). 
Verrassend genoeg verhoogden de DEU en FC diëten de IL-1β mRNA niveaus 
in AβPP-PS1 en wild-type muizen. Aangezien IL-1β ook betrokken is bij de 
productie van overlevingssignalen zoals “zenuw groeifactor” (nerve growth 
factor) [92, 93] en de remyelinisatie van het centrale zenuwstelsel door het 
stimuleren van de ontwikkeling en groei van oligodendrocyten [94, 95], 
suggereren wij dat de toename in IL-1β mRNA door de samengestelde diëten 
een eerste reactie van het immuunsysteem zou kunnen reflecteren om 
degeneratieve processen tegen te gaan. Een aanvullende studie van ons lab heeft 
aangetoond dat beide diëten inderdaad de myeline afbraak en axonale en 
neuronale beschadiging in verschillende hersengebieden konden voorkomen in 
12 maanden oude wild-type en AβPP-PS1 muizen, alhoewel deze effecten het 
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meest uitgesproken waren in de dieren op het FC dieet (ingediende artikel, 
[48]). Echter, een langdurige verhoging van IL-1β kan leiden tot chronische 
ontstekingsreacties, en daarom moet verder onderzoek uitwijzen of de 
verhoging van IL-1β door de specifieke samengestelde diëten op de lange 
termijn een positief of negatief effect heeft in het AβPP-PS1 muismodel.   
 
Apolipoprotein E muismodellen 
 
De humane apoEε4/ε4-dragende (apoE4) en apoE knockout (B6, 129P-
Apoe
tm1Unc
/J) muismodellen, beschreven in hoofdstuk 5, werden gebruikt als 
model voor vasculaire risicofactoren in de ontwikkeling van AD. ApoE4 
muizen hebben een verhoogd risico op het ontwikkelen van vasculaire 
aandoeningen wegens een afwijkend cholesterol metabolisme [28]. ApoE 
knockout muizen ontwikkelen spontaan ernstige hypercholesterolemie en 
atherosclerose [27, 96]. In hoofdstuk 5 van dit proefschrift hebben we de apoE 
knockout en apoE4 muismodellen bestudeerd op de leeftijd van 12 maanden om 
te onderzoeken in welke mate deze “vasculaire” modellen gedrags- en 
neuropathologische kenmerken van AD ontwikkelen. Daarnaast hebben we het 
specifieke samengestelde Fortasyn
®
 Connect (FC) dieet getest in deze 
muismodellen.    
 
Effecten van genotype 
Wij hebben bevestigd dat apoE knockout muizen spontaan ernstige 
hypercholesterolemie ontwikkelen, aangezien de concentratie serum cholesterol 
zo’n 5,5× hoger was in apoE knockout muizen dan in wild-type muizen 
(hoofdstuk 5). Hoewel er nauwelijks veranderingen waarneembaar waren in de 
CBV (hoofdstuk 5), toonde een vervolgstudie aan dat de CBF, gemeten met 
behulp van FAIR-ASL, was verlaagd in de hippocampus, cortex en thalamus 
van 12 maanden oude apoE knockout muizen (ingediend artikel, [97]). ApoE 
knockout muizen ontwikkelen atherosclerotische plaques in de aorta, 
longslagaders en halsslagaders, maar niet in de cerebrale slagaders [96]. De 
aanwezigheid van atherosclerotische plaques in de lichaamscirculatie kan een 
nadelig effect hebben op de cerebrale perfusie (CBF) zonder rechtstreeks 
afbreuk te doen aan de structuur van de bloedvaten in het brein (CBV).  
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Daarnaast hebben we een verhoogde neurogenese (aanmaak van nieuwe 
zenuwcellen) laten zien in 12 maanden oude apoE knockout muizen, terwijl er 
(nog) geen veranderingen waarneembaar waren in de hoeveelheid presynapsen 
of in de concentraties van verscheidene metabolieten in de hippocampus 
(hoofdstuk 5). Er is gesuggereerd dat neurogenese, net als synaptogenese, een 
compenserende rol zou kunnen spelen in de vroege stadia van de ziekte van 
Alzheimer om de effecten van een verminderde hersendoorbloeding, resulterend 
in een suboptimale werking en verlies van zenuwcellen en synapsen, tegen te 
gaan [98-105].  
 
Een meer recente studie uitgevoerd in ons laboratorium heeft aangetoond dat 12 
maanden oude apoE knockout muizen verminderde functionele connectiviteit 
laten zien tussen de hippocampus, thalamus en verschillende corticale gebieden, 
gemeten met behulp van resting-state fMRI (ingediende artikel, [97]). Ook laten 
12 maanden oude apoE knockout muizen een disorganisatie van axonale vezels 
zien  in de hippocampus, zoals bepaald met behulp van DT-MRI (ingediende 
artikel, [97]). Ondanks deze neuropathologische veranderingen was er geen 
cognitieve achteruitgang waarneembaar in het apoE knockout muismodel op de 
leeftijd van 12 maanden (hoofdstuk 5). Dit was in tegenstelling tot onze 
verwachtingen, omdat eerdere studies hadden aangetoond dat apoE knockout 
muizen slecht presteren in de MWM [106-109]. Andere studies hebben echter 
laten zien dat de cognitieve achteruitgang in apoE knockout muizen volledig 
herstelde wanneer de dieren herhaaldelijk werden blootgesteld aan stressvolle 
stimuli. “Gestresste” apoE knockout muizen voerden de MWM taak net zo goed 
of zelfs beter uit dan “gestresste” wild-type muizen, en dit effect bleek 
veroorzaakt te worden door een verhoogde emotionele reactiviteit en een 
afwijkende corticosteron respons in de apoE knockout muizen [110-113]. Door 
de verhoogde emotionele reactiviteit van de apoE knockout muizen [114, 115], 
zoals ook blijkt uit het verhoogde angst-gerelateerd gedrag (hoofdstuk 5), kan 
de normale dagelijkse verzorging van de dieren, zoals het oppakken van de 
muizen, schoonmaken van de kooien en het vervoer van en naar de 
gedragskamer, al hebben gezorgd voor een stressreactie in de apoE knockout 
muizen, wat mogelijkerwijs een positieve invloed heeft gehad op hun prestatie 
in de Morris water maze taak [116-118].         
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In tegenstelling tot de apoE knockout muizen lieten de 12 maanden oude apoE4 
muizen weinig verschillen zien in vergelijking met wild-type dieren. Hoewel er 
kleine veranderingen waarneembaar waren in de concentraties van bepaalde 
sterolen (duidend op een afwijkend cholesterol metabolisme), was er geen 
verschil te zien in de CBV (hoofdstuk 5) of in de CBF (ingediende artikel, 
[97]). Eerdere studies hebben aangetoond dat het apoE4 muismodel een 
verhoogd risico heeft op het ontwikkelen van vasculaire aandoeningen. Echter, 
de ontwikkeling van vasculaire aandoeningen was het meest uitgesproken 
wanneer de dieren werden gevoerd met een cholesterol- en vetrijk dieet [28]. 
Het gebrek aan cerebrovasculaire veranderingen op deze leeftijd zou het gebrek 
aan neuropathologische veranderingen (neurogenese, hoeveelheid presynapsen, 
concentraties van verschillende metabolieten in de hippocampus) mogelijk 
kunnen verklaren (hoofdstuk 5).  
 
Twaalf maanden oude apoE4 muizen lieten echter wel verminderde cognitie 
zien in vergelijking met wild-type muizen (hoofdstuk 5). Deze resultaten 
komen overeen met eerdere studies, waaruit blijkt dat humane apoEε4/ε4-
dragende muizen een leeftijdsafhankelijke cognitieve achteruitgang vertonen 
zonder dat er pathologische kenmerken van AD waarneembaar zijn. Dit 
impliceert dat het apoE-ε4 allel zelf een schadelijk effect heeft op het behoud 
van het geheugen tijdens normale veroudering [119, 120]. Een vervolgstudie, 
uitgevoerd in ons laboratorium, heeft aangetoond dat 12 maanden oude apoE4 
muizen atrofie en witte stof afwijkingen vertonen in de mediale temporale 
kwab, terwijl de functionele connectiviteit en dichtheid van postsynapsen 
behouden is gebleven in deze gebieden (ingediende artikel, [97]). Deze 
resultaten suggereren dat apoE4 muizen al op jonge leeftijd, maar onafhankelijk 
van cerebrovasculaire veranderingen, afwijkingen in axonale dichtheid, opbouw 
van axonale membranen en myelineschedes ontwikkelen die kunnen bijdragen 
aan de cognitieve stoornissen in dit muismodel. Deze structurele afwijkingen 
staan mogelijkerwijs in verband met de isovorm-specifieke rol van apoE4 bij de 
ontwikkeling van synapsen, vorming van dendrieten en axonale geleiding [121]. 
Bijvoorbeeld, na een laesie in de entorhinale schors vertonen apoE4 transgene 
muizen minder uitgroei van axonen en dendrieten en minder synaptogenese in 
vergelijking met apoE3 transgene muizen [122]. Op de leeftijd van 18 maanden 
waren de atrofie en witte stof afwijkingen verergerd in het apoE4 muismodel, in 
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combinatie met een afname van de functionele connectiviteit en een daling in de 
postsynaptische dichtheid  (ingediende artikel, [97]). 
 
Effecten van dieet 
In hoofdstuk 5 hebben we het specifieke samengestelde Fortasyn
®
 Connect 
(FC) dieet getest in de 12 maanden oude apoE4 en apoE knockout muizen. We 
hebben laten zien dat het FC dieet in staat was om de niveaus van bepaalde 
vetzuren in het brein van wild-type, apoE knockout en apoE4 muizen te 
veranderen. Het FC dieet zorgde voor een verlaging in de relatieve concentraties 
van omega-6 vetzuren en een verhoging in de relatieve concentraties van 
omega-3 vetzuren (hoofdstuk 5). Deze resultaten kunnen er mogelijk op wijzen 
dat omega-6 vetzuren in de celmembranen zijn vervangen door omega-3 
vetzuren, wat weer een gunstig effect zou kunnen hebben op de vloeibaarheid 
van membranen, en de signaaloverdracht in en tussen zenuwcellen [85-88]. 
Daarnaast hebben we aangetoond dat het FC dieet de concentratie van bepaalde 
sterolen in het serum van wild-type en apoE4 muizen verlaagde, maar niet in het 
serum van apoE knockout muizen. Zowel de concentraties van cholesterol, 
lathosterol en 24S-hydroxycholesterol waren verlaagd in het serum van apoE4 
en wild-type muizen door de inname van het FC dieet gedurende 10 maanden 
lang, wat zou kunnen bijdragen aan een verminderd risico op de ontwikkeling 
van hypercholesterolemie en andere vasculaire aandoeningen (hoofdstuk 5). 
Ondanks het gebrek aan veranderingen in de concentraties van de serum 
sterolen in de apoE knockout muizen was het FC dieet wel in staat om de CBV 
te verhogen in de aderen die de middenhersenen en de parieto-temporale cortex 
voeden (hoofdstuk 5). Verschillende epidemiologische en klinische studies 
hebben aangetoond dat inname van omega-3 lc-PUFAs gecorreleerd is aan 
verbeterde autonome functie van het cerebrale vasculaire systeem, verlaagde 
bloeddruk, verminderde atherosclerose en verbeterde endotheel-afhankelijke 
vaatverwijding [64, 123]. Al deze factoren zouden kunnen bijdragen aan een 
verbeterde functionaliteit van het vasculaire systeem in het brein, met name in 
de apoE knockout muizen.   
 
We hebben ook aangetoond dat het FC dieet het niveau van glutamaat verlaagde 
in de hippocampus van apoE knockout muizen, zoals bepaald door middel van 
1
H MRS (hoofdstuk 5). Glutamaat is de belangrijkste stimulerende 
neurotransmitter in de hersenen en het ruggenmerg. Glutamaat en glutamaat-
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receptoren spelen een fundamentele rol in de groei en differentiatie van 
zenuwcellen, in synaptische plasticiteit en in neurotransmissie (communicatie 
tussen zenuwcellen). In vele neurodegeneratieve ziektes, zoals AD, zijn de 
glutamaat levels hoger dan bij normale veroudering het geval is. Cerebrale 
ischemie kan leiden tot een overmatige afgifte van glutamaat, wat schadelijk is 
voor het brein (excitotoxiciteit). Het zou daarom gesuggereerd kunnen worden 
dat de daling in glutamaat door het FC dieet gekoppeld is aan een verbeterde 
doorbloeding van het brein in de apoE knockout dieren. Deze interpretatie moet 
echter met enige voorzichtigheid worden benaderd, omdat de synaptische 
glutamaat slechts een kleine fractie is van de totale hoeveelheid glutamaat in het 
brein.   
 
Ten slotte hebben we laten zien dat het FC dieet angst-gerelateerd gedrag 
verminderde in de apoE knockout en wild-type muizen (hoofdstuk 5), wat in 
overeenstemming is met de resultaten gevonden in het AβPPswe-PS1dE9 
muismodel (hoofdstuk 4).  
 
Conclusies 
 
Samengevat, de resultaten beschreven in dit proefschrift ondersteunen de 
CATCH hypothese (“Critical Attained Threshold of Cerebral Hypoperfusion”) 
van de la Torre. In deze hypothese wordt verondersteld dat door een gevorderde 
leeftijd en in combinatie met een vasculaire aandoening er een kritisch punt 
wordt bereikt waarop de chronisch verminderde doorbloeding van de hersenen 
leidt tot een energie crisis in het brein en daaropvolgende neurodegeneratie, 
cognitieve achteruitgang en uiteindelijk de ziekte van Alzheimer [124, 125]. We 
hebben laten zien dat verstoringen in de cerebrale (capillaire) bloedcirculatie al 
op jonge leeftijd waarneembaar zijn [34], en dat deze voorafgaan aan ernstige 
neuropathologische veranderingen (hoofdstuk 3 en hoofdstuk 5). Deze 
resultaten bevestigen dat cerebrale hypoperfusie en cerebrovasculaire 
pathologie één van de vroegste kenmerken zijn in de ontwikkeling van AD en 
dat ze vele jaren voor de klinische manifestatie van de ziekte al kunnen worden 
waargenomen [126-128]. In het AβPPswe-PS1dE9 muismodel wordt een 
afname in de cerebrale perfusie waarschijnlijk veroorzaakt door de interactie 
van (oplosbare) Aβ eiwitten met endotheelcellen waardoor er vasoconstrictie 
optreedt. In het apoE knockout muismodel wordt een afname in de cerebrale 
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perfusie waarschijnlijk veroorzaakt door atherosclerotische plaques in de 
circulatie van het lichaam. Ondanks dat apoE4 muizen een verhoogd risico 
hebben om vasculaire aandoeningen te ontwikkelen (voornamelijk wanneer ze 
gevoerd worden met een vetrijk dieet) vertonen zij pas verstoringen in de 
cerebrale bloedcirculatie op een latere leeftijd (18 maanden oud) als ze zijn 
gevoerd met een normaal controle dieet (ingediende artikel, [97]), wat zou 
kunnen verklaren waarom er nog geen substantiële pathologische veranderingen 
waarneembaar zijn in deze muizen op de leeftijd van 12 maanden.  
 
Verstoringen in de cerebrale (capillaire) bloedcirculatie verminderen de aanvoer 
en afgifte van zuurstof en voedingstoffen in het brein, waardoor zenuwcellen 
minder goed of zelfs abnormaal gaan functioneren in kwetsbare gebieden zoals 
de hippocampus. Dit kan leiden tot milde cognitieve achteruitgang en 
gedragsveranderingen zoals we hebben aangetoond in de 8 maanden oude 
AβPP-PS1 muizen (hoofdstuk 3). Wij veronderstellen dat deze verstoringen in 
cerebrale (capillaire) doorbloeding zouden kunnen leiden tot een verhoogde 
aanmaak van nieuwe zenuwcellen (neurogenese) ter compensatie, in een poging 
om neuronale connectiviteit te handhaven en cognitieve functies te behouden, 
zoals we hebben laten zien in de 12 maanden oude apoE knockout muizen 
(hoofdstuk 5) en zoals eerder is aangetoond in 9 maanden oude AβPP-PS1 
muizen [129].  
 
Naarmate de cerebrale hypoperfusie verergerd worden er processen getriggerd 
die bijdragen tot een verlaagde cerebrale energie metabolisme (energie crisis), 
zoals oxidatieve stress, mitochondriële dysfunctie, verminderde glucose opname 
en een overmatige afgifte van glutamaat. Hierdoor ontstaat er een vijandige 
omgeving voor zenuwcellen en glia cellen, wat bijdraagt aan een verminderde 
gezondheid en integriteit van de zenuwcellen, een verminderd vermogen om 
nieuwe zenuwcellen aan te maken, het verlies van zenuwcellen, en een 
verhoogde productie van pro-inflammatoire cytokines zoals wij hebben laten 
zien in de 12 maanden oude AβPP-PS1 muizen (hoofdstuk 4). Het compensatie 
mechanisme van verhoogde synaptogenese, dat wij hebben aangetoond in de 15 
maanden oude AβPP-PS1 muizen, zou mogelijk een laatste poging van het 
brein kunnen weerspiegelen om de functionele integriteit van het brein te 
behouden (hoofdstuk 2). Echter, vanwege de aanhoudende neurodegeneratieve 
en inflammatoire processen zal het synaptische compensatie mechanisme 
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uiteindelijk ook falen, wat resulteert in een wijdverspreid verlies van synapsen 
en zenuwcellen, en ernstige cognitieve stoornissen en gedragsveranderingen die 
overeenkomen met de klinische manifestatie van de ziekte van Alzheimer (Fig. 
1) .   
 
 
Fig. 1. Schematische weergave van de gesuggereerde opeenvolging van gebeurtenissen 
in de ontwikkeling van de ziekte van Alzheimer (AD), en de mechanismen waarop het 
Fortasyn® Connect (FC) dieet aangrijpt om AD-gerelateerde processen te voorkomen.  
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Invloed van voeding 
Dit proefschrift toont aan dat voeding een grote invloed heeft op de 
ontwikkeling van de ziekte van Alzheimer door aan te grijpen op verscheidene 
processen (Fig. 1). Eén van de belangrijkste mechanismen waarop voeding 
invloed uitoefent op de ontwikkeling van AD is de cerebrale doorbloeding. In 
overeenstemming met epidemiologische bevindingen, die een verband leggen 
tussen een hoge inname van cholesterol en een verhoogd risico op AD [9-13], 
hebben wij aangetoond dat de inname van een typisch Westers dieet, verrijkt 
met cholesterol, hypercholesterolemie veroorzaakt en de CBV vermindert [32], 
waardoor er een versnelde behoefte ontstaat aan een compenserende toename in 
het aantal synapsen (hoofdstuk 2). AD preventie zou zich daarom ook moeten 
focussen op een gezonde levensstijl, met voldoende lichaamsbeweging en een 
gebalanceerd dieet, gedurende het gehele leven om de concentratie van 
cholesterol in het bloed en hemodynamische parameters op een normaal niveau 
te kunnen blijven handhaven. Daarnaast hebben we laten zien dat specifieke 
samengestelde diëten, verrijkt met omega-3 vetzuren (n3 lc-PUFAs) and 
uridinemonofosfaat (UMP), de concentratie cholesterol in het bloed verlagen 
(hoofdstuk 4 en hoofdstuk 5) en de cerebrale doorbloeding verbeteren 
(ingediende artikel, [48]). Het samengestelde Fortasyn
®
 Connect (FC) dieet, dat 
nog extra was verrijkt met choline, vitamines B6, B9, B12, C en E, foliumzuur, 
selenium and fosfolipiden, bleek zelfs nog effectiever te zijn in het voorkomen 
van cerebrale hypoperfusie dan het DEU dieet, dat alleen was verrijkt met n3 lc-
PUFAs en UMP (ingediende artikel, [48]). Het FC dieet biedt daarom een 
veelbelovende preventieve voedingsinterventie voor vasculaire aandoeningen en 
AD. De verhoogde effectiviteit van het FC dieet zou mogelijk gerelateerd 
kunnen zijn aan de extra antioxidanten in dit dieet. Het wordt gesuggereerd dat 
de ontwikkeling van vasculaire dysfunctie in de ziekte van Alzheimer mede 
wordt veroorzaakt door verhoogde levels van reactieve zuurstofverbindingen 
(“reactive oxygen species”) in de endotheelcellen [130]. Antioxidanten zijn in 
staat om de hoeveelheid reactieve zuurstofverbindingen te verlagen, en kunnen 
op deze wijze bijdragen aan een verbetering van het vasculaire systeem.    
 
Een ander mechanisme waardoor voeding invloed kan uitoefenen op de 
ontwikkeling van AD is het veranderen van de membraan eigenschappen van 
zenuwcellen. Celmembranen van Alzheimer patiënten zijn onderworpen aan 
kwalitatieve en kwantitatieve veranderingen in fosfolipiden, de bouwstenen van 
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celmembranen, waardoor de zenuwcellen suboptimaal gaan presteren. Terwijl 
de hoeveelheid PUFAs in de celmembranen afneemt, neemt de hoeveelheid 
verzadigde vetzuren (zoals cholesterol) toe [131], resulterend in een verlaagde 
vloeibaarheid van membranen. Daarnaast vindt er ook verlies van de 
celmembranen zelf plaats [132]. Voedingsinterventies die de synthese van 
celmembranen zouden stimuleren en die de celmembranen zouden onderhouden 
kunnen daarom mogelijk bescherming bieden tegen AD-gerelateerde 
neurodegeneratieve processen. We hebben aangetoond dat beide samengestelde 
diëten (DEU en FC) de hoeveelheid PUFA in het brein verhogen (hoofdstuk 4 
en hoofdstuk 5), wat een gunstig effect zou kunnen hebben op de vloeibaarheid 
van membranen, signaaloverdracht in en tussen zenuwcellen, en op een 
vermindering van de Aβ productie door middel van de niet-amyloïdogene 
verwerking van het AβPP eiwit [85-88]. Het FC dieet, dat verrijkt was met 
voorloper eiwitten en cofactoren die belangrijk zijn voor de vorming en het 
behoud van neuronale membranen (via de Kennedy synthese cyclus [83]), was 
daarnaast ook in staat om het dynamische verloop van neuronale membranen 
(wat getriggerd kan worden door neurodegeneratieve processen) te verlagen en 
om de aanmaak van nieuwe zenuwcellen (neurogenese) volledig te herstellen 
(hoofdstuk 4). Het FC dieet biedt daarom een veelbelovende strategie om AD-
gerelateerde neurodegeneratieve processen te voorkomen.  
 
Slotopmerkingen 
 
Hoewel hoofdstuk 1 tot en met hoofdstuk 5 veel nieuwe inzichten geven in de 
processen die bijdragen aan de ontwikkeling en de progressie van de ziekte van 
Alzheimer en de manieren waarop voeding de pathogenese van AD zou kunnen 
beïnvloeden, moet er in gedachten worden gehouden dat alle experimenten zijn 
uitgevoerd in transgene muismodellen. Het wordt steeds duidelijker dat 
preklinische studies met diermodellen meer de prodromale fase van humane AD 
weerspiegelen (voor de manifestatie van klinische kenmerken), en dat de 
resultaten van interventiestudies in transgene diermodellen derhalve 
geïnterpreteerd dienen te worden in het kader van ziekte preventie en niet 
zozeer in het kader van ziekte behandeling [133, 134]. 
 
Het AβPPswe-PS1dE9 muismodel is een veelgebruikt diermodel om 
neurodegeneratieve processen in AD te onderzoeken, omdat het al op relatief 
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jonge leeftijd cognitieve stoornissen en Aβ pathologie ontwikkelt. AβPP-PS1 
muizen ontwikkelen echter niet alle pathologische kenmerken van de ziekte, 
want ze vertonen geen neurofibrillaire tangles of wijdverspreide 
neurodegeneratie zoals wel het geval is in AD patiënten. Bovendien is het 
AβPP-PS1 model gericht op één specifiek aspect van AD, namelijk de enorme 
promotor-gedreven productie van Aβ. Het is daarom belangrijk om voorzichtig 
te zijn met de interpretatie van resultaten gevonden in AβPP-PS1 muizen en met 
de vertaalslag naar de humane situatie van AD [135]. Desalniettemin hebben we 
laten zien dat een verstoorde cerebrale circulatie al op jonge leeftijd aanwezig is 
in het AβPP-PS1 muismodel [34], voordat er andere substantiële 
neuropathologische veranderingen te vinden zijn behalve Aβ pathologie 
(hoofdstuk 2 en hoofdstuk 3). We kunnen daarom concluderen dat 
veranderingen in de hemodynamiek een belangrijke rol spelen in de progressie 
en het verloop van AD. Dit is in overeenstemming met een studie die heeft 
aangetoond dat er reeds verminderde cerebrale doorbloeding waarneembaar is 
in de hippocampus en parieto-frontale gebieden van asymptomatische 
volwassen personen van middelbare leeftijd met een familiegeschiedenis van 
AD [136]. 
 
Om het effect van humane Aβ uit te sluiten en een duidelijker antwoord te 
krijgen op de vraag of vasculaire aandoeningen een causale rol spelen in de 
ontwikkeling van AD, hebben we gebruik gemaakt van de apoE knockout en 
apoE4 muismodellen. Het apoE knockout muismodel is een veelgebruikt 
diermodel om hypercholesterolemie en atherosclerose, wat belangrijke 
risicofactoren zijn voor de ontwikkeling van AD, te bestuderen [27, 137]. Dit 
model wordt echter ook vaak gebruikt om de functie van apoE en de effecten 
van apoE deficiëntie te bestuderen. ApoE speelt een fundamentele rol in het 
onderhoud en reparatie van zenuwcellen, anti-ontstekingsprocessen, antioxidatie 
en het verwijderen van Aβ via de bloed-hersenbarrière [138-140]. Deze 
processen kunnen daarom aangetast zijn in de apoE knockout muizen, al 
voordat er cerebrovasculaire veranderingen waarneembaar zijn. Desalniettemin 
hebben we aangetoond dat dit muismodel op de leeftijd van 12 maanden 
hypercholesterolemie en cerebrovasculaire verstoringen laten zien, tezamen met 
enkele pathologische veranderingen die een vroeg stadium van de AD 
ontwikkeling weerspiegelen (hoofdstuk 5). Op basis van deze resultaten 
suggereren we daarom dat vasculaire aandoeningen een belangrijke rol zouden 
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kunnen spelen in de ontwikkeling van de ziekte van Alzheimer. Het zou echter 
interessant zijn om dit muismodel ook longitudinaal te onderzoeken, op 
verschillende leeftijden, om een beter inzicht te krijgen in de opeenvolging van 
gebeurtenissen die bijdragen aan de ontwikkeling van AD. Het gebruik van het 
apoE knockout muismodel als diermodel voor vasculaire aandoeningen in de 
ontwikkeling van AD heeft echter wel beperkingen. ApoE knockout muizen 
hebben een verhoogde emotionele reactiviteit en een afwijkende respons op 
stressvolle situaties, wat storende factoren bleken te zijn bij het bestuderen van 
cognitie en cognitieve achteruitgang in dit muismodel (hoofdstuk 5). 
Toekomstige studies zouden daarom moeten proberen om apoE knockout 
muizen zo min mogelijk bloot te laten stellen aan stressvolle stimuli, 
bijvoorbeeld door het minimaliseren van het aantal verschillende 
dierverzorgers, de kooien van de dieren minder frequent schoon te maken, en de 
dieren voor een langere periode te laten wennen aan een nieuwe omgeving 
nadat ze van hun huisvestingskamer zijn verplaatst naar de gedragskamer [118].  
 
Het apoE4 muismodel is een veelgebruikt diermodel om de effecten van het 
humane apoE4 allel te bestuderen, aangezien de aanwezigheid van het apoE4 
allel op dit moment als één van de meest belangrijke genetische risicofactor 
wordt beschouwd in de ontwikkeling van AD. Steeds meer studies suggereren 
dat apoE4 via verschillende mechanismen kan bijdragen aan de ontwikkeling 
van AD. In vergelijking met de andere isovormen van apoE is apoE4 minder 
efficiënt in het transporteren van cholesterol, hetgeen bijdraagt aan de 
ontwikkeling van hypercholesterolemie en atherosclerose [141, 142]. Daarnaast 
is apoE4 minder efficiënt in het herstel en herstructuren van beschadigde 
synapsen [143], en minder efficiënt in het verwijderen van Aβ via de bloed-
hersenbarrière [144, 145]. Hoewel het apoE4 muismodel een verhoogd risico 
zou hebben op het ontwikkelen van hypercholesterolemie en atherosclerose 
wegens een afwijkend cholesterol metabolisme, konden wij geen 
cerebrovasculaire verstoringen detecteren totdat de muizen de leeftijd van 18 
maanden hadden bereikt (ingediende artikel, [97]). ApoE4 muizen zijn daarom 
waarschijnlijk niet het beste model om vasculaire risicofactoren in de 
ontwikkeling van AD te bestuderen, tenzij de muizen worden gevoerd met een 
cholesterol- en vetrijk dieet om de ontwikkeling van vasculaire aandoeningen te 
versnellen. Ondanks het gebrek aan verstoringen in de cerebrale circulatie lieten 
12 maanden oude apoE4 muizen wel cognitieve achteruitgang zien (hoofdstuk 
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5), in combinatie met regionale atrofie en witte stof afwijkingen (ingediende 
artikel, [97]). Deze resultaten impliceren dat het apoE4 allel een direct 
schadelijk isovorm-specifiek effect heeft op het neuronale onderhoud, reparatie 
en functie [140, 146]. Dit zal echter moeten worden bevestigd door een 
vervolgstudie waarin humane apoE3 muizen worden gebruikt als controle 
muizen.   
 
Ondanks hun beperkingen zijn transgene muismodellen waardevolle 
hulpmiddelen om de mechanismen die bijdragen aan de ontwikkeling van AD te 
kunnen ontrafelen en om nieuwe therapeutische middelen te kunnen testen 
[147]. Hoewel wij in dit proefschrift al gebruik hebben gemaakt van een breed 
scala aan verschillende methodieken, zou het interessant zijn om in de toekomst 
ook gebruik te maken van 
31
P MRS. Deze techniek stelt ons in staat om een 
beter inzicht te krijgen in het cerebrale energie metabolisme van deze 
diermodellen, en zou kunnen bevestigen dat cerebrale hypoperfusie leidt tot een 
energie crisis in het brein en daaropvolgende AD-gerelateerde pathologische 
veranderingen. Daarnaast stelt deze techniek ons in staat om de effecten van 
voeding op energie en neuronale membraan metabolieten te bestuderen. Ook 
zou het waardevol zijn om in toekomstige studies gebruik te maken van  
“positron emission tomography” (PET) met [18F] flurodeoxyglucose, om in vivo 
de longitudinale veranderingen in  het glucose metabolisme te kunnen 
bestuderen. Andere parameters, zoals de bloeddruk, zouden ook erg informatief 
zijn, aangezien veel studies een verband aantonen tussen dementie en hoge 
bloeddruk (hypertensie) op middelbare leeftijd of lage bloeddruk (hypotensie) 
op oudere leeftijd [148]. Daarnaast adviseren wij om immunohistochemische 
kleuringen te gebruiken in combinatie met moleculaire technieken zoals ELISA, 
Western blotting en kwantitatieve real-time PCR (qRT-PCR) om een beter 
inzicht te krijgen hoe voeding invloed heeft op de regionale verdeling van 
eiwitten in het brein, de concentratie van bepaalde eiwitten en de niveaus van 
mRNA. Als laatste stellen wij voor om in toekomstige studies een meer 
gedetailleerde analyse van de zoekstrategieën in de Morris water maze (MWM) 
toe te voegen. Zoals vermeldt in hoofdstuk 3 en hoofdstuk 4 is de MWM een 
veel gebruikte gedragstest om het ruimtelijk leer- en geheugenvermogen te 
bestuderen. Echter, de standaard analyse parameters van de MWM, zoals de 
benodigde tijd om het platform te vinden tijdens de training, de tijd die het dier 
doorbrengt in het kwadrant waar het platform zich bevond, of de frequentie van 
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platform kruisingen, kunnen van meer factoren afhankelijk zijn dan alleen het 
visueel-ruimtelijke leervermogen en geheugen capaciteit. Toekomstige studies 
zouden daarom ook de zoekstrategieën, die de dieren gebruiken om het 
verborgen platform te lokaliseren in de MWM, moeten analyseren om een 
onderscheid te kunnen maken tussen hippocampus-afhankelijk leren en 
hippocampus-onafhankelijk leren [84, 149].    
 
Samengevat, de resultaten in dit proefschrift laten zien dat de cerebrale 
circulatie een belangrijke rol speelt in de ontwikkeling van AD. AD preventie 
zou zich daarom moeten richten op het handhaven van normale (gezonde) 
hemodynamische parameters gedurende het gehele leven. Veranderingen in 
levensstijl, zoals voldoende lichaamsbeweging en een gebalanceerd dieet, 
kunnen hierbij een belangrijk hulpmiddel zijn. We hebben aangetoond dat een 
typisch Westers dieet, rijk aan cholesterol, het ontstaan van AD-gerelateerde 
neurodegeneratieve processen kan versnellen (hoofdstuk 2). Wegens de 
beperkte uitwisseling van cholesterol via de bloed-hersenbarrière [150, 151], 
veronderstellen wij dat cholesterol de ontwikkeling van AD voornamelijk 
versnelt door het verminderen van de lichaams- en cerebrale circulatie. We 
hebben verder aangetoond dat het specifieke samengestelde Fortasyn
®
 Connect 
dieet, met daarin veel voedingscomponenten die ook voorkomen in een 
Mediterraans dieet, het ontstaan van AD-gerelateerde neurodegeneratieve 
processen kan voorkomen of vertragen (hoofdstuk 4 en hoofdstuk 5). Naast 
een gunstige invloed op het cardiovasculaire systeem kunnen de bestanddelen 
van dit dieet ook direct een invloed uitoefenen op neuronale membraan 
eigenschappen en ontstekingsprocessen, waardoor de integriteit van het brein op 
meerdere niveaus wordt beschermd.  
 
Aangezien de dieren vanaf een jong volwassen leeftijd (2 maanden) gevoerd 
werden met de specifieke diëten, dus nog voordat er cognitieve achteruitgang of 
pathologische veranderingen waarneembaar waren, levert dit proefschrift bewijs 
dat voeding het risico op het ontwikkelen van AD op latere leeftijd kan 
beïnvloeden. Echter, het geeft geen antwoord op de vraag of interventie met een 
“gezond dieet” een effectieve behandeling zou kunnen zijn voor Alzheimer 
patiënten. Klinische studies in patiënten met een milde vorm van Alzheimer 
lieten positieve effecten zien van een medisch voedingsmiddel, verrijkt met 
Fortasyn
®
 Connect dieet, op leer- en geheugen prestaties en op de functionele 
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connectiviteit van het brein, gemeten met EEG [89-91]. Om de humane situatie 
van de milde vorm van AD nauwer na te bootsen zou het daarom waardevol zijn 
om te testen via welke mechanismen het Fortasyn® Connect dieet een 
beschermend effect zou kunnen hebben op het moment dat er een omvangrijke 
productie van Aβ waarneembaar is in het AβPP-PS1 muismodel (4-6 maanden), 
en na de ontwikkeling van atherosclerotische plaques in het apoE knockout 
muismodel (> 4 maanden).  
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List of frequently used abbreviations 
 
AA   arachidonic acid 
Aβ   amyloid-β 
ACg   anterior cingulate gyrus 
AD   Alzheimer’s disease 
apoE   apolipoprotein E 
AβPP   amyloid-β precursor protein 
BCH   biochemistry 
BSA   bovine serum albumin 
CAA   cerebral amyloid angiopathy 
CATCH  critically attained threshold of cerebral    
   hypoperfusion 
CBF   cerebral blood flow 
CBV   cerebral blood volume 
CO   control diet 
Cre   creatine 
DAB-Ni  3-3’diaminobenzidin tetra hydrochloride with   
   ammonium nickel sulphate 
Dcx   doublecortin 
DG   dentate gyrus 
DHA   docosahexaenoic acid 
DEU multi-nutrient diet enriched with docosahexaenoic acid, 
eicosapentaenoic acid, and uridine monophosphate 
EPA   eicosapentaenoic acid 
FC Fortasyn
®
 Connect multi-nutrient diet enriched with 
docosahexaenoic acid, eicosapentaenoic acid, uridine 
monophosphate, phospholipids, choline, folic acid, 
vitamins B6, B12, C, E and selenium 
GC-FID  gas-chromatography-flame-ionization-detector 
GC-MS-SIM  gas-chromatography-mass-spectrometry-selected  
   ionmonitoring 
Glu   glutamate 
GLUT-1  glucose transporter type 1 
IHC   immunohistochemistry 
IML   inner molecular layer (of the dentate gyrus) 
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lc-PUFAs  long-chain polyunsaturated fatty acids 
LXR   liver X receptor 
MCI   mild cognitive impairment 
mI   myo-Inositol 
MRI   magnetic resonance imaging 
(
1
H) MRS  proton magnetic resonance spectroscopy 
MUFA   mono unsaturated fatty acids 
MWM   Morris water maze 
n3   omega-3 fatty acids 
n6   omega-6 fatty acids  
NAA   N-acetylaspartate 
NFTs   neurofibrillary tangles 
OA   oleic acid 
OML   outer molecular layer (of the dentate gyrus) 
PB   phosphate buffer 
PBS   phosphate buffered saline 
PLA   prelimbic area 
PS1   presenilin 1 
rMWM   reverse Morris water maze 
ROI   region of interest 
SFA    saturated fatty acids 
SIPBs   synaptophysin-immunoreactive presynaptic boutons 
SL   stratum lucidum (of the CA3 area) 
SR   stratum radiatum (of the CA1 area) 
SYN-IR  synaptophysin immunoreactivity 
Tau   taurine 
TBS   Tris buffered saline 
tCho choline-containing compounds (choline + 
glycerophosphocholine + phosphocholine) 
tCre   total creatine-containing compounds (creatine +  
   phosphocreatine) 
tNAA total NAA-containing compounds (N-acetylaspartate + 
N-acetylaspartylglutamate) 
TWD   typical Western diet 
UMP   uridine monophosphate 
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Nu de wetenschappelijke inhoud van dit proefschrift is afgerond, wil ik 
overgaan tot het bedanken van alle mensen die, op welke manier dan ook, 
hebben bijgedragen aan de totstandkoming van dit boekje. Gedurende de 
afgelopen 5 jaar zijn er veel mensen betrokken geweest bij mijn promotietraject, 
en bij deze zou ik graag iedereen willen bedanken voor het steentje dat ze 
hebben bijgedragen en voor de fijne samenwerking. Een aantal mensen zal ik 
hieronder nog in het bijzonder benoemen, maar als ik desondanks nog iemand 
vergeet te vermelden, dan wijt ik het aan het feit dat ik niet genoeg 
Mediterraans voedsel eet……. 
 
Allereerst wil ik de mensen bedanken die direct betrokken waren mijn 
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ondanks alle tegenslagen die wij hebben gehad. Ik heb ontzettend veel van je 
geleerd, niet alleen over de inhoudelijke kant van het onderzoek, maar ook over 
de positie van de vrouw in het academisch wetenschappelijke onderzoek. Ik 
wens je alle succes toe voor de toekomst, en ik hoop ooit zelf zo’n mooi project 
te kunnen opstarten en begeleiden.    
 
Beste Stan, alhoewel u als promotor niet direct betrokken ben geweest bij de 
inhoudelijke kant van mijn onderzoek, ben ik u zeer erkentelijk voor het advies 
dat u mij gedurende mijn promotietraject heeft gegeven. Ondanks uw drukke 
schema was u altijd bereid om niet alleen de voortgang, maar ook de knelpunten 
van het onderzoek, te bespreken. Daarvoor dan ook mijn dank. 
 
Beste Arend, bedankt voor de kennis die u mij heeft bijgebracht met betrekking 
tot magnetic resonance imaging. Tevens ben ik erg blij met alle uren die wij 
hebben mogen gebruiken op de MRI scanner. Ook wil ik u bedanken voor alle 
constructieve feedback die u heeft geleverd op mijn manuscripten.  
 
Dear Valerio, thank you very much for our collaboration the past 4.5 years on 
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“technical” person and me as the “biological” person. Without your expertise on 
MRI measurements, we wouldn’t have been able to perform such cutting-edge 
and translational research. I am grateful for all the work you have done, not only 
in terms of performing and processing the MRI experiments, but also in helping 
me with the supervision of all the students we have had throughout the years, 
and the fruitful discussions about the interpretation of our results. I would like 
to wish you the best of luck with your own thesis defense later this year, and all 
the best for the future!  
 
Mijn lieve paranimfen Carola en Ilse. Bedankt dat jullie mij op 25 november 
(weer eens) wilden bijstaan. Niet alleen als studenten hebben jullie enorm 
bijgedragen aan de totstandkoming van dit proefschrift, ook als zeer 
gewaardeerde collega’s hebben jullie mij dikwijls gesteund. Ik heb veel aan 
jullie gezelschap en vriendschap gehad. Jullie waren altijd bereid om te 
luisteren, te discussiëren over de resultaten of mee te helpen waar nodig (uitleg 
geven aan studenten, helpen met opslepen, data analyse, etc). Ik wens jullie het 
beste toe voor de toekomst en veel succes met de afronding van jullie eigen 
promoties. Ik verwacht uiteraard wel een uitnodiging te krijgen als jullie zelf 
jullie proefschriften moeten verdedigen !  
 
I would also like to thank the members of the reading committee, prof. Marcel 
Olde Rikkert, prof. Heikki Tanila and prof. Paul Luiten for their willingness 
to sacrifice (a part of) their summer holidays to read and approve my thesis 
manuscript.  
Prof. Paul Luiten wil ik in het bijzonder nog bedanken. Dankzij u heb ik 
gesolliciteerd op dit promotieonderzoek, met als resultaat dit mooie proefschrift 
5 jaar later. Ik voel mij zeer vereerd en ik ben zeer erkentelijk dat u mij 
gedurende de afgelopen jaren heeft gesteund en gevolgd in mijn carrière, eerst 
als student bij u op de afdeling in Groningen, en later als PhD student in 
Nijmegen.  
 
Maar er zijn natuurlijk nog veel meer mensen die bedankt moeten worden. Jos 
en Maartje, jullie hulp op het lab, uitleg over de immunohistochemie en het 
gebruik van de Neurolucida hebben ervoor gezorgd dat ik vele manuscripten 
heb kunnen schrijven en illustreren. Ook Bram moet ik hierbij vermelden voor 
zijn hulp bij de uitvoering van de immunohistochemische kleuringen van het 
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laatste LipiDiDiet experiment, waarvan de resultaten helaas niet meer konden 
worden opgenomen in dit proefschrift. Ook mijn andere collega’s van de 
afdeling Anatomie wil ik bedanken, en met name mijn nog niet genoemde 
kamergenoten, Rick en Maximilian.  
Lieve Max, ook jou ben ik zeer erkentelijk voor alle hulp, gezelschap en steun 
die jij mij hebt geboden de afgelopen 3 jaar, niet alleen tijdens jouw stage op het 
LipiDiDiet project maar ook als collega PhD student. Mede door jouw enorme 
inzet is dit boekje zo dik geworden. Al dacht ik dat de PhD kamer al erg 
gezellig was, de komst van Rick maakte het nog aangenamer vanwege zijn 
constructieve commentaar en af en toe droge opmerkingen. Ook jullie wil ik 
beiden veel succes toewensen met de afronding van jullie eigen 
promotieonderzoeken.  
 
Ook collega’s van andere afdelingen binnen het UMC St. Radboud zou ik graag 
nog in het bijzonder willen bedanken. Allereerst Nienke van de afdeling 
Neurologie, zonder jouw protocollen, uitleg en advies had ik de AβPP-PS1 en 
wild-type muizen niet kunnen genotyperen. Ook later heb jij mij nog geholpen 
door het aanleveren van protocollen voor het uitvoeren van ELISA’s. Bedankt 
dat jij altijd bereid was om mijn vragen te beantwoorden, en voor alle 
gezelligheid in Florence en tijdens het werk bij jullie op het lab. Van de afdeling 
Radiologie wil ik in het bijzonder Andor, Sjaak, Bob en Alan bedanken voor 
hun technische ondersteuning en hulp bij de data analyse van de MRI 
experimenten. Ook Judith Homberg (afdeling Cognitive Neuroscience) en 
Ineke van der Zee (afdeling Celbiologie) zou ik graag willen bedanken voor 
het respectievelijk beschikbaar stellen van de gedragskamer en de uitleg over de 
gedragstesten gedurende de eerste experimenten van mijn onderzoek. Van de 
afdeling Interne Geneeskunde wil ik graag Leo Joosten, Malgorzata Miller-
Tomaszewska en Zewen Zhang bedanken voor hun hulp bij de qRT-PCR’s.  
 
Uiteraard mogen alle (nog niet genoemde) studenten die de afgelopen 5 jaar de 
revue hebben gepasseerd ook niet ontbreken op de lijst. Zonder hun inzet was 
dit proefschrift een stuk beknopter geweest. Dus Anne H, Anna-Lena, Cindy, 
Bastian, Daan, Marjolein, Lianne, Nicole, Luutsen, Kees, Anne R, Tsong, 
Roy, Maarten, Tim, Karin en Sabine, ik vond het erg leuk en leerzaam om 
jullie te begeleiden en ik ben jullie zeer erkentelijk voor alle hulp en  
D 
315 
 
gezelligheid. Ook Ilse M, Laura, Robert en Rikko wil ik graag bedanken voor 
het steentje dat ze hebben bijgedragen aan het laatste LipiDiDiet experiment.   
 
Nu komen we bij de mensen buiten Nijmegen waaraan ik dank verschuldigd 
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